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How MEDICARE p ART D, MEDICAID,

The Board's opinion is not and cannot be altered by representations that a particular CRNA [Certified Registered Nurse
Anesthetist] has received postdoctoral training in such areas or
has performed such activities in this or another state. A nonphysician may have education, training, and, indeed, expertise
in such an area but expertise cannot, in and of itself, supply authority under law to practice medicine. 286
As a legal matter, the analysis may be trivially correct: education,
training, experience, and expertise do not, in themselves, bestow legal
authority or lift statutory prohibitions .. As a policy matter, however,
we might wonder about the bases on which we both assign and limit
the authority to meet demand - unmet needs - for health care.
However we allocate research resources, tolerate uncertainty, and
calibrate substantiation standards, we might say this much when
substantiation appears to approach zero: based on competition
principles at least, nothing ought to beget nothing, except, perhaps,
scrutiny.

ELECTRONIC PRESCRIBING, AND ICD-

10 COULD IMPROVE PUBLIC HEALTH
(BUT ONLY IF CMS LETS THEM)
Jennifer L. Herbstt
ABSTRACT

A simple change to the Medicare and Medicaid outpatient prescription drug billing systems could improve patient safety and the systems'
long-term fiscal stability. Including diagnosis codes on prescription drug
claims (codes already in use for other billing purposes) would transform
the Medicare Part D and Medicaid prescription drug claims databases
into powerful public health research tools - ones that could provide
much-needed (and, to date, elusive) information on how prescription
drugs work in vulnerable patient populations underrepresented in clinical
research.
Achieving the full potential of this proposal, though, depends upon
the federal agency responsible for Medicare and Medicaid, the Centers
for Medicare and Medicaid Services (CMS), maintaining its current
reimbursement policy, which is perhaps best characterized as one of
benign neglect of the statutory standard for coverage. If, instead of
continuing coverage for the vast majority of prescription drugs, CMS
decided to deny payment for the millions of prescriptions falling short of
the statutory standard (and thus avoid spending billions of federal
health care dollars), prescribers would find themselves in an ethical
dilemma between truth-telling and effectively treating their patients.
Due to the systemic incentives for prescribers and pharmacists to
miscode diagnoses in order to get CMS to pay for the prescription drugs
needed by patients, the decision to treat patients effectively in the shortterm under a strict coverage enforcement policy would undermine the
potential to more effectively treat vulnerable patients, reduce prescription errors, and properly allocate federal health care dollars in the
future. Even in the midst of a financial crisis, or perhaps especially
because of our current financial crisis, we cannot afford to sacrifice

t

286. Safriet, supra note 97, at 454.
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improved patient safety and better informed long-term management of
federal health care dollars for a short-term reduction in federal spending
on prescription drugs.

tested for safety and efficacy in our most vulnerable populations
children, pregnant women, the chronically disabled, and elderly - and
yet they are the most likely to need and receive prescription drugs
covered by government insurance programs. 3 Between the expansion of
Medicaid coverage under the Patient Protection and Affordable Care
Act (the primary insurance coverage for over 32 million American
children) 4 and the 65-plus-year-old Medicare-eligible population growing
from 40 million people to 72 million people in the next twenty years, 5 the
federal health care systems' payment of prescription drugs for our most
vulnerable populations will only continue to increase. 6 The Food and
Drug Administration (FDA)'s prescription drug review and approval
process is unable to detect effectively many risks of prescription drugs
until after they have been approved and used by thousands or millions of
patients. 7 It is not much of a stretch to suggest that our Medicare and
Medicaid programs are paying for an uncontrolled trial of prescription
drugs in vulnerable populations without much prospect for collecting
meaningful data to inform future treatment decisions in these populations.
A single, simple step (to the billing system, of all things) could start
to remedy these ills: Make patient diagnosis codes a necessary condition
for payment of outpatient prescription drugs by Medicare Part D and
Medicaid. With the increasing adoption of electronic medical records and
electronic prescribing (aided in large part by federal incentive pro-
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PROVIDED FOR MEDICALLY ACCEPTED INDICATIONS 6 (2011) [hereinafter
OIG
p ART
D
REIMBURSEMENT
REPORT],
available
at
https://oig.hhs.gov/oei/reports/oei-07-08-00152.pdf;
CONG. BUDGET
OFFICE, MARCH 2012 MEDICARE BASELINE 1 (2012), available at
http://cbo.gov/sites/default/files/cbofiles/attachments/43060_Medicare.p
df.
3.

More specifically, the clinical studies used for FDA approval are not
designed to test safety (instead they are focused primarily on efficacy) and
tend to exclude the frail elderly, young children, pregnant women, and
patients with comorbidities that could interact with the drugs. Aaron S.
Kesselheim, Off-Label Drug Use and Promotion: Balancing Public Health
Goals and Commercial Speech, 37 AM. J.L. & MED. 225, 233-38 (2011).

4.

Distribution of Medicaid Enrollees by Enrollment Group, FY2010, KAISER
FAM. FOUND., http://kff.org/medicaid/state-indicator/distribution-byenrollment-group/ (last visited Apr. 18, 2014).

5.

WAN HE ET AL., U.S. CENSUS BUREAU, CURRENT POPULATION REPORTS,
65+ IN THE UNITED STATES: 2005, at 12 (2005), available at
http://www.census.gov/prod/2006pubs/p23-209.pdf.

INTRODUCTION

The United States' health care system is broken. An estimated 1.5
million people are sickened or killed every year due to preventable
prescription drug errors. 1 As much as half of the $65.8 billion (and
growing) spent annually by the Medicare program on outpatient prescription drugs is being misspent. 2 Most prescription drugs have not been
1.

PHILIP ASPDEN ET AL., INST. OF MED., PREVENTING MEDICINE ERRORS:
QUALITY CHASM SERIES 5 (2007).

2.

OFFICE OF INSPECTOR GEN., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
ENSURING THAT MEDICARE PART D REIMBURSEMENT IS LIMITED TO DRUGS

210

6.

CONG. BUDGET OFFICE, supra note 2.

7.

Kesselheim, supra note 3, at 233 ("New drugs commonly are tested at most
on a few thousand patients, so even the more common side effects may
occur only in a handful of cases, and rare but deadly side effects may not
emerge at all.").
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improved patient safety and better informed long-term management of
federal health care dollars for a short-term reduction in federal spending
on prescription drugs.

tested for safety and efficacy in our most vulnerable populations
children, pregnant women, the chronically disabled, and elderly - and
yet they are the most likely to need and receive prescription drugs
covered by government insurance programs. 3 Between the expansion of
Medicaid coverage under the Patient Protection and Affordable Care
Act (the primary insurance coverage for over 32 million American
children) 4 and the 65-plus-year-old Medicare-eligible population growing
from 40 million people to 72 million people in the next twenty years, 5 the
federal health care systems' payment of prescription drugs for our most
vulnerable populations will only continue to increase. 6 The Food and
Drug Administration (FDA)'s prescription drug review and approval
process is unable to detect effectively many risks of prescription drugs
until after they have been approved and used by thousands or millions of
patients. 7 It is not much of a stretch to suggest that our Medicare and
Medicaid programs are paying for an uncontrolled trial of prescription
drugs in vulnerable populations without much prospect for collecting
meaningful data to inform future treatment decisions in these populations.
A single, simple step (to the billing system, of all things) could start
to remedy these ills: Make patient diagnosis codes a necessary condition
for payment of outpatient prescription drugs by Medicare Part D and
Medicaid. With the increasing adoption of electronic medical records and
electronic prescribing (aided in large part by federal incentive pro-
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grams), 8 the automatic inclusion of diagnostic coding generated for the
health care provider's patient files (and already necessary for provider
billing purposes) on outpatient prescriptions would be relatively easy to
build into the record and prescribing systems. This article strives to
explain how the addition of diagnosis codes to outpatient prescriptions
for Medicare Part D and Medicaid beneficiaries could significantly
improve pharmacists' review of prescriptions for errors, the drug safety
surveillance efforts of the FDA, and the appropriate allocation of
Medicare and Medicaid resources by CMS, but only if CMS is willing to
continue its current policy of paying for all outpatient prescriptions not
subject to prior authorization (contrary to the letter of the Medicare
Part D and Medicaid statutes). 9
In Part I, I explain the role of diagnostic information in the current
legal framework for Medicare and Medicaid reimbursement of outpatient
prescription drugs as well as the federal government's current billing and
enforcement policy in spite of the legal framework. Part II then looks at
the potential disadvantages of strict enforcement of the Medicare Part D
and Medicaid coverage laws (at least in the short term) due to (A) the
disconnect between "medically accepted indications" (the statutory
standard for coverage by the Medicare Part D and Medicaid programs)
and the actual practice of medicine, (B) the informational uncertainty
accompanying the pending transition from the current diagnostic coding
system, ICD-9-CM, to its successor, ICD-10-CM, and (C) the systemic
incentives for miscoding created by coverage denials based upon the
diagnostic information.
As seen in Part III, the significant public health interests potentially
served by adding diagnostic codes to outpatient prescriptions - better
informed pharmacist review of prescriptions for medication errors,

improved drug safety surveillance and comparative effectiveness research
based on actual prescribing practices and patient adherence data - will
only be realized if the information in the outpatient prescription drug
claims database is an accurate reflection of actual medical practice and
pharmacy. This information has been historically elusive for health care
practitioners, researchers, and policymakers alike and an outpatient
prescription drug claims database with diagnostic information would be
a tremendously valuable public health research tool. In order to increase
the likelihood that the diagnostic information submitted for payment is
accurate, prescribers and pharmacists will need to understand diagnostic
coding as a part of effective, coordinated patient care as opposed to a
mere administrative requirement for payment.
I conclude by suggesting an incremental implementation process in
order for CMS and FDA (and, by proxy, patients, health care providers,
and taxpayers) to benefit from the outpatient prescription drug use data
generated by the federal health care system.

8.

9.

The American Recovery and Reinvestment Act of 2009 provided financial
incentives for health care providers to adopt electronic health records. See
CTRS. FOR MEDICARE & MEDICAID SERVS., CMS PROPOSES DEFINITION OF
MEANINGFUL USE OF CERTIFIED ELECTRONIC HEALTH RECORDS (EHR)
TECHNOLOGY
(2009),
available
at
http://www.cms.hhs.gov/ apps/media/fact_sheets.asp.
While Medicare Part D sponsors (the contractors charged with
administering the Medicare prescription drug benefit on behalf of CMS) are
technically supposed to ensure that the drugs paid for by the Medicare
Part D program are used exclusively for "medically-accepted indications,"
sponsors are not expected to recoup any incorrect payments from
pharmacists or patients unless the drug was subject to a sponsor's prior
authorization. As a result, sponsors pay most prescriptions dispensed for
Medicare Part D beneficiaries, regardless of use, with little to no risk to the
sponsor, pharmacist, or patient. See generally CTRS. FOR MEDICARE AND
MEDICAID SERVS., MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL §§
10.6,
10.6.1
(2010),
available
at
http://www.cms.gov/Medicare/Prescription-DrugCoverage /PrescriptionDrugCovContra/Downloads/ Chapter6. pdf;
OIG
PART D REIMBURSEMENT REPORT, supra note 2.
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I.

THE ROLE OF DIAGNOSTIC INFORMATION IN THE CURRENT

LEGAL FRAMEWORK FOR REIMBURSEMENT OF OUTPATIENT
PRESCRIPTION DRUGS UNDER MEDICARE AND MEDICAID

Federal statutes make Medicare Part D and Medicaid outpatient
prescription drug coverage contingent on whether a patient's diagnosis is
one of the indications for which the FDA has approved the drug or
otherwise supported by peer-reviewed scientific evidence summarized in
recognized drug compendia. Congress chose to call this universe of drug
uses "medically accepted indications. " 10 In order to determine the
eligibility of a particular prescription for Medicare or Medicaid coverage,
the claims administrator needs to know the drug name, dosage, quantity,
and patient diagnosis. 11 At present, outpatient prescriptions lack patient
10.

42 U.S.C. § 1396a(a)(54) (2012) (indicating that if a state decides to
extend Medicaid coverage to outpatient prescription drugs, coverage must
comply with the federal requirements for payment for covered outpatient
drugs under 42 U.S.C. § 1396r-8; § 1396r-8(k)(6) (defining "medically
accepted indication" for Medicaid statute in terms of FDA-approved
indications and compendia identified in § 1396r-8(g)(l)(B)(i)); § 1396r8(d)(4)(C) (indicating that a drug may be excluded from a state's
Medicaid formulary if the use is not a medically accepted indication). See
also§ 1396r-8(k)(2) (defining "covered outpatient drug" for Medicaid);§
1395w-102(e) (defining "covered Part D drug" and "medically accepted
indication"); 42 C.F.R. § 423.100 (2012) (defining Medicare "Part D drug"
by referring to Medicaid statute definition of "medically accepted
indication" at 42 U.S.C. § 1396r-8(k)(6)).

11.

E.g., Prescription Drug Claim Form-Medicare Part D, BLUECROSS
BLUESIDELD
OF
LA.,
https://www.bcbsla.com/Docs/RxBL UE_Prescription_Claim_Form. pdf
(last visited Apr. 18, 2014) (requiring information on drug name, dosage,
and quantity for Medicare Part D reimbursement). See supra note 10;

213

HEALTH MATRIX· VOLUME 24 · 2014
Medicare Part D, Medicaid, E-Prescrib'ing, ICD-10, & Publ'ic Health

HEALTH MATRIX· VOLUME 24 · 2014
Medicare Part D, Medicaid, E-Prescribing, ICD-10, & Public Health

grams), 8 the automatic inclusion of diagnostic coding generated for the
health care provider's patient files (and already necessary for provider
billing purposes) on outpatient prescriptions would be relatively easy to
build into the record and prescribing systems. This article strives to
explain how the addition of diagnosis codes to outpatient prescriptions
for Medicare Part D and Medicaid beneficiaries could significantly
improve pharmacists' review of prescriptions for errors, the drug safety
surveillance efforts of the FDA, and the appropriate allocation of
Medicare and Medicaid resources by CMS, but only if CMS is willing to
continue its current policy of paying for all outpatient prescriptions not
subject to prior authorization (contrary to the letter of the Medicare
Part D and Medicaid statutes). 9
In Part I, I explain the role of diagnostic information in the current
legal framework for Medicare and Medicaid reimbursement of outpatient
prescription drugs as well as the federal government's current billing and
enforcement policy in spite of the legal framework. Part II then looks at
the potential disadvantages of strict enforcement of the Medicare Part D
and Medicaid coverage laws (at least in the short term) due to (A) the
disconnect between "medically accepted indications" (the statutory
standard for coverage by the Medicare Part D and Medicaid programs)
and the actual practice of medicine, (B) the informational uncertainty
accompanying the pending transition from the current diagnostic coding
system, ICD-9-CM, to its successor, ICD-10-CM, and (C) the systemic
incentives for miscoding created by coverage denials based upon the
diagnostic information.
As seen in Part III, the significant public health interests potentially
served by adding diagnostic codes to outpatient prescriptions - better
informed pharmacist review of prescriptions for medication errors,

improved drug safety surveillance and comparative effectiveness research
based on actual prescribing practices and patient adherence data - will
only be realized if the information in the outpatient prescription drug
claims database is an accurate reflection of actual medical practice and
pharmacy. This information has been historically elusive for health care
practitioners, researchers, and policymakers alike and an outpatient
prescription drug claims database with diagnostic information would be
a tremendously valuable public health research tool. In order to increase
the likelihood that the diagnostic information submitted for payment is
accurate, prescribers and pharmacists will need to understand diagnostic
coding as a part of effective, coordinated patient care as opposed to a
mere administrative requirement for payment.
I conclude by suggesting an incremental implementation process in
order for CMS and FDA (and, by proxy, patients, health care providers,
and taxpayers) to benefit from the outpatient prescription drug use data
generated by the federal health care system.

8.

9.

The American Recovery and Reinvestment Act of 2009 provided financial
incentives for health care providers to adopt electronic health records. See
CTRS. FOR MEDICARE & MEDICAID SERVS., CMS PROPOSES DEFINITION OF
MEANINGFUL USE OF CERTIFIED ELECTRONIC HEALTH RECORDS (EHR)
TECHNOLOGY
(2009),
available
at
http://www.cms.hhs.gov/ apps/media/fact_sheets.asp.
While Medicare Part D sponsors (the contractors charged with
administering the Medicare prescription drug benefit on behalf of CMS) are
technically supposed to ensure that the drugs paid for by the Medicare
Part D program are used exclusively for "medically-accepted indications,"
sponsors are not expected to recoup any incorrect payments from
pharmacists or patients unless the drug was subject to a sponsor's prior
authorization. As a result, sponsors pay most prescriptions dispensed for
Medicare Part D beneficiaries, regardless of use, with little to no risk to the
sponsor, pharmacist, or patient. See generally CTRS. FOR MEDICARE AND
MEDICAID SERVS., MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL §§
10.6,
10.6.1
(2010),
available
at
http://www.ems.gov/Medicare /Prescription-DrugCoverage /PrescriptionDrugCovContra/Downloads/ Chapter6. pdf;
OIG
PART D REIMBURSEMENT REPORT, supra note 2.
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otherwise supported by peer-reviewed scientific evidence summarized in
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diagnostic information (the "information gap" identified in a prior
article), 12 making real-time review for coverage eligibility impossible. In
order to close this information gap, CMS could require patient diagnosis
information, in the form of an International Classification of Diseases
(ICD) code, for reimbursement of outpatient prescription drugs under
Medicare and Medicaid.
My proposal for CMS to require diagnostic information, in the form
of _an ICD code, for reimbursement of outpatient prescription drug
claims merely suggests an extension of the existing billing policy for the
small group of outpatient drugs currently covered by Medicare Part B.
Generally, Medicare Pa.rt B covers "reasonable and necessary" outpatient medical services and items for the "diagnosis or treatment of illness
or injury or to improve the functioning of a malformed body member. "13
Medicare Part B does not cover most outpatient prescription drugs - it
has historically only covered drugs, which are administered by doctors
during office or hospital visits. 14 This relatively limited Part B coverage
has been extended, though, to include a handful of other specific classes
of prescription drugs and biologics that may be purchased at retail
pharmacies, including blood clotting factors for hemophilia patients, 15
immunosuppressive therapy after organ transplantation, 16 erythropoietin
for dialysis patients, 17 and anti-nausea drugs for those undergoing
anticancer chemotherapy. 18 In each of these statutorily defined exceptions to the general Part B rule covering only drugs that "are not
usually self-administered by the patient," Congress limited coverage to

use for specific patient diagnoses (i.e., hemophilia, organ failure, kidney
disease, cancer). CMS, in tum, has required diagnosis codes on all claims
for reimbursement of prescription drugs under Part B, whether furnished
by a physician or self-administered by a patient. 19
The vast majority of outpatient prescription drugs taken by Medicare beneficiaries went uncovered by the program20 until the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 added
a prescription drug benefit to the Medicare program - Medicare Part
D.21 Pa.rt D was considered at the time to be "the most significant
change to the Medicare program since its inception in 1965. "22 Unlike the
broad "reasonable and necessary" standard for Medicare Part B reimbursement, the legal framework for Medicare Part D limits federal
reimbursement of outpatient prescription drugs to "medically accepted
indication[s]," as defined by the Medicaid statute, allowing, but not

19.

See CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE CLAIMS
PROCESSING
MANUAL
§
70
(2003),
available
at
http://www.cms.gov/Regulations-andGuidance/Guidance/Manuals/Internet-Only-Manuals-IOMsItems/CMS018912.html (explaining an exception to the general Part B
coverage rule that self-administered drugs, including self-administered oral
versions of covered injectable cancer drugs, furnished to outpatients for
therapeutic purposes are not covered by Medicare unless those drugs must
be put directly into an item of durable medical equipment or a prosthetic
device); Id. at § 80.1.3 ("A cancer diagnosis code must be reported when
billing for [oral cancer drugs using] these HCPCS [Healthcare Common
Procedure Coding System] codes. If there is no cancer diagnosis the claim
is denied."); CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE BENEFIT
POLICY MANUAL§ 50.4.1 (2009) [hereinafter MEDICARE BENEFIT POLICY
MANUAL],
available
at
http://www.cms.hhs.gov/Manuals/downloads/bpl02c15.pdf ("Use of the
drug or biological must be safe and effective and otherwise reasonable and
necessary ... Drugs or biologicals approved for marketing by the [FDA]
are considered safe and effective for purposes of this requirement when
used for indications specified on the labeling.").

20.

Some Medicare patients are able to get additional insurance through
Medicaid, in which case Medicaid could cover the outpatient prescription
drugs not paid for by Medicare. These patients are known as "dual eligible
beneficiaries." MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE
CONG.: NEW APPROACHES IN MEDICARE 71-72 (2004), available at
http://www.medpac.gov/publications/congressional_reports/June04_ch3.p
df.

21.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2071-72 (2003). OIG PART D
REIMBURSEMENT REPORT, supra note 2, at 2 ("Since January 1, 2006, most
outpatient prescription drugs for Medicare beneficiaries and dually eligible
beneficiaries ... have been covered by the Medicare Part D program.").

22.

Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194,
4197 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.).

CTRS. FOR MEDICARE AND MEDICAID SERVS., supra note 9, at § 10.6
(providing authority on need for diagnostic information).
12.

Jennifer L. Herbst, The Short-Sighted Value of Inefficiency: Why We
Should Mind the Gap in the Reimbursement of Outpatient Prescription
Drugs, 2 CASE W. RES. J.L. TECH. & INTERNET 1 (2011).

13.

42 U.S.C. § 1395y(a)(l)(A) (2012).

14.

U.S. Gov'T ACCOUNTING OFFICE, MEDICARE: PRESCRIPTION DRUG ISSUES 3
(1987) ("Outpatient prescription drugs are generally not covered by
Medicare Part B, with the exception of drugs that require injection by a
physician or nurse."). 42 U.S.C § 1395k(a)(2)(B) (2012) (providing
Medicare Part B coverage for "medical and other health services" rendered
in an outpatient setting); § 1395x(s)(2) (A) (defining the term "medical and
other health services" to include, in relevant part, "services and supplies
(including drugs and biologicals which are not usually self-administered by
the patient) furnished as an incident to a physician's professional service of
kinds which are commonly furnished in physicians' offices and ~re
commonly either rendered without charge or included in the physicians'
bills .... " (emphasis added)).

15.

§ 1395k(a)(2)(I).

16.

§ 1395k(a)(2)(J).

17.

§ 1395k(a)(2)(0).

18.

§ 1395k(a)(2)(Q).
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diagnostic information (the "information gap" identified in a prior
article), 12 making real-time review for coverage eligibility impossible. In
order to close this information gap, CMS could require patient diagnosis
information, in the form of an International Classification of Diseases
(ICD) code, for reimbursement of outpatient prescription drugs under
Medicare and Medicaid.
My proposal for CMS to require diagnostic information, in the form
of an ICD code, for reimbursement of outpatient prescription drug
claims merely suggests an extension of the existing billing policy for the
small group of outpatient drugs currently covered by Medicare Part B.
Generally, Medicare Part B covers "reasonable and necessary" outpatient medical services and items for the "diagnosis or treatment of illness
or injury or to improve the functioning of a malformed body member. "13
Medicare Part B does not cover most outpatient prescription drugs - it
has historically only covered drugs, which are administered by doctors
during office or hospital visits. 14 This relatively limited Part B coverage
has been extended, though, to include a handful of other specific classes
of prescription drugs and biologics that may be purchased at retail
pharmacies, including blood clotting factors for hemophilia patients, 15
immunosuppressive therapy after organ transplantation, 16 erythropoietin
for dialysis patients,1 7 and anti-nausea drugs for those undergoing
anticancer chemotherapy. 18 In each of these statutorily defined exceptions to the general Part B rule covering only drugs that "are not
usually self-administered by the patient," Congress limited coverage to

use for specific patient diagnoses (i.e., hemophilia, organ failure, kidney
disease, cancer). CMS, in turn, has required diagnosis codes on all claims
for reimbursement of prescription drugs under Part B, whether furnished
by a physician or self-administered by a patient. 19
The vast majority of outpatient prescription drugs taken by Medicare beneficiaries went uncovered by the program20 until the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 added
a prescription drug benefit to the Medicare program - Medicare Part
D.2 1 Part D was considered at the time to be "the most significant
change to the Medicare program since its inception in 1965." 22 Unlike the
broad "reasonable and necessary" standard for Medicare Part B reimbursement, the legal framework for Medicare Part D limits federal
reimbursement of outpatient prescription drugs to "medically accepted
indication[s]," as defined by the Medicaid statute, allowing, but not

19.

See CTRS. FOR MEDICARE & MEDICAID 8ERVS., MEDICARE CLAIMS
PROCESSING
MANUAL
§
70
(2003),
available
at
http://www.cms.gov/Regulations-andGuidance/Guidance/Manuals/Internet-Only-Manuals-IOMsItems/CMS018912.html (explaining an exception to the general Part B
coverage rule that self-administered drugs, including self-administered oral
versions of covered injectable cancer drugs, furnished to outpatients for
therapeutic purposes are not covered by Medicare unless those drugs must
be put directly into an item of durable medical equipment or a prosthetic
device); Id. at § 80.1.3 ("A cancer diagnosis code must be reported when
billing for [oral cancer drugs using] these HCPCS [Healthcare Common
Procedure Coding System] codes. If there is no cancer diagnosis the claim
is denied."); CTHS. FOR MEDICARE & MEDICAID SERVS., MEDICARE BENEFIT
POLICY MANUAL§ 50.4.1 (2009) [hereinafter MEDICARE BENEFIT POLICY
MANUAL],
available
at
http://www.cms.hhs.gov/Manuals/downloads/bpl02cl5.pdf ("Use of the
drug or biological must be safe and effective and otherwise reasonable and
necessary ... Drugs or biologicals approved for marketing by the [FDA]
are considered safe and effective for purposes of this requirement when
used for indications specified on the labeling.").

20.

Some Medicare patients are able to get additional insurance through
Medicaid, in which case Medicaid could cover the outpatient prescription
drugs not paid for by Medicare. These patients are known as "dual eligible
beneficiaries." MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE
CONG.: NEW APPROACHES IN MEDICARE 71-72 (2004), available at
http://www.medpac.gov/publications/congressional_reports/June04_ch3.p
df.

21.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2071-72 (2003). OIG PART D
REIMBURSEMENT REPOHT, supra note 2, at 2 ("Since January 1, 2006, most
outpatient prescription drugs for Medicare beneficiaries and dually eligible
beneficiaries ... have been covered by the Medicare Part D program.").

22.

Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194,
4197 (Jan. 28, 2005) (codified at scattered parts of 42 C.F .R.).

CTRS. FOR MEDICARE AND MEDICAID SERVS., supra note 9, at § 10.6
(providing authority on need for diagnostic information).
12.

Jennifer L. Herbst, The Short-Sighted Value of Inefficiency: Why We
Should Mind the Gap in the Reimbursement of Outpatient Prescription
Drugs, 2 CASE w. R.Es. J.L. TECH. & INTERNET 1 (2011).

13.

42 U.S.C. § 1395y(a)(l)(A) (2012).

14.

U.S. Gov'T ACCOUNTING OFFICE, MEDICARE: PRESCRIPTION DRUG ISSUES 3
(1987) ("Outpatient prescription drugs are generally not covered by
Medicare Part B, with the exception of drugs that require injection by a
physician or nurse."). 42 U.S.C § 1395k(a)(2)(B) (2012) (providing
Medicare Part B coverage for "medical and other health services" rendered
in an outpatient setting);§ 1395x(s)(2)(A) (defining the term "medical and
other health services" to include, in relevant part, "services and supplies
(including drugs and biologicals which are not usually self-administered by
the patient) furnished as an incident to a physician's professional service of
kinds which are commonly furnished in physicians' offices and ~re
commonly either rendered without charge or included in the physicians'
bills . . . . " (emphasis added)).

15.

§ 1395k(a)(2)(I).

16.

§ 1395k(a)(2)(J).

17.

§ 1395k(a)(2)(0).

18.

§ 1395k(a)(2)(Q).
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requiring, states to limit their coverage of outpatient prescription drugs
to "medically accepted indication[s]." 23
"Medically accepted indications" include any specific indication
listed on the drug's labeling as approved by the FDA (also known as an
"on-label" use) or any use supported by one or more citations found in
recognized drug compendia, including the American Hospital Formulary
Service Drug Information (AHFS-DI), the United States PharmacopeiaDrug Information (USP-DI), and the DrugDEX Information System. 24 In
addition to the on-label and compendia-listed indications, Medicaid also
allows reimbursement for any use that is supported by peer-reviewed
medical literature, 25 but medical literature alone is not enough to provide
Part D coverage26 unless the drug is "used in an anticancer chemotherapeutic regimen" .27 The uses supported by compendia citations or peer-

reviewed medical literature include both on-label uses as well as uses
that are not included on the FDA-approved labeling for a drug ("offlabel" uses) .28
Despite the statutory language limiting Medicare Part D and Medicaid payment for drugs to "medically accepted indications," there is no
single database within the federal health care system in which a patient's
outpatient prescription drug use can be cross-referenced with his medical
diagnoses. 29 The claims administrators for Medicare Part D, known as
Part D Plan (PDP) sponsors, "do not routinely collect diagnosis information because CMS does not require diagnoses as a data element for
Part D claims. PDP sponsors do not collect related diagnoses for Part D
claims from pharmacies because it is not standard practice for prescribers to provide the diagnoses. "30 As a result, there is no real time,
resource-efficient means of determining whether an outpatient prescription is appropriately reimbursed under Medicare Part D or Medicaid.
As a result, current CMS policy is not to enforce the coverage statutes at the time of payment (either the patient's payment for the
prescription or the government's payment of the dispensing pharmacist)
or to recoup mispaid funds from pharmacists or patients. 31 Instead, the
government has generally been paying for outpatient prescriptions,
regardless of diagnosis, then trying to recoup inappropriate payments for
outpatient prescriptions for uses other than those considered "medically
appropriate indications," through False Claims Act suits brought against
pharmaceutical companies by the U.S. Department of Justice and state
attorneys general. 32 If either the multi-million and -billion dollar settle-

23.

24.

See 42 U.S.C. § 1396d(a)(12) (2012) (defining the Medicaid program's
"medical assistance" coverage to include payment for "prescribed drugs");
§ 1396r-8(k)(2)(A)(i) (defining the Medicaid program's "covered outpatient
drugs" to include all prescription drugs approved by the FDA); § 1396r8(d)(l)(B)(i) (allowing states to limit coverage of outpatient drugs to
"medically accepted indications"); § 1396r-8(k)(6) (defining "medically
accepted indication" for Medicaid program). See also § 1395w-102(e); 42
C.F.R. § 423.100 (defining Medicare "Part D drug" by referring to
Medicaid statute definition of "medically accepted indication" at 42 U.S.C.
§ 1396r-8(k)(6) (2012)). At least one federal court has decided that the
regulation limiting Part D coverage to "medically accepted indications" is
not consistent with Congressional intent. Layzer v. Leavitt, 770 F. Supp.
2d 579, 586 (S.D.N.Y. 2011). But see Kilmer v. Leavitt, 609 F. Supp. 2d
750, 753 (S.D. Ohio 2009) ("This Court is constrained by the plain
language of the [Part D] statutory scheme to conclude that the medically
accepted indication clause must be read as a limitation."); Nievod v.
Sebellius, 2013 WL 503089, at *9 (N.D. Cal. 2013) (concluding "it is clear
from the plain terms of the statute that a covered Part D drug is one that
comports with the medically accepted indication requirement"); Rickhoff v.
U.S. Sec'y ex rel. Dep't of Health & Human Servs., 2012 WL 6177411, at
*4 (D. Ariz. 2012) ("Fentanyl in lozenge form is not a 'medically accepted
indication' for non-cancer patients and thus is not a covered Part D
drug.").
42 U.S.C. § 1396r-8(g)(l)(B)(i) (2012). In 2008, CMS approved two
compendia in addition to those specifically referenced in the statute: the
National Comprehensive Cancer Network Drugs & Biologics Compendium
and Clinical Pharmacology. Ross MCKINNEY ET AL., AGENCY FOR
HEALTHCARE RESEARCH AND QUALITY, WHITE PAPER: POTENTIAL
CONFLICT OF INTEREST IN THE PRODUCTION OF DRUG COMPENDIA 5 (2009),
available
at
http://www.cms.gov/Medicare / Coverage/DeterminationProcess /downloads
/id64TA.pdf.

25.

§ 1396r-8(g)(l)(B)(ii).

26.

Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194,
4228-29 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.).

27.

Compare 42 U.S.C. § 1395w-102 (e)(4)(A)(i) (defining drugs used for
oncology purposes in terms of § 1395x(t)(2)(B), which includes uses
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supported by "clinical evidence in peer reviewed medical literature"), with
§ 1396r-8(k)(6) (noting the standard for all uses unrelated to cancer, which
does not include uses supported by "clinical evidence in peer reviewed
medical literature").
28.

§ 1395x(t)(2)(B). See also OIG PART D REIMBURSEMENT REPORT, supra
note 2, at 3 ("Only one compendium needs to support an off-label use for
that use to meet the medically accepted indications requirement for
Medicare Part D reimbursement.").

29.

Reconciling the pharmacy-generated outpatient prescription drug claim
databases with the physician-generated office visit claim databases is
currently time- and cost-prohibitive on a large scale. See OIG PART D
REIMBURSEMENT REPORT, supra note 2.

30.

Id. at 5.

31.

CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 9, at§ 10.6.l ("When
it was not reasonable to expect a Part D sponsor to require prior
authorization to ensure a drug is being used for an accepted medical
indication, CMS would not expect the sponsor to recover payments made to
pharmacies or attempt to obtain reimbursement from enrollees." (emphasis
added)).

32.

In a prior article, I argued that the enforcement of the federal coverage law
should be shifted away from the Department of Justice and state attorneys
general to a real-time review of prescriptions at the time of payment by the
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requiring, states to limit their coverage of outpatient prescription drugs
to "medically accepted indication[s]." 23
"Medically accepted indications" include any specific indication
listed on the drug's labeling as approved by the FDA (also known as an
"on-label" use) or any use supported by one or more citations found in
recognized drug compendia, including the American Hospital Formulary
Service Drug Information (AHFS-DI), the United States PharmacopeiaDrug Information (USP-DI), and the DrugDEX Information System. 24 In
addition to the on-label and compendia-listed indications, Medicaid also
allows reimbursement for any use that is supported by peer-reviewed
medical literature, 25 but medical literature alone is not enough to provide
Part D coverage26 unless the drug is "used in an anticancer chemotherapeutic regimen". 27 The uses supported by compendia citations or peer-

reviewed medical literature include both on-label uses as well as uses
that are not included on the FDA-approved labeling for a drug ("offlabel" uses) .28
Despite the statutory language limiting Medicare Part D and Medicaid payment for drugs to "medically accepted indications," there is no
single database within the federal health care system in which a patient's
outpatient prescription drug use can be cross-referenced with his medical
diagnoses. 29 The claims administrators for Medicare Part D, known as
Part D Plan (PDP) sponsors, "do not routinely collect diagnosis information because CMS does not require diagnoses as a data element for
Part D claims. PDP sponsors do not collect related diagnoses for Part D
claims from pharmacies because it is not standard practice for prescribers to provide the diagnoses. "30 As a result, there is no real time,
resource-efficient means of determining whether an outpatient prescription is appropriately reimbursed under Medicare Part D or Medicaid.
As a result, current CMS policy is not to enforce the coverage statutes at the time of payment (either the patient's payment for the
prescription or the government's payment of the dispensing pharmacist)
or to recoup mispaid funds from pharmacists or patients. 31 Instead, the
government has generally been paying for outpatient prescriptions,
regardless of diagnosis, then trying to recoup inappropriate payments for
outpatient prescriptions for uses other than those considered "medically
appropriate indications," through False Claims Act suits brought against
pharmaceutical companies by the U.S. Department of Justice and state
attorneys general. 32 If either the multi-million and -billion dollar settle-

23.

24.

See 42 U.S.C. § 1396d(a)(12) (2012) (defining the Medicaid program's
"medical assistance" coverage to include payment for "prescribed drugs");
§ 1396r-8(k)(2)(A)(i) (defining the Medicaid program's "covered outpatient
drugs" to include all prescription drugs approved by the FDA); § 1396r8(d)(l)(B)(i) (allowing states to limit coverage of outpatient drugs to
"medically accepted indications"); § 1396r-8(k)(6) (defining "medically
accepted indication" for Medicaid program). See also§ 1395w-102(e); 42
C.F.R. § 423.100 (defining Medicare "Part D drug" by referring to
Medicaid statute definition of "medically accepted indication" at 42 U.S.C.
§ 1396r-8(k)(6) (2012)). At least one federal court has decided that the
regulation limiting Part D coverage to "medically accepted indications" is
not consistent with Congressional intent. Layzer v. Leavitt, 770 F. Supp.
2d 579, 586 (S.D.N.Y. 2011). But see Kilmer v. Leavitt, 609 F. Supp. 2d
750, 753 (S.D. Ohio 2009) ("This Court is constrained by the plain
language of the [Part DJ statutory scheme to conclude that the medically
accepted indication clause must be read as a limitation."); Nievod v.
Sebellius, 2013 WL 503089, at *9 (N.D. Cal. 2013) (concluding "it is clear
from the plain terms of the statute that a covered Part D drug is one that
comports with the medically accepted indication requirement"); Rickhoff v.
U.S. Sec'y ex rel. Dep't of Health & Human Servs., 2012 WL 6177411, at
*4 (D. Ariz. 2012) ("Fentanyl in lozenge form is not a 'medically accepted
indication' for non-cancer patients and thus is not a covered Part D
drug.").
42 U.S.C. § 1396r-8(g)(l)(B)(i) (2012). In 2008, CMS approved two
compendia in addition to those specifically referenced in the statute: the
National Comprehensive Cancer Network Drugs & Biologics Compendium
and Clinical Pharmacology. Ross MCKINNEY ET AL., AGENCY FOR
HEALTHCARE RESEARCH AND QUALITY, WHITE PAPER: POTENTIAL
CONFLICT OF INTEREST IN THE PRODUCTION OF DRUG COMPENDIA 5 (2009),
available
at
http://www.cms.gov/Medicare / Coverage/DeterminationProcess /downloads
/id64TA.pdf.

25.

§ 1396r-8(g)(l)(B)(ii).

26.

Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194,
4228-29 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.).

27.

Compare 42 U.S.C. § 1395w-102 (e)(4)(A)(i) (defining drugs used for
oncology purposes in terms of § 1395x(t)(2)(B), which includes uses
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supported by "clinical evidence in peer reviewed medical literature"), with
§ 1396r-8(k)(6) (noting the standard for all uses unrelated to cancer, which
does not include uses supported by "clinical evidence in peer reviewed
medical literature").
28.

§ 1395x(t)(2)(B). See also OIG PART D REIMBURSEMENT REPORT, supra
note 2, at 3 ("Only one compendium needs to support an off-label use for
that use to meet the medically accepted indications requirement for
Medicare Part D reimbursement.").

29.

Reconciling the pharmacy-generated outpatient prescription drug claim
databases with the physician-generated office visit claim databases is
currently time- and cost-prohibitive on a large scale. See OIG PART D
REIMBURSEMENT REPORT, supra note 2.

30.

Id. at 5.

31.

CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 9, at§ 10.6.l ("When
it was not reasonable to expect a Part D sponsor to require prior
authorization to ensure a drug is being used for an accepted medical
indication, CMS would not expect the sponsor to recover payments made to
pharmacies or attempt to obtain reimbursement from enrollees." (emphasis
added)).

32.

In a prior article, I argued that the enforcement of the federal coverage law
should be shifted away from the Department of Justice and state attorneys
general to a real-time review of prescriptions at the time of payment by the
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ment agreements with pharmaceutical companies 33 or the recent memorandum from the Deputy Inspector General for the U.S. Department of
Health and Human Services finding "50 percent of Medicare Part D
claims of Medicare Part D claims for atypical antipsychotic drugs
received by elderly nursing home residents from January 1 through June
30, 2007 were erroneous because the claimed drugs were not provided for
medically accepted indications" 34 are any indication of the scope of the
overpayment by the federal government for outpatient prescriptions, the
practical result of this policy is a significant misspending of billions of
taxpayer dollars within the federal health care system.

and (C) the incentives for miscoding created by coverage denials based
upon the diagnostic information.

II. How

STRICT ENFORCEMENT OF THE COVERAGE LAW
WOULD UNDERMINE LONG-TERM PATIENT SAFETY BY lNCENTIVIZING MISCODING FOR SHORT-TERM PATIENT BENEFIT

While the recent multi-million and -billion dollar False Claims Act
settlements with pharmaceutical companies and the audit findings of
erroneously paid Part D claims mentioned above may suggest a significant misallocation of federal health care dollars, they also point to a real
likelihood that strict enforcement of the coverage laws at the time of
payment would result in widespread coverage denials, perhaps on the
scale of millions of prescriptions. Given the socioeconomic situation of
the majority of Medicare and Medicaid beneficiaries, coverage denials
effectively prevent patient access to the prescribed drugs despite the fact
that the health care providers who write the prescriptions have deemed
them to be the best treatment for their patients. When confronted with
administrative technicalities perceived as arbitrary or harmful to their
patients, prescribers and pharmacists may decide to tailor their diagnostic coding practices for payment (and thus, effective treatment) purposes
rather than reflecting their patients' actual diagnoses. This section looks
at the potential disadvantages of strict enforcement of the Medicare and
Medicaid coverage laws due to (A) the disconnect between the statutory
definition of "medically appropriate indications" and actual medical
practice; (B) the further uncertainty accompanying the transition from
one diagnostic coding system to another scheduled for October 1, 2015;

A. Limitations of Labels and Compendia: An Inherent Disconnect
between Medicine and Science

Medicine is a professional practice focused on diagnosing and treating individual patients' diseases or injuries. The traditional goals of
medicine include physicians' obligations to 1) prevent and diagnose
disease or injury; 2) cure or treat the disease/injury; 3) reduce suffering
or, if that is not possible, help patients cope with a disease or injury; 4)
educate patients about disease/injury and prognosis; 5) help patients die
in peace and with dignity; 6) reassure the "worried well" who do not
have a disease/injury. 35
Just as the practice of law requires advising an actual client, the
practice of medicine requires an actual patient. Patients are as similar to
one another, and as different from one another, as clients are. Medical
advice, like legal advice, is individualized. 36 Science, by comparison, is
focused "on understanding nature and the universe through human
observation, using theories that the human mind can reason from those
observations, and reaching conclusions that can be tested through
further observations of the universe. "37 Science is interested in creating
generalizable knowledge and theories of how nature and the universe
work. 38 It need not, and indeed cannot, limit itself to individual, anecdotal information. And there lies the rub - while science is a criticallyimportant tool for informing treatment decisions, it cannot account for
all of the individual differences that medicine must consider. Yet the
term "medically accepted indications" is defined in terms of scientific
35.

Dan Larriviere et al., Responding to Requests from Adult Patients for
Neuroenhancements: Guidance of the Ethics, Law, and Humanities
Committee, 73 NEUROLOGY 1406, 1407 (2009) (citing Howard Brody &
Franklin G. Miller, The Internal Morality of Medicine: Explication and
Application to Managed Care, 23 J. MED. & PHIL. 384, 386-87 (1998)
(emphasis added)).

36.

Danielle Ofri, How Creative Is Your Doctor?, N.Y. TIMES (Mar. 14, 2013),
http://well.blogs.nytimes.com/2013/03/14/how-creative-is-your-doctor
("Patients and diseases do not come as prepackaged widgets. A slavish
approach to standardized treatments without any creativity can do more
harm than good.").

37.

ROBIN FELDMAN, THE ROLE OF SCIENCE IN LAW 115-16 (2009) (emphasis
added).

38.

MEDICARE COVERAGE ADVISORY COMM., PROCESS FOR EVALUATION OF
EFFECTIVENESS & COMM. OPERATIONS 3 (2006), available at
http://www.ems.gov/Regulations-andGuidance/ Guidance/F ACA/ downloads/recommendations.pdf
("The
committee's definition of adequate [scientific] evidence includes both the
validity of the evidence and its general applicability to the population of
interest, i.e. generalizability." (emphasis added)).

Centers for Medicare and Medicaid Services (CMS) for efficiency purposes.
Herbst, supra note 12, at 40.
33.

34.

See, e.g., Press Release, U.S. Dep't of Justice, Office of Public Affairs,
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud
Allegations and Failure to Report Safety Data (July 2, 2012), available at
http://www.justice.gov/ opa/pr/2012/ July /12-civ-842.html (explaining that
GlaxoSmithKline agreed to pay $2 billion to resolve its civil liabilities with
the federal government under the False Claims Act, as well as the states).
OIG PART D REIMBURSEMENT REPORT, supra note 2.
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ment agreements with pharmaceutical companies33 or the recent memorandum from the Deputy Inspector General for the U.S. Department of
Health and Human Services finding "50 percent of Medicare Part D
claims of Medicare Part D claims for atypical antipsychotic drugs
received by elderly nursing home residents from January 1 through June
30, 2007 were erroneous because the claimed drugs were not provided for
medically accepted indications" 34 are any indication of the scope of the
overpayment by the federal government for outpatient prescriptions, the
practical result of this policy is a significant misspending of billions of
taxpayer dollars within the federal health care system.

and (C) the incentives for miscoding created by coverage denials based
upon the diagnostic information.

II. How STRICT ENFORCEMENT OF THE COVERAGE LAW
WOULD UNDERMINE LONG-TERM PATIENT SAFETY BY lNCENTIVIZING MISCODING FOR SHORT-TERM PATIENT BENEFIT
While the recent multi-million and -billion dollar False Claims Act
settlements with pharmaceutical companies and the audit findings of
erroneously paid Part D claims mentioned above may suggest a significant misallocation of federal health care dollars, they also point to a real
likelihood that strict enforcement of the coverage laws at the time of
payment would result in widespread coverage denials, perhaps on the
scale of millions of prescriptions. Given the socioeconomic situation of
the majority of Medicare and Medicaid beneficiaries, coverage denials
effectively prevent patient access to the prescribed drugs despite the fact
that the health care providers who write the prescriptions have deemed
them to be the best treatment for their patients. When confronted with
administrative technicalities perceived as arbitrary or harmful to their
patients, prescribers and pharmacists may decide to tailor their diagnostic coding practices for payment (and thus, effective treatment) purposes
rather than reflecting their patients' actual diagnoses. This section looks
at the potential disadvantages of strict enforcement of the Medicare and
Medicaid coverage laws due to (A) the disconnect between the statutory
definition of "medically appropriate indications" and actual medical
practice; (B) the further uncertainty accompanying the transition from
one diagnostic coding system to another scheduled for October 1 2015·

'

A. Limitations of Labels and Compendia: An Inherent Disconnect
between Medicine and Science
Medicine is a professional practice focused on diagnosing and treating individual patients' diseases or injuries. The traditional goals of
medicine include physicians' obligations to 1) prevent and diagnose
disease or injury; 2) cure or treat the disease/injury; 3) reduce suffering
or, if that is not possible, help patients cope with a disease or injury; 4)
educate patients about disease/injury and prognosis; 5) help patients die
in peace and with dignity; 6) reassure the "worried well" who do not
have a disease/injury. 35
Just as the practice of law requires advising an actual client, the
practice of medicine requires an actual patient. Patients are as similar to
one another, and as different from one another, as clients are. Medical
advice, like legal advice, is individualized. 36 Science, by comparison, is
focused "on understanding nature and the universe through human
observation, using theories that the human mind can reason from those
observations, and reaching conclusions that can be tested through
further observations of the universe. "37 Science is interested in creating
generalizable knowledge and theories of how nature and the universe
work. 38 It need not, and indeed cannot, limit itself to individual, anecdotal information. And there lies the rub - while science is a criticallyimportant tool for informing treatment decisions, it cannot account for
all of the individual differences that medicine must consider. Yet the
term "medically accepted indications" is defined in terms of scientific
35.

Dan Larriviere et al., Responding to Requests from Adult Patients for
N euroenhancements: Guidance of the Ethics, Law, and Humanities
Committee, 73 NEUROLOGY 1406, 1407 (2009) (citing Howard Brody &
Franklin G. Miller, The Internal Morality of Medicine: Explication and
Application to Managed Care, 23 J. MED. & PHIL. 384, 386-87 (1998)
(emphasis added)).

36.

Danielle Ofri, How Creative Is Your Doctor?, N.Y. TIMES (Mar. 14, 2013),
http://well.blogs.nytimes.com/2013/03/14/how-creative-is-your-doctor
("Patients and diseases do not come as prepackaged widgets. A slavish
approach to standardized treatments without any creativity can do more
harm than good.").

37.

ROBIN FELDMAN, THE ROLE OF SCIENCE IN LAW 115-16 (2009) (emphasis
added).

38.

MEDICARE COVERAGE ADVISORY COMM., PROCESS FOR EVALUATION OF
EFFECTIVENESS & COMM. OPERATIONS 3 (2006), available at
http://www.cms.gov/Regulations-andGuidance/ Guidance/F ACA/ downloads/recommendations.pdf
("The
committee's definition of adequate [scientific] evidence includes both the
validity of the evidence and its general applicability to the population of
interest, i.e. generalizability." (emphasis added)).

'

Centers for Medicare and Medicaid Services (CMS) for efficiency purposes.
Herbst, supra note 12, at 40.
33.

34.

See, e.g., Press Release, U.S. Dep't of Justice, Office of Public Affairs,
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud
Allegations and Failure to Report Safety Data (July 2, 2012), available at
http://www.justice.gov/opa/pr/2012/July/12-civ-842.html (explaining that
GlaxoSmithKline agreed to pay $2 billion to resolve its civil liabilities with
the federal government under the False Claims Act, as well as the states).
OIG PART D REIMBURSEMENT REPORT, supra note 2.
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evidence - specifically the clinical trials underpinning the FDA approval
process for prescription drugs and compendia listings.
FDA-approved "on-label" indications are reflective of the patient
populations and endpoints studied in clinical trials funded and designed
by manufacturers with the FDA's review and approval. 39 The compendia
are "listing[s] of drugs ... which summarizeD evidence on the effectiveness of each drug . . . and provide0 information regarding clinical
indications and proper dosing. "40 The compendia are not overseen or
published by any governmental body but instead by various institutions
and traditional reference book publishing houses, 41 in different formats,
and updated at different intervals. 42
The "evidence" summarized in the compendia need not (and, in
many cases, does not) reflect the current or best clinical trials. 43 Further,
the generalizable knowledge summarized in the compendia is not
available simply because of its persuasive value as scientific evidence.
Rather, the evidence is limited to research deemed worth a manufacturer's (or perhaps the government's) significant financial investment in the
research, and the resulting data is persuasive enough to pass muster with
the multiple entities involved in compendia development. 44 While the
compendia may be the best compilations of empirical information
currently available for purposes of making decisions about appropriate
drug use, they are neither representative of how doctors, physician
assistants, and nurse practitioners prescribe nor how patients respond
outside of a controlled research setting. 45 In adopting the compendia as

the standard for "medically accepted indications," Congress conflated
science with medicine. In doing so, it disconnected outpatient prescription drug coverage from actual medical practice and individual patients
(who, as discussed in more detail below in Part III, may or may not be
represented in the clinical studies informing the FDA and compendia). 46
As Robin Feldman observed, "Science begins with observations and
theories that are rationally acceptable and well supported, which is
something far less than certain and infallible. Ignoring these qualifications, law tries to translate science into social and legal conclusions
without understanding the perils of that translation. "47 In the context of
Medicare Part D and Medicaid outpatient prescription drug coverage,
one such peril of that translation is a disconnection between medical
practice and the so-called "medically accepted indications." This disconnection, in turn, provides prescribers and pharmacists reason to question
the legitimacy of coverage denials based solely upon lack of FDA or
compendia recognition. 48

39.

See generally U.S. Gov'T ACCOUNTABILITY OFFICE, NEW DRUG
DEVELOPMENT: SCIENCE, BUSINESS, REGULATORY, AND INTELLECTUAL
PROPERTY ISSUES CITED AS HAMPERING DRUG DEVELOPMENT EFFORTS
(2006).

40.

MCKINNEY ET AL., supra note 24, at 3.

41.

Medicare Program; Medicare Prescription Drug Benefit, 74 Fed. Reg.
61,738, 61,901-02 (Nov. 25, 2009) (codified as amended at scattered parts
of 42 C.F.R.).

42.

OIG PART D REIMBURSEMENT REPORT, supra note 2, at 3.

43.

"It found that the compendia often did not cite the most current or best
performed clinical trials as part of their evidence base. There were large
variations in whether, and how quickly, off-label indications were added to
the compendia included in the study." MCKINNEY ET AL., supra note 24, at
4.

44.

"By definition, drug compendia include information that has major
financial implications for drug manufacturers. Listing of a product in an
approved compendium confers a financial advantage to industry." Id. at 6.
"Multiple parties are affected by decisions made during the development of
drug compendia. These parties include the public, health care providers,
pharmaceutical companies, private insurers, com:pe11dia staff, editorial
boards of compendia, and compendia publishers." Id. at 6-7.

45.

See Leslie L. Roos et al., Strengths and Weaknesses of Health Insurance
Data Systems for Assessing Outcomes, in 1 INST. OF MED., MODERN
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B. Transition from ICD-9-CM to ICD-10-CM: Diagnostic Coding in a
State of Flux

In addition to the systemic disconnect between medical practice and
"medically accepted indications," U.S. health care providers are in the
midst of a transition from one diagnostic coding system to another.
Pursuant to the Health Insurance Portability and Accountability Act of
1996 (HIPAA)'s provisions on "Administrative Simplification," the U.S.
health care system requires providers to use the diagnostic coding system
of International Classification of Diseases (ICD), Clinical Modification
(currently the ICD-9-CM, but the ICD-10-CM will go into effect on
October 1, 2015) when submitting electronic claims for diseases, injuries,
impairments, other health-related problems, their manifestations, and

METHODS OF CLINICAL INVESTIGATION 47, 50-51 (Annetine C. Gelijns ed.,
1990), available at http://www.nap.edu/openbook.php?record_id=1550.
46.

See, e.g., Layzer v. Leavitt, 770 F. Supp. 2d 579, 582 (S.D.N.Y. 2011)
(finding "the medical necessity of Cetrntide to treat [Mrs. Layzer's] ovarian
cancer ... has been firmly established ... No other drug on the Plan's
formulary is as effective as Cetrotide for treating [her]," but the lack of the
compendia listing barred Medicare Part D coverage of Cetrotide for her
cancer); Nievod v. Sebellius, 2013 WL 503089, at *4 (N.D. Cal. 2013)
("[T]he [administrative law judge] concluded that Plaintiff 'has such a rare
disease that it may not appear in the approved references and drug
compendia."' (citation omitted)).

47.

FELDMAN, supra note 37, at 140 (citing SHEILA JASANOFF, SCIENCE AT THE
BAR: LAW, SCIENCE & TECHNOLOGYIN AMERICA xiii-xiv (1995)).

48.

Here, the concept of "legitimacy" is understood to be "the belief that
authorities, institutions, and social arrangements are appropriate, proper,
and just." Tom R. Tyler, Psychological Perspectives on Legitimacy and
Legitimation, 57 ANN. REV. PSYCHOL. 375, 376 (2006).
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evidence - specifically the clinical trials underpinning the FDA approval
process for prescription drugs and compendia listings.
FDA-approved "on-label" indications are reflective of the patient
populations and endpoints studied in clinical trials funded and designed
by manufacturers with the FDA's review and approval. 39 The compendia
are "listing[s] of drugs ... which summarizeD evidence on the effectiveness of each drug . . . and provide0 information regarding clinical
indications and proper dosing. "40 The compendia are not overseen or
published by any governmental body but instead by various institutions
and traditional reference book publishing houses, 41 in different formats,
and updated at different intervals. 42
The "evidence" summarized in the compendia need not (and, in
many cases, does not) reflect the current or best clinical trials. 43 Further,
the generalizable knowledge summarized in the compendia is not
available simply because of its persuasive value as scientific evidence.
Rather, the evidence is limited to research deemed worth a manufacturer's (or perhaps the government's) significant financial investment in the
research, and the resulting data is persuasive enough to pass muster with
the multiple entities involved in compendia development. 44 While the
compendia may be the best compilations of empirical information
currently available for purposes of making decisions about appropriate
drug use, they are neither representative of how doctors, physician
assistants, and nurse practitioners prescribe nor how patients respond
outside of a controlled research setting. 45 In adopting the compendia as

the standard for "medically accepted indications," Congress conflated
science with medicine. In doing so, it disconnected outpatient prescription drug coverage from actual medical practice and individual patients
(who, as discussed in more detail below in Part III, may or may not be
represented in the clinical studies informing the FDA and compendia). 46
As Robin Feldman observed, "Science begins with observations and
theories that are rationally acceptable and well supported, which is
something far less than certain and infallible. Ignoring these qualifications, law tries to translate science into social and legal conclusions
without understanding the perils of that translation. "47 In the context of
Medicare Part D and Medicaid outpatient prescription drug coverage,
one such peril of that translation is a disconnection between medical
practice and the so-called "medically accepted indications." This disconnection, in turn, provides prescribers and pharmacists reason to question
the legitimacy of coverage denials based solely upon lack of FDA or
compendia recognition. 48

39.

See generally U.S. Gov'T ACCOUNTABILITY OFFICE, NEW DRUG
DEVELOPMENT: SCIENCE, BUSINESS, REGULATORY, AND INTELLECTUAL
PROPERTY ISSUES CITED AS HAMPERING DRUG DEVELOPMENT EFFORTS
(2006).

40.

McKINNEY ET AL., supra note 24, at 3.

41.

Medicare Program; Medicare Prescription Drug Benefit, 74 Fed. Reg.
61, 738, 61,901-02 (Nov. 25, 2009) (codified as amended at scattered parts
of 42 C.F.R.).

42.

OIG PART D REIMBURSEMENT REPORT, supra note 2, at 3.

43.

"It found that the compendia often did not cite the most current or best
performed clinical trials as part of their evidence base. There were large
variations in whether, and how quickly, off-label indications were added to
the compendia included in the study." MCKINNEY ET AL., supra note 24, at
4.

44.

"By definition, drug compendia include information that has major
financial implications for drug manufacturers. Listing of a product in an
approved compendium confers a financial advantage to industry." Id. at 6.
"Multiple parties are affected by decisions made during the development of
drug compendia. These parties include the public, health care providers,
pharmaceutical companies, private insurers, compe11dia staff, editorial
boards of compendia, and compendia publishers." Id. at 6-7.

45.

See Leslie L. Roos et al., Strengths and Weaknesses of Health Insurance
Data Systems for Assessing Outcomes, in 1 INST. OF MED., MODERN
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B. Transition from ICD-9-CM to ICD-10-CM: Diagnostic Coding in a
State of Flux

In addition to the systemic disconnect between medical practice and
"medically accepted indications," U.S. health care providers are in the
midst of a transition from one diagnostic coding system to another.
Pursuant to the Health Insurance Portability and Accountability Act of
1996 (HIPAA)'s provisions on "Administrative Simplification," the U.S.
health care system requires providers to use the diagnostic coding system
of International Classification of Diseases (ICD), Clinical Modification
(currently the ICD-9-CM, but the ICD-10-CM will go into effect on
October 1, 2015) when submitting electronic claims for diseases, injuries,
impairments, other health-related problems, their manifestations, and

METHODS OF CLINICAL INVESTIGATION 47, 50-51 (Annetine C. Gelijns ed.,
1990), available at http://www.nap.edu/openbook.php?record_id=1550.
46.

See, e.g., Layzer v. Leavitt, 770 F. Supp. 2d 579, 582 (S.D.N.Y. 2011)
(finding "the medical necessity of Cetrotide to treat [Mrs. Layzer's] ovarian
cancer ... has been firmly established ... No other drug on the Plan's
formulary is as effective as Cetrotide for treating [her]," but the lack of the
compendia listing barred Medicare Part D coverage of Cetrotide for her
cancer); Nievod v. Sebellius, 2013 WL 503089, at *4 (N.D. Cal. 2013)
("[T]he [administrative law judge] concluded that Plaintiff 'has such a rare
disease that it may not appear in the approved references and drug
compendia."' (citation omitted)).

47.

FELDMAN, supra note 37, at 140 (citing SHEILA JASANOFF, SCIENCE AT THE
BAR: LAW, SCIENCE & TECHNOLOGYJN AMERICA xiii-xiv (1995)).

48.

Here, the concept of "legitimacy" is understood to be "the belief that
authorities, institutions, and social arrangements are appropriate, proper,
and just." Tom R. Tyler, Psychological Perspectives on Legitimacy and
Legitimation, 57 ANN. REV. PSYCHOL. 375, 376 (2006).

221

HEALTH MATRIX· VOLUME 24 · 2014

HEALTH MATRIX· VOLUME 24 · 2014

Medicare Part D, Medicaid, E-Prescribing, ICD-101 & Public Health

Medicare Part D, Medicaid, E-Prescribing ICD-10 & Pubb:c Health

causes of injury, disease, impairment, or other health-related problems. 49
The ICD was initially developed by the World Health Organization
(WHO) as a means to classify causes of death. 50 Relying heavily on the
WHO's work, the U.S. Centers for Disease Control and Prevention
(CDC) National Center for Health Statistics developed a clinical modification of the classification to include morbidity (or non-fatal disease)
purposes, the ICD-9-CM (soon to be the ICD-10-CM). 51
The ICD-10-CM is made up of approximately 70,000 diagnosis codes
comprised of three to seven alphanumeric characters, a significant
expansion in detail and precision from the approximately 14,500 diagnosis codes comprising the ICD-9-CM. 52 This expansion was meant to
address the ICD-9-CM's inability to accommodate new codes for diagnoses and procedures that have been added to the health care repertoire
since its inception in 1979. 53 The ICD-10-CM provides more information

and detail within the codes than ICD-9-CM, including "more detail on
socioeconomics, ambulatory care conditions, problems related to lifestyle,
and the results of screening tests. "54
Even though diagnostic information is necessary for enforcement of
the Medicare Part D and Medicaid coverage laws, the ICD-10-CM
coding system may not be sufficient for all coverage determinations.
While many of the codes signify a single diagnosis, some codes (known
as "combination codes") in both the ICD-9-CM and ICD-10-CM contain
more than one diagnosis. 55 Few, if any, prescription drugs are indicated
for multiple, concurrent diagnoses. In addition, the ICD-10-CM codes
may not reflect the level of diagnostic particularity reflected in either the
on-label or compendia indications. For example,
[E]ven if diagnosis information were available on both the prescription and the claim, sponsors may not be able to ascertain that the
prescribed drug was used for a medically accepted indication using
current coding standards. For example, the drug Zelboraf (vemurafenib)
is only on-label, on-compendia for a specific type of melanoma (BRAF
V6003 mutation positive). The diagnosis information would not be
detailed enough to determine whether the patient has a BRAF V6003
mutation, as the International Classification of Diseases (ICDlO) does
not specify that level of granularity (e.g., ICDlO for malignant melanoma of trunk is C43.5). Thus the medically-accepted indication in the
compendia may rely on information below the level of coding in ICDlO.

49.

Protecting Access to Medicare Act of 2014, Pub. L. No. 113-93, § 212, 128
Stat. 1040, 1047 (2014); 45 C.F.R. § 162.1002 (2012); Health Insurance
Reform: Standards for Electronic Transactions, 65 Fed. Reg. 50,312, 50,324
(Aug. 17, 2000) (codified as amended at 42 C.F.R. 160, 162);
Administrative Simplification: Adoption of a Standard for a Unique Health
Plan Identifier; Addition to the National Provider Identifier Requirements;
and a Change to the Compliance Date for the International Classification
of Diseases, 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data
Code Sets, 77 Fed. Reg. 54,664 (Sept. 5, 2012). Drugs, by contrast, are
coded pursuant to "the National Drug Codes maintained and distributed
by the U.S. Department of Health and Human Services, in collaboration
with drug manufacturers." Health Insurance Reform: Standards for
Electronic Transactions, 65 Fed. Reg. 50,313, 50,324-25 (Aug. 17, 2000)
(codified at 45 C.F.R. §§ 160, 162).

50.

"The 11th revision of the classification has already started and will
continue until 2015." International Classification of Diseases, WORLD
HEALTH 0RG, http://www.who.int/classifications/icd/en/ (last visited Apr.
18, 2014).

51.

See Classifications of Diseases1 Functioning, and Disability, CTR. FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/nchs/icd.htm (last
updated June 19, 2013).

52.

CTRS. FOR DISEASE CONTROL AND PREVENTION, DIAGNOSIS CODE SET
GENERAL EQUIVALENCE MAPPINGS: ICD-10-CM TO ICD-9-CM AND ICD-9CM
TO
ICD-10-CM
(2013),
available
at
ftp://ftp.cdc.gov/pub /Health_Statistics /N CHS /Publications /ICD lOCM/2
013 / (select guest as username, download zip file).

53.

HIP AA Administrative Simplification: Modifications to Medical Data Code
Set Standards to Adopt ICD-10-CM and ICD-10-PCS, 74 Fed. Reg. 3328,
3330 (Jan. 16, 2009) (to be codified at 45 C.F.R § 162). See also Anna
Wilde Mathews, Walked into a Lamppost? Hurt While Crocheting? Help Is
on the Way: New Medical-Billing System Provides Precision; Nine Codes
for
Macaw
Mishaps,
WALL
ST.
J.
(Sept.
13,
2011),
http://online.wsj.com/article/SB1000142405311190410340457656074274602
1106.html ("To~ay, hospitals and doctors use a system of about 18,000
codes to descnbe medical services in bills they send to insurers.
Apparently, that doesn't allow for quite enough nuance. A new federally
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1

56

Even with its limitations, though, the ICD coding system remains
the diagnostic coding system for federal health care billing and the
mandated version will expand the number to around 140,000-adding
codes that describe precisely what bone was broken, or which artery is
receiving a stent. It will also have a code for recording that a patient's
injury occurred in a chicken coop. Indeed, health plans may never again
wonder where a patient got hurt. There are codes for injuries in opera
houses, art galleries, squash courts and nine locations in and around a
mobile home, from the bathroom to the bedroom.").
54.

Health Insurance Reform: Modifications to the Health Insurance
Portability and Accountability Act (HIPAA) Electronic Transaction
Standards, 74 Fed. Reg. 3296, 3330 (Jan. 16, 2009) (codified at 45 C.F.R. §
162).

55.

Some examples provided by the CDC include a combination code that
includes both ((a chronic condition [and] a current acute manifestation, as
in ICD-9 code 250.21 Diabetes with hyperosmolarity, type I (juvenile type),
not stated as uncontrolled , .. a combination code that ... consists of two
acute conditions found together, as in ICD-10 code R65.21 Severe sepsis
with septic shock, or a combination code that consists of an acute condition
and its external cause, as in I-10 code T58.01 Toxic effect of carbon
monoxide from motor vehicle exhaust, accidental (unintentional)." CTRS.
FOR DISEASE CONTROL AND PREVENTION' supra note 52, at 3.

56.

OIG PART D REIMBURSE.MENT REPORT, supra note 2, at 8-9.
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causes of injury, disease, impairment, or other health-related problems. 49
The ICD was initially developed by the World Health Organization
(WHO) as a means to classify causes of death. 50 Relying heavily on the
WHO's work, the U.S. Centers for Disease Control and Prevention
(CDC) National Center for Health Statistics developed a clinical modification of the classification to include morbidity (or non-fatal disease)
purposes, the ICD-9-CM (soon to be the ICD-10-CM). 51
The ICD-10-CM is made up of approximately 70,000 diagnosis codes
comprised of three to seven alphanumeric characters, a significant
expansion in detail and precision from the approximately 14,500 diagnosis codes comprising the ICD-9-CM. 52 This expansion was meant to
address the ICD-9-CM's inability to accommodate new codes for diagnoses and procedures that have been added to the health care repertoire
since its inception in 1979. 53 The ICD-10-CM provides more information

and detail within the codes than ICD-9-CM, including "more detail on
socioeconomics, ambulatory care conditions, problems related to lifestyle,
and the results of screening tests. "54
Even though diagnostic information is necessary for enforcement of
the Medicare Part D and Medicaid coverage laws, the ICD-10-CM
coding system may not be sufficient for all coverage determinations.
While many of the codes signify a single diagnosis, some codes (known
as "combination codes") in both the ICD-9-CM and ICD-10-CM contain
more than one diagnosis. 55 Few, if any, prescription drugs are indicated
for multiple, concurrent diagnoses. In addition, the ICD-10-CM codes
may not reflect the level of diagnostic particularity reflected in either the
on-label or compendia indications. For example,
[E]ven if diagnosis information were available on both the prescription and the claim, sponsors may not be able to ascertain that the
prescribed drug was used for a medically accepted indication using
current coding standards. For example, the drug Zelboraf (vemurafenib)
is only on-label, on-compendia for a specific type of melanoma (BRAF
V6003 mutation positive). The diagnosis information would not be
detailed enough to determine whether the patient has a BRAF V6003
mutation, as the International Classification of Diseases (ICDlO) does
not specify that level of granularity (e.g., ICDlO for malignant melanoma of trunk is C43.5). Thus the medically-accepted indication in the
compendia may rely on information below the level of coding in ICDlO.

49.

Protecting Access to Medicare Act of 2014, Pub. L. No. 113-93, § 212, 128
Stat. 1040, 1047 (2014); 45 C.F.R. § 162.1002 (2012); Health Insurance
Reform: Standards for Electronic Transactions, 65 Fed. Reg. 50,312, 50,324
(Aug. 17, 2000) (codified as amended at 42 C.F.R. 160, 162);
Administrative Simplification: Adoption of a Standard for a Unique Health
Plan Identifier; Addition to the National Provider Identifier Requirements;
and a Change to the Compliance Date for the International Classification
of Diseases, 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data
Code Sets, 77 Fed. Reg. 54,664 (Sept. 5, 2012). Drugs, by contrast, are
coded pursuant to "the National Drug Codes maintained and distributed
by the U.S. Department of Health and Human Services, in collaboration
with drug manufacturers." Health Insurance Reform: Standards for
Electronic Transactions, 65 Fed. Reg. 50,313, 50,324-25 (Aug. 17, 2000)
(codified at 45 C.F.R. §§ 160, 162).

50.

"The 11th revision of the classification has already started and will
continue until 2015." International Classification of Diseases, WORLD
HEALTH 0RG, http://www.who.int/classifications/icd/en/ (last visited Apr.
18, 2014).

51.

See Classifications of Diseases, Functioning, and Disability, CTR. FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/nchs/icd.htm (last
updated June 19, 2013).

52.

CTRS. FOR DISEASE CONTROL AND PREVENTION, DIAGNOSIS CODE SET
GENERAL EQUIVALENCE MAPPINGS: ICD-10-CM TO ICD-9-CM AND ICD-9CM
TO
ICD-10-CM
(2013),
available
at
ftp://ftp.cdc.gov/ pub /Health_Statistics /N CHS /Publications /ICD lOCM/2
013 / (select guest as username, download zip file).

53.

HIP AA Administrative Simplification: Modifications to Medical Data Code
Set Standards to Adopt ICD-10-CM and ICD-10-PCS, 74 Fed. Reg. 3328,
3330 (Jan. 16, 2009) (to be codified at 45 C.F.R § 162). See also Anna
Wilde Mathews, Walked into a Lamppost? Hurl While Crocheting? Help Is
on the Way: New Medical-Billing System Provides Precision; Nine Codes
for
Macaw
Mishaps,
WALL
ST.
J.
(Sept.
13,
2011),
http://online.wsj.com/article/SB1000142405311190410340457656074274602
1106.html ("Today, hospitals and doctors use a system of about 18,000
codes to describe medical services in bills they send to insurers.
Apparently, that doesn't allow for quite enough nuance. A new federally
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56

Even with its limitations, though, the ICD coding system remains
the diagnostic coding system for federal health care billing and the
mandated version will expand the number to around 140,000-adding
codes that describe precisely what bone was broken, or which artery is
receiving a stent. It will also have a code for recording that a patient's
injury occurred in a chicken coop. Indeed, health plans may never again
wonder where a patient got hurt. There are codes for injuries in opera
houses, art galleries, squash courts and nine locations in and around a
mobile home, from the bathroom to the bedroom.").
54.

Health Insurance Reform: Modifications to the Health Insurance
Portability and Accountability Act (HIP AA) Electronic Transaction
Standards, 74 Fed. Reg. 3296, 3330 (Jan. 16, 2009) (codified at 45 C.F.R. §
162).

55.

Some examples provided by the CDC include a combination code that
includes both "a chronic condition [and] a current acute manifestation, as
in ICD-9 code 250.21 Diabetes with hyperosmolarity, type I (juvenile type),
not stated as uncontrolled , .. a combination code that ... consists of two
acute conditions found together, as in ICD-10 code R65.21 Severe sepsis
with septic shock, or a combination code that consists of an acute condition
and its external cause, as in I-10 code T58.01 Toxic effect of carbon
monoxide from motor vehicle exhaust, accidental (unintentional)." CTRS.
FOR DISEASE CONTROL AND PREVENTION, supra note 52, at 3.

56.

OIG PART D REIMBURSEMENT REPORT, supra note 2, at 8-9.
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primary data point for determining appropriate coverage in the context
of Medicare Part B reimbursement of prescription drugs. 57 Extending use
of ICD-10-CM to coverage determinations for Part D and Medicaid
would be consistent with the existing Part B policy but hardly perfect in
its ability to communicate accurately the complexity of individualized
medical practice.
While a number of studies have found the transition from ICD-9 to
ICD-10 to be fairly smooth in terms of maintaining data quality, 58 these
studies have been limited to inpatient hospital systems (in Australia and
Canada) rather than reflective of outpatient coding practices in the
United States. The new code "represents a significant break from ICD-9CM, "59 and the transition to ICD-10-CM will come with a learning curve
for prescribers and pharmacists alike. Providers in smaller (primarily
outpatient) practice settings have been slower to adapt to the pending
transition from ICD-9-CM to ICD-10-CM. 60 It remains to be seen
whether the transition will go smoothly in the U.S, although a preliminary study suggests at least a third of initial ICD-10 coding in the U.S.
will be inaccurate. 61

As the critical data point used to determine whether a particular
prescription is for a "medically accepted indication," any additional
uncertainty created by the transition to ICD-10-CM will likely increase
the perceived gap (if not the actual gap) between medical practice and
"medically accepted indications," especially for prescribers and pharmacists working in smaller practices. Even so, the potential public health
benefits of including the diagnosis codes on outpatient prescriptions
described in Part III below outweigh the limitations of the coding or
perceived gap, but only if strict enforcement of the coverage law is
suspended until prescribers and pharmacists have gotten accustomed to
and accepted the new coding system.

57.

See, e.g., MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.6
("The Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 provides coverage of intravenous immune globulin (IVIG) for the
treatment of primary immune deficiency diseases (ICD-9 diagnosis codes
219.04, 219.05, 219.06, 219.12, and 219.2) in the home." (emphasis
added)).

58.

See Toni Henderson et al., Quality of Diagnosis and Procedure Coding in
ICD-10 Administrative Data, 44 MED. CARE 1011, 1016 (2006); Rude Quan
et al., Assessing Validity of ICD-9-CM and ICD-10 Administrative Data in
Recording Clinical Conditions in a Unique Dually Coded Database, 43
HEALTH SERV. RES. 1424, 1437 (2008).

59.

Steven J. Steindel, Taking ICD-10-CM in Parts, J. AM. HEALTH INFO.
MGMT. Ass'N. (2011), http:/ /journal.ahima.org/2011/01/01/taking-icd-10cm-in-parts/.

60.

Administrative Simplification: Adoption of a Standard for a Unique Health
Plan Identifier; Addition to the National Provider Identified Requirements;
and a Change to the Compliance Date for the International Classification
of Diseases 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data
Code Sets, 77 Fed. Reg. 54664, 54665 (Sept. 5, 2012) (to be codified at 45
C.F.R. 162) (citing KETCHUM INC., VERSION 5010 AND ICD-10 READINESS
ASSESSMENT: CONDUCTED AMONG HEALTH CARE PROVIDERS, PAYER.SAND
VENDORS FOR. THE CENTERS FOR MEDICARE & MEDICAID SERVICES (2011)
available
at
http://www.ems.gov/Medicare/ Coding/ICD 10 /Downloads/ReadinessAsses
smentSummary-.pdf)).

61.

HEALTHCARE INFO. AND MGMT. SYS. Soc'y & W ORKGROUP FOR ELEC. DATA
INTERCHANGE, ICD-10 NATIONAL PILOT PROGRAM: OUTCOMES REPORT 17
(2013),
available
at
http://www.himss.org/files/HIMSSorg/Content/files/ICDlO_NPP_Outcomes_Report.pdf ("The average accuracy of the testing
facility coders was 63%.").
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C. Incentives for Prescribers and Pharmacists to Misrepresent Patient
Diagnoses

With the disconnect between "medical acceptance" and "scientific
acceptance," as well as the uncertainty inherent in the transition from
ICD-9-CM to ICD-10-CM, the use of diagnostic information for billing
and reimbursement of outpatient prescription drugs (or denials thereof)
may create incentives for prescribers and pharmacists to misrepresent
patient diagnoses on prescriptions and claims for reimbursement. 62
The role of a third-party payor as the gatekeeper to treatment can
put health care providers in an ethical dilemma where they are asked to
choose between truth-telling (i.e., accurately describing the patient
diagnosis and prescribed treatment when submitting bills for services
and products) and effectively treating their patients when the effective
treatment is not covered by the payor (i.e., when the treatment is truly
medically accepted but still not found on the FDA-approved label or in
the compendia). 63 This dilemma exists especially for providers who treat
patients living on limited and fixed incomes - a majority of the beneficiaries of Medicare and Medicaid-where out-of-pocket payment is not a
viable option for patients. 64 Strict enforcement of the Medicare Part D
62.

Peter Jaret, Mining Electronic Records for Revealing Health Data, N.Y.
TIMES
(Jan.
14,
2013),
http://www.nytimes.com/2013/01/15/health/mining-electronic-records-forrevealing-health-data.html ("The information entered into a medical record
may be wrong, and diagnostic codes are notoriously unreliable, according
to Dr. Tatonetti, partly because they are also used for billing.").

63.

Off-label use of drugs unsupported by strong clinical evidence is quite
common in oncology and neuropsychiatry generally, as well as in treating
the frail elderly, very young children, high-risk pregnant women, and
patients with extremely rare diseases. Kesselheim, supra note 3, at 234-38.

64.

Pursuant to the Affordable Care Act's revisions to the Medicaid program,
Medicaid eligibility is contingent on an annual income of less than 1333
the federal poverty level - $15,281.70 for an individual or $31,321 for a
family of four. See Medicaid Program: Eligibility Changes Under the
Affordable Care Act of 2010, 77 Fed. Reg. 17,143, 17,145 (Mar. 23, 2012)
(codified at 42 C.F.R. §§ 431, 435, 457); Annual Update of the HHS
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primary data point for determining appropriate coverage in the context
of Medicare Part B reimbursement of prescription drugs. 57 Extending use
of ICD-10-CM to coverage determinations for Part D and Medicaid
would be consistent with the existing Part B policy but hardly perfect in
its ability to communicate accurately the complexity of individualized
medical practice.
While a number of studies have found the transition from ICD-9 to
ICD~lO to be fairly smooth in terms of maintaining data quality, 58 these
studies have been limited to inpatient hospital systems (in Australia and
Canada) rather than reflective of outpatient coding practices in the
United States. The new code "represents a significant break from ICD-9CM,"59 and the transition to ICD-10-CM will come with a learning curve
for prescribers and pharmacists alike. Providers in smaller (primarily
outpatient) practice settings have been slower to adapt to the pending
transition from ICD-9-CM to ICD-10-CM. 60 It remains to be seen
whether the transition will go smoothly in the U.S, although a preliminary study suggests at least a third of initial ICD-10 coding in the U.S.
will be inaccurate. 61
57.

See, e.g., MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.6
("The Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 provides coverage of intravenous immune globulin (IVIG) for the
treatment of primary immune deficiency diseases (ICD-9 diagnosis codes
279.04, 279.05, 279.06, 279.12, and 279.2) in the home." (emphasis
added)).

58.

See Toni Henderson et al., Quality of Diagnosis and Procedure Coding in
ICD-10 Administrative Data, 44 MED. CARE 1011, 1016 (2006); Rude Quan
et al., Assessing Validity of ICD-9-CM and ICD-10 Administrative Data in
Recording Clinical Conditions in a Unique Dually Coded Database, 43
HEALTH SERV. RES. 1424, 1437 (2008).

59.

Steven J. Steindel, Taking ICD-10-CM in Parts, J. AM. HEALTH INFO.
MGMT. Ass'N. (2011), http://journal.ahima.org/2011/0l/01/taking-icd-10cm-in-parts/.

60.

Administrative Simplification: Adoption of a Standard for a Unique Health
Plan Identifier; Addition to the National Provider Identified Requirements;
and a Change to the Compliance Date for the International Classification
of Diseases 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data
Code Sets, 77 Fed. Reg. 54664, 54665 (Sept. 5, 2012) (to be codified at 45
C.F.R. 162) (citing KETCHUM INC., VERSION 5010 AND ICD-10 READINESS
ASSESSMENT: CONDUCTED AMONG HEALTH CARE PROVIDERS, PAYERS AND
VENDORS FOR THE CENTERS FOR MEDICARE & MEDICAID SERVICES (2011)
available
at
http://www.ems.gov/Medicare/ Coding/ICDlO /Downloads/ReadinessAsses
smentSummary-.pdf)).

61.

HEALTHCARE INFO. AND MGMT. SYS. Soc'y & WORKGROUP FOR ELEC. DATA
INTERCHANGE, ICD-10 NATIONAL PILOT PROGRAM: OUTCOMES REPORT 17
available
at
(2013),
http://www.himss.org/files/HIMSSorg/Content/files/ICDlO_NPP_Outcomes_Report.pdf ("The average accuracy of the testing
facility coders was 633.").
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As the critical data point used to determine whether a particular
prescription is for a "medically_ ~ccepted indication,''. a~y ad_ditional
uncertainty created by the trans1t10n to ICD-10-CM will likely mcrease
the perceived gap (if not the actual gap) between medical practice and
"medically accepted indications," especially for prescribers and pharmacists working in smaller practices. Even so, the potential public health
benefits of including the diagnosis codes on outpatient prescriptions
described in Part III below outweigh the limitations of the coding or
perceived gap, but only if strict enforcement of the coverage law is
suspended until prescribers and pharmacists have gotten accustomed to
and accepted the new coding system.
C. Incentives for Prescribers and Pharmacists to Misrepresent Patient
Diagnoses
With the disconnect between "medical acceptance" and "scientific
acceptance," as well as the uncertainty inherent in the transition from
ICD-9-CM to ICD-10-CM, the use of diagnostic information for billing
and reimbursement of outpatient prescription drugs (or denials thereof)
may create incentives for prescribers and pharmacists to misrepresent
patient diagnoses on prescriptions and claims for reimbursement. 62
The role of a third-party payor as the gatekeeper to treatment can
put health care providers in an ethical dilemma where they are asked to
choose between truth-telling (i.e., accurately describing the patient
diagnosis and prescribed treatment when submitting bills for services
and products) and effectively treating their patients when the effective
treatment is not covered by the payor (i.e., when the treatment is truly
medically accepted but still not found on the FDA-approved label or in
the compendia). 63 This dilemma exists especially for providers who treat
patients living on limited and fixed incomes - a majority of the beneficiaries of Medicare and Medicaid - where out-of-pocket payment is not a
viable option for patients. 64 Strict enforcement of the Medicare Part D
62.

Peter Jaret, Mining Electronic Records for Revealing Health Data, N.Y.
TIMES
(Jan.
14,
2013),
http://www.nytimes.com/2013/01/15/health/mining-electronic-records-forrevealing-health-data.html ("The information entered into a medical record
may be wrong, and diagnostic codes are notoriously unreliable, according
to Dr. Tatonetti, partly because they are also used for billing.").

63.

Off-label use of drugs unsupported by strong clinical evidence is quite
common in oncology and neuropsychiatry generally, as well as in treating
the frail elderly, very young children, high-risk pregnant women, and
patients with extremely rare diseases. Kesselheim, supra note 3, at 234-38.

64.

Pursuant to the Affordable Care Act's revisions to the Medicaid program,
Medicaid eligibility is contingent on an annual income of less than 1333
the federal poverty level - $15,281. 70 for an individual or $31,321 for a
family of four. See Medicaid Program: Eligibility Changes Under the
Affordable Care Act of 2010, 77 Fed. Reg. 17,143, 17,145 (Mar. 23, 2012)
(codified at 42 C.F.R. §§ 431, 435, 457); Annual Update of the HHS
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statute (and many states' Medicaid statutes) would significantly limit
outpatient prescription drug coverage for the many medically accepted
uses with little scientific evidence to support them. As a result, many
patients would no longer be able to access their prescribed medications;
that is, unless their prescribers or pharmacists decided that the patients'
best interests were served by using inaccurate, but otherwise covered,
diagnoses on prescriptions and claims. There are a number of characteristics of a strict enforcement policy that would make diagnostic
miscoding more justifiable for prescribers and pharmacists concerned
about patients' inability to access the most effective treatment.
First, the most likely immediate outcome of miscoding (as seen from
the prescriber or pharmacist's perspective) would be better, or at least
sustained, patient health - a favorable outcome. Decisions resulting in
favorable outcomes are more likely to be judged as good than those with
poor outcomes (such as a decline in patient health due to lack of
treatment). 65 Second, the people most likely to be harmed by accurately
reporting diagnoses under a strictly enforced Medicare Part D coverage
law (again, from the prescriber and pharmacist's perspective) will be the
patients denied treatment - identifiable victims. Identifiable victims are
more likely to create an empathic response on the part of prescribers and
pharmacists than the "statistical victims" of miscoding - the taxpayers
or beneficiaries of other governmental programs denied funding due to
rising health care costs. 66 Third, coverage denials, especially where a

treatment was previously paid for (albeit in contravention of the
coverage law), are inherently perceived as losses to patients and providers, increasing the likelihood of misrepresentation by providers as a
means of avoiding the loss. 67 Lastly, rationalizations for miscoding are
especially likely where prescribers and pharmacists see their misrepresentations as beneficial for their patients who, but for their financial
circumstances, would be able to access the treatment. 68 Prescribers and
pharmacists will need to see denials of coverage as legitimate or else the
perceived illegitimacy of the denials may justify misrepresentation of
diagnostic information in order to secure federal payment for patients
otherwise unable to pay for their prescriptions. 69
As a result, a federal health care system in which truthful reporting
of diagnostic information results in a loss of coverage, and accordingly a
loss of treatment, would likely encourage prescribers and pharmacists to

Poverty Guidelines, 78 Fed. Reg. 5182, 5183 (Jan. 24, 2013). Likewise, the
majority of Medicare beneficiaries live on modest incomes, with a median
annual income of $22,800. JULIETTE CUBANSKI ET AL., KAISER FAMILY
FOUND., MEDICARE CHARTBOOK 15 (4th ed. 2010), available at
http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8103.pdf.
65.

66.

When evaluating decisions, a "bad outcome" (the visible result of a
decision) as a result of a particular decision, such as a decline in health, is
often attributed to "bad decision making." See Jonathan Baron & John C.
Hershey, Outcome Bias in Decision Evaluation, 54 J. PERSONALITY AND
Soc. PSYCHOL. 569, 569-70 (1988). Similarly, to the extent that good
outcomes are perceived as the result of good decision making and a good
health outcome is understood to be dependent on a particular treatment, a
deCision to ensure access to the treatment will likely be considered "good."
Id. at 569. See also Francesca Gino et al., Nameless + Harmless =
Blameless: When Seemingly Irrelevant Factors Influence Judgment of
(Un)ethical Behavior, 111 0RG. BEHAV. & HUM. DECISION PROCESSES 93
96 (2010) (noting people tend to judge behavior as more unethical whe~
the behavior leads to a negative rather than positive outcome).
The most important factor in the disparate treatment between identifiable
and statistical victims appears to be the perception that a high proportion
of the identifiable victims "can be saved," as compared to the uncertainty
of "saving" the unknown number of adversely affected taxpayers or
beneficiaries of other government programs denied funding. Karen E. Jenni
& George Lowenstein, Explaining the "Identifiable Victim Effect," 14 J.
RISK & UNCERTAINTY 235, 254 (1997). See also Gino et al., supra note 65,
at 96 (noting that people tend to judge behavior as more unethical when
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identifiable vs. unidentifiable victims are involved). The identifiable victim
effect may be counteracted, however, where the individual is perceived to
be responsible for her situation and thus no longer a "victim." Deborah A.
Small & George A. Lowenstein, Helping a Victim or Helping the Victim:
Altruism and Identifiability, 26 J. RISK & UNCERTAINTY 5, 14 (2003).
67.

A feeling of falling short of one's potential success, as doctors, physician
assistants, and nurses may have when their patients' health declines due to
a perceived arbitrary coverage determination, can motivate cheating.
Jessica S. Cameron & Dale T. Miller, Ethical Standards in Gain Versus
Loss Frames, in PSYCHOLOGICAL PERSPECTIVES ON ETHICAL BEHAVIOR AND
DECISION MAKING 91, 100 (David De Cremer ed., 2009). Similarly, cheating
may also be prompted by the frustration felt when "honest effort" will not
achieve what is perceived to be "deserved." Id.

68.

"[P]eople tend to discount the wrongness of dishonest actions when those
actions restore equity than when they do not." Francesca Gino & Lamar
Pierce, Lying to Level the Playing Field: Why People May Dishonestly Help
or Hurt Others to Create Equity, 95 J. Bus. ETHICS 89, 100 (2011). In the
case where the actor perceives herself to be better situated than another
person (likely a common situation for prescribers and pharmacists treating
Medicare and Medicaid patients), she often experiences guilt, which in turn
motivates her to act dishonestly to help the other person. Id. at 92. See
also Francesca Gino & Lamar Pierce, Robin Hood Under the Hood:
Wealth-Based Discrimination in fllicit Customer Help, 21 0RG. SCI. 1176,
1176 (2010); Francesca Gino & Lamar Pierce, Dishonesty in the Name of
Equity, 20 PSYCHOL. SCI. 1153, 1159 (2009).

69.

Tyler, supra note 48, at 379 ("Consistent with the longstanding arguments
of legitimacy theories, recent studies suggest that having legitimacy
facilitates the ability to gain decision acceptance and to promote rulefollowing. "). See also Am. Med. Ass'n, Code of Med. Ethics, Op. 1.02 The Relation of Law and Ethics (1994), available at http://www.amaassn.org/ ama/ pub/ physician-resources/ medical-ethics/ code-medicalethics. page ("In some cases, the law mandates unethical conduct. In
general, when physicians believe a law is unjust, they should work to
change the law. In exceptional circumstances of unjust laws, ethical
responsibilities should supersede legal obligations.").
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statute (and many states' Medicaid statutes) would significantly limit
outpatient prescription drug coverage for the many medically accepted
uses with little scientific evidence to support them. As a result, many
patients would no longer be able to access their prescribed medications;
that is, unless their prescribers or pharmacists decided that the patients'
best interests were served by using inaccurate, but otherwise covered,
diagnoses on prescriptions and claims. There are a number of characteristics of a strict enforcement policy that would make diagnostic
miscoding more justifiable for prescribers and pharmacists concerned
about patients' inability to access the most effective treatment.
First, the most likely immediate outcome of miscoding (as seen from
the prescriber or pharmacist's perspective) would be better, or at least
sustained, patient health - a favorable outcome. Decisions resulting in
favorable outcomes are more likely to be judged as good than those with
poor outcomes (such as a decline in patient health due to lack of
treatment). 65 Second, the people most likely to be harmed by accurately
reporting diagnoses under a strictly enforced Medicare Part D coverage
law (again, from the prescriber and pharmacist's perspective) will be the
patients denied treatment - identifiable victims. Identifiable victims are
more likely to create an empathic response on the part of prescribers and
pharmacists than the "statistical victims" of miscoding - the taxpayers
or beneficiaries of other governmental programs denied funding due to
rising health care costs. 66 Third, coverage denials, especially where a

treatment was previously paid for (albeit in contravention of the
coverage law), are inherently perceived as losses to patients and providers, increasing the likelihood of misrepresentation by providers as a
means of avoiding the loss. 67 Lastly, rationalizations for miscoding are
especially likely where prescribers and pharmacists see their misrepresentations as beneficial for their patients who, but for their financial
circumstances, would be able to access the treatment. 68 Prescribers and
pharmacists will need to see denials of coverage as legitimate or else the
perceived illegitimacy of the denials may justify misrepresentation of
diagnostic information in order to secure federal payment for patients
otherwise unable to pay for their prescriptions. 69
As a result, a federal health care system in which truthful reporting
of diagnostic information results in a loss of coverage, and accordingly a
loss of treatment, would likely encourage prescribers and pharmacists to

Poverty Guidelines, 78 Fed. Reg. 5182, 5183 (Jan. 24, 2013). Likewise, the
majority of Medicare beneficiaries live on modest incomes, with a median
annual income of $22,800. JULIETTE CUBANSKI ET AL., KAISER FAMILY
FOUND., MEDICARE CHARTBOOK 15 (4th ed. 2010), available at
http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8103.pdf.
65.

66.

When evaluating decisions, a "bad outcome" (the visible result of a
decision) as a result of a particular decision, such as a decline in health, is
often attributed to "bad decision making." See Jonathan Baron & John C.
Hershey, Outcome Bias in Decision Evaluation, 54 J. PERSONALITY AND
Soc. PSYCHOL. 569, 569-70 (1988). Similarly, to the extent that good
outcomes. are perceived as the result of good decision making and a good
health outcome is understood to be dependent on a particular treatment, a
dedsion to ensure access to the treatment will likely be considered "good."
Id. at 569. See also Francesca Gino et al., Nameless + Harmless =
Blameless: When Seemingly Irrelevant Factors Influence Judgment of
(Un)ethical Behavior, 111 0RG. BEHAV. & HUM. DECISION PROCESSES 93
96 (2010) (noting people tend to judge behavior as more unethical whe~
the behavior leads to a negative rather than positive outcome).
The most important factor in the disparate treatment between identifiable
and statistical victims appears to be the perception that a high proportion
of the identifiable victims "can be saved," as compared to the uncertainty
of "saving" the unknown number of adversely affected taxpayers or
beneficiaries of other government programs denied funding. Karen E. Jenni
& George Lowenstein, Explaining the "Identifiable Victim Effect," 14 J.
RISK & UNCERTAINTY 235, 254 (1997). See also Gino et al., supra note 65,
at 96 (noting that people tend to judge behavior as more unethical when
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identifiable vs. unidentifiable victims are involved). The identifiable victim
effect may be counteracted, however, where the individual is perceived to
be responsible for her situation and thus no longer a "victim." Deborah A.
Small & George A. Lowenstein, Helping a Victim or Helping the Victim:
Altruism and Identifiability, 26 J. RISK & UNCERTAINTY 5, 14 (2003).
67.

A feeling of falling short of one's potential success, as doctors, physician
assistants, and nurses may have when their patients' health declines due to
a perceived arbitrary coverage determination, can motivate cheating.
Jessica S. Cameron & Dale T. Miller, Ethical Standards in Gain Versus
Loss Frames, in PSYCHOLOGICAL PERSPECTIVES ON ETHICAL BEHAVIOR AND
DECISION MAKING 91, 100 (David De Cremer ed., 2009). Similarly, cheating
may also be prompted by the frustration felt when "honest effort" will not
achieve what is perceived to be "deserved." Id.

68.

"[P]eople tend to discount the wrongness of dishonest actions when those
actions restore equity than when they do not." Francesca Gino & Lamar
Pierce, Lying to Level the Playing Field: Why People May Dishonestly Help
or Hurt Others to Create Equity, 95 J. Bus. ETHICS 89, 100 (2011). In the
case where the actor perceives herself to be better situated than another
person (likely a common situation for prescribers and pharmacists treating
Medicare and Medicaid patients), she often experiences guilt, which in turn
motivates her to act dishonestly to help the other person. Id. at 92. See
also Francesca Gino & Lamar Pierce, Robin Hood Under the Hood:
Wealth-Based Discrimination in fllicit Customer Help, 21 ORG. Sc1. 1176,
1176 (2010); Francesca Gino & Lamar Pierce, Dishonesty in the Name of
Equity, 20 PSYCHOL. Ser. 1153, 1159 (2009).

69.

Tyler, supra note 48, at 379 ("Consistent with the longstanding arguments
of legitimacy theories, recent studies suggest that having legitimacy
facilitates the ability to gain decision acceptance and to promote rulefollowing. "). See also Am. Med. Ass'n, Code of Med. Ethics, Op. 1.02 The Relation of Law and Ethics (1994), available at http://www.amaassn.org/ ama/ pub /physician-resources/ medical-ethics/ code-medicalethics. page ("In some cases, the law mandates unethical conduct. In
general, when physicians believe a law is unjust, they should work to
change the law. In exceptional circumstances of unjust laws, ethical
responsibilities should supersede legal obligations.").
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tailor diagnoses for payment purposes rather than treatment purposes or
at least make justification of miscoding easier for individual prescribers
or pharmacists. Systemic miscoding would, in turn, significantly undermine the public safety benefits potentially gained through the more
thorough pharmacist review of outpatient prescriptions for medication
errors and increased drug safety surveillance efforts described in Part III.

Historically, the practice of pharmacy was limited to the making
(through a practice called compoun~i~g) and_ dispensing _of drugs V:ith
prescribers solely responsible for adv1smg patients on their appropriate
use.73 More recently, pharmacists have become, and continue to be,
recognized as highly educated, licensed professionals entrusted with
evaluating confidential patient information in order to dispense medications with both great treatment potential and great (even fatal) risk if
misused. 74
The practice of pharmacy, like the practices of medicine, nursing,
and law, is primarily governed by state law and includes not only
dispensing drugs and custom compounding medications for patients
contraindicated for commercially prepared products, but also consulting
(with both patients and prescribers) about the contents, therapeutic
values, interactions, and uses of any prescription drug; the review and
monitoring of a patient's drug therapy regimen; assisting the patient in
managing his or her drug therapy; and communicating with the patient's
prescribing health care provider in the event that the pharmacist or
patient has a question about a treatment regimen. 75 Indeed, the increas-

III.

How INCREMENTAL IMPLEMENTATION OF THE LAW

WOULD SUPPORT BOTH PATIENT SAFETY AND BETTER
MANAGEMENT OF FEDERAL HEALTH CARE FUNDS

Instead of relying, as suggested by CMS Administrator Donald Berwick, primarily on prior authorization strategies for drugs that are at
high risk for prescription without a medically accepted indication (or the
nearly impossible retrospective review), 70 I propose that CMS require
submission of ICD-10-CM codes for reimbursement of outpatient
prescription drug claims, but limit the current use of those codes for
pharmacist prescription review, not coverage denials. In doing so, CMS
would encourage more thorough real-time pharmacist review of prescriptions for patient safety purposes as well as truthful reporting of
diagnostic and prescribing habits for future pharmacosurveillance and
comparative effectiveness efforts. 71

73.

RICHARD R. ABOOD, PHARMACY PRACTICE AND THE LAW 324 (Jack
Bruggeman et al. eds., 4th ed. 2005).

74.

Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1123 (Ill. 2002)
(quoting Kirby v. Gen. Paving Co., 229 N.E.2d 777, 779 (Ill. App. Ct.
1967)) ("A duty to warn exists where there is unequal knowledge, actual or
constructive [of a dangerous condition], and the defendant[,] possessed of
such knowledge, knows or should know that harm might or could occur if
no warning is given."); Anonymous, 728 N .Y.S.2d at 338 (citing Lutz v.
Houck, 188 N.E. 274 (N.Y. 1933)) ("While the role of a pharmacist may
not equal that of a physician treating a patient, surely access and the right
to collect private medical information on one's customers does not make a
pharmacist merely 'the dispenser of a commercial product."'); Morgan v.
Wal-Mart Stores, Inc., 30 S.W.3d 455, 469 (Tex. Ct. App. 2000) ("[T]he
pharmacist's role has changed in the last few decades from a mere
dispenser of medication to a trusted professional who plays a vital role in
patient treatment."); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa.
Super. Ct. 1986) (rejecting the argument that a pharmacy is strictly a
warehouse of drugs and that a pharmacist should unquestionably obey the
written orders of physicians).

75.

The following state statutes define "practice of pharmacy," "practice of the
profession of pharmacy," and/or the scope of the practice of pharmacy.
ARIZ. REV. STAT. ANN. § 32-1901(69) (2012); ARK. CODE ANN. § 17-92101(16)(A) (West 2012); CAL. Bus. & PROF. CODE § 4052 (West 2013);
CONN. GEN. STAT. § 20-571(21) (2012); COLO. REV. STAT. ANN. § 12-42.5102(31) (West 2012); DEL. CODE ANN. tit. 24, § 2502(19) (2012); D.C. CODE
§ 3-1201.02(11)(A) (2012); FLA. STAT. ANN. § 465.003(13) (2012); GA.
CODE ANN. § 26-4-4 (2012); HAW. REV. STAT.§ 461-1 (2012); IDAHO CODE
ANN.§ 54-1704 (2012) (as amended by 2013 Idaho Laws Ch. 28 (H.B. 17),
2013 Idaho Laws Ch. 28 (H.B. 17)); 225 ILL. COMP. STAT. ANN. 85/3(d)
(2012); IND. CODE ANN. § 25-26-13-2 (West 2010 & Supp. 2012); IOWA
CODE ANN. § 155A.3(34) (West 2005 & Supp. 2013); KAN. STAT. ANN. §
65-1626a(b) (2002); KY. REV. STAT. ANN. § 315.010(19) (2011); LA. REV.

A. Role of Diagnosis in Pharmacists' Standard of Care

With the increasingly commercial nature of drug store chains and
grocery store pharmacy counters in the second half of the twentieth
century, pharmacists are often misunderstood to be glorified sales clerks
who merely count pills, but that understanding is simply not accurate. 72
70.

OIG PART D REIMBURSEMENT REPORT, supra note 2, at 9.

71.

By reframing the goal of accurate diagnostic coding from a mere billing
necessity to a critical step in preventing medication errors (a negative
outcome that can be avoided), this subtle change may significantly
influence truthful prescriber and pharmacist reporting behavior. Francesca
Gino & Joshua D. Margolis, Bringing Ethics Into Focus: How Regulatory
Focus and Risk Preferences Influence (Un)ethical Behavior, 115 ORG.
BEHAV. & HUM. DECISION PROCESSES 145, 154 (2011).

72.

Anonymous v. CVS Corp., 728 N.Y.S.2d 333, 337 (N.Y. Sup. Ct. 2001)
("Unlike in a traditional commercial transaction, pharmacists are required
to collect otherwise confidential medical information, and are obligated to
review that information before each prescription is dispensed." (citations
omitted)). Horner v. Spalitto, 1 S.W.3d 519, 524 (Mo. Ct. App. 1999)
("We agree that a physician typically is in a superior position to judge the
propriety of a particular patient's drug regimen, but this should not
relegate the pharmacist to the role of being merely an order filler."); Jones
v. Irvin, 602 F. Supp. 399, 400 (S.D. Ill. 1985) (citations omitted) (noting
"a pharmacist is not strictly liable under a products liability theory since
he is not a retailer").
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tailor diagnoses for payment purposes rather than treatment purposes or
at least make justification of miscoding easier for individual prescribers
or pharmacists. Systemic miscoding would, in turn, significantly undermine the public safety benefits potentially gained through the more
thorough pharmacist review of outpatient prescriptions for medication
errors and increased drug safety surveillance efforts described in Part III.

Historically, the practice of pharmacy was limited to the making
(through a practice called compoun~i~g) and_ dispensing _of drugs ':ith
prescribers solely responsible for advrnmg patients on their appropriate
use.73 More recently, pharmacists have become, and continue to be,
recognized as highly educated, licensed professionals entrusted with
evaluating confidential patient information in order to dispense medications with both great treatment potential and great (even fatal) risk if
misused. 74
The practice of pharmacy, like the practices of medicine, nursing,
and law, is primarily governed by state law and includes not only
dispensing drugs and custom compounding medications for patients
contraindicated for commercially prepared products, but also consulting
(with both patients and prescribers) about the contents, therapeutic
values, interactions, and uses of any prescription drug; the review and
monitoring of a patient's drug therapy regimen; assisting the patient in
managing his or her drug therapy; and communicating with the patient's
prescribing health care provider in the event that the pharmacist or
patient has a question about a treatment regimen. 75 Indeed, the increas-

III.

How INCREMENTAL IMPLEMENTATION OF THE LAW

WOULD SUPPORT BOTH PATIENT SAFETY AND BETTER
MANAGEMENT OF FEDERAL HEALTH CARE FUNDS

Instead of relying, as suggested by CMS Administrator Donald Berwick, primarily on prior authorization strategies for drugs that are at
high risk for prescription without a medically accepted indication (or the
nearly impossible retrospective review), 70 I propose that CMS require
submission of ICD-10-CM codes for reimbursement of outpatient
prescription drug claims, but limit the current use of those codes for
pharmacist prescription review, not coverage denials. In doing so, CMS
would encourage more thorough real-time pharmacist review of prescriptions for patient safety purposes as well as truthful reporting of
diagnostic and prescribing habits for future pharmacosurveillance and
comparative effectiveness efforts. 71

73.

RICHARD R. ABOOD, PHARMACY PRACTICE AND THE LAW 324 (Jack
Bruggeman et al. eds., 4th ed. 2005).

74.

Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1123 (Ill. 2002)
(quoting Kirby v. Gen. Paving Co., 229 N.E.2d 777, 779 (Ill. App. Ct.
1967)) ("A duty to warn exists where there is unequal knowledge, actual or
constructive [of a dangerous condition], and the defendant[,] possessed of
such knowledge, knows or should know that harm might or could occur if
no warning is given."); Anonymous, 728 N.Y.S.2d at 338 (citing Lutz v.
Houck, 188 N.E. 274 (N.Y. 1933)) ("While the role of a pharmacist may
not equal that of a physician treating a patient, surely access and the right
to collect private medical information on one's customers does not make a
pharmacist merely 'the dispenser of a commercial product.'"); Morgan v.
Wal-Mart Stores, Inc., 30 S.W.3d 455, 469 (Tex. Ct. App. 2000) ("[T]he
pharmacist's role has changed in the last few decades from a mere
dispenser of medication to a trusted professional who plays a vital role in
patient treatment."); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa.
Super. Ct. 1986) (rejecting the argument that a pharmacy is strictly a
warehouse of drugs and that a pharmacist should unquestionably obey the
written orders of physicians).

75.

The following state statutes define "practice of pharmacy," "practice of the
profession of pharmacy," and/or the scope of the practice of pharmacy.
ARIZ. REV. STAT. ANN. § 32-1901(69) (2012); ARK. CODE ANN. § 17-92101(16)(A) (West 2012); CAL. Bus. & PR.OF. CODE § 4052 (West 2013);
CONN. GEN. STAT. § 20-571(21) (2012); COLO. REV. STAT. ANN. § 12-42.5102(31) (West 2012); DEL. CODE ANN. tit. 24, § 2502(19) (2012); D.C. CODE
§ 3-1201.02(11)(A) (2012); FLA. STAT. ANN. § 465.003(13) (2012); GA.
CODE ANN. § 26-4-4 (2012); HAW. REV. STAT.§ 461-1 (2012); IDAHO CODE
ANN.§ 54-1704 (2012) (as amended by 2013 Idaho Laws Ch. 28 (H.B. 17),
2013 Idaho Laws Ch. 28 (H.B. 17)); 225 ILL. COMP. STAT. ANN. 85/3(d)
(2012); IND. CODE ANN. § 25-26-13-2 (West 2010 & Supp. 2012); IOWA
CODE ANN. § 155A.3(34) (West 2005 & Supp. 2013); KAN. STAT. ANN. §
65-1626a(b) (2002); KY. REV. STAT. ANN. § 315.010(19) (2011); LA. REV.

A. Role of Diagnosis in Pharmacists' Standard of Care

With the increasingly commercial nature of drug store chains and
grocery store pharmacy counters in the second half of the twentieth
century, pharmacists are often misunderstood to be glorified sales clerks
who merely count pills, but that understanding is simply not accurate. 72
70.

OIG PART D REIMBURSEMENT REPORT, supra note 2, at 9.

71.

By reframing the goal of accurate diagnostic coding from a mere billing
necessity to a critical step in preventing medication errors (a negative
outcome that can be avoided), this subtle change may significantly
influence truthful prescriber and pharmacist reporting behavior. Francesca
Gino & Joshua D. Margolis, Bringing Ethics Into Focus: How Regulatory
Focus and Risk Preferences Influence (Un)ethical Behavior, 115 ORG.
BEHAV. & HUM. DECISION PROCESSES 145, 154 (2011).

72.

Anonymous v. CVS Corp., 728 N.Y.S.2d 333, 337 (N.Y. Sup. Ct. 2001)
("Unlike in a traditional commercial transaction, pharmacists are required
to collect otherwise confidential medical information, and are obligated to
review that information before each prescription is dispensed." (citations
omitted)). Horner v. Spalitto, 1 S.W.3d 519, 524 (Mo. Ct. App. 1999)
("We agree that a physician typically is in a superior position to judge the
propriety of a particular patient's drug regimen, but this should not
relegate the pharmacist to the role of being merely an order filler."); Jones
v. Irvin, 602 F. Supp. 399, 400 (S.D. Ill. 1985) (citations omitted) (noting
"a pharmacist is not strictly liable under a products liability theory since
he is not a retailer").
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ing reliance on prescription drugs, and increasing number of prescription
drugs available for use has led many pharmacists to play a greater role
in coordinating drug therapy for patients than ever before.
In addition to the state laws regulating the practice of pharmacy,
federal law has relied heavily on pharmacists' professional standards in
structuring the federal health care delivery system (specifically in the
l~ws governing both Medicaid 76 and Medicare77) and regulation of drugs
(m the context of the federal Food, Drug and Cosmetic Act (FDCA)7s

and Controlled Substances Act). 79 To the extent that state laws governing the practice of pharmacy are not as rigorous as the federal
expectations, the federal statutes have created both regulatory and
statutory consequences for pharmacists who fall short of the federal
standards. 80
Despite the myriad state and federal laws governing the pharmacistpatient relationship, pharmacists have never had a general duty to warn
patients about the risks associated with prescription drugs; this duty to
warn has traditionally fallen instead into the realm of medicine (and
more recently nursing) than pharmacy. Like all professionals, though,
pharmacists are responsible for exercising due care in the course of their
practice. As explained below, adding diagnosis codes to prescriptions
would not affect the existing boundaries between the practices of
medicine, nursing, and pharmacy, but would likely increase the level of
care expected of pharmacists.

STAT. ANN. § 37:1164(41) (2007); ME. REV. STAT. tit. 32, § 13702-A (28)
(2012); MD. CODE ANN., HEALTH Occ. § 12-lOl(t)(l) (Supp. 2012); MICH.
COMP. LAWS ANN. § 333.17707(5) (West 2008); MINN. STAT. ANN. §
151.01(27) (West 2011 & Supp. 2013); Mrss. CODE ANN. § 73-21-73(bb)
(2012); Mo. ANN. STAT. § 338.010(1) (2012); 2013 Montana Laws 220
(codified with some differences in language at MONT. CODE ANN. § 37-7101(34) (2012)); NEB. REV. STAT. § 38-2837(1) (2012); NEV. REV. STAT.
ANN. § 639.0124 (West 2012); N.H. REV. STAT. ANN.§ 318:1(XIV) (2013);
N.J. REV. STAT.§ 45:14-41 (2013); N.M. STAT. ANN. § 61-ll-2(BB) (2012);
N.Y. EDUC. LAW § 6801(1) (2012); N.C. GEN. STAT. ANN. § 90-85.3(r)
(2012); N.D. CENT. CODE ANN. § 43-15-01(24) (2012); Omo REV. CODE
ANN.§ 4729.0l(B) (LexisNexis 2012); OKLA. STAT. ANN. tit. 59, § 353.1(28)
(West 2012); OR. REV. STAT. § 689.005(28) (2012); 63 PA. STAT. ANN.§
390-2(11) (West 2012); R.I. GEN. LAWS § 5-19.1-2 (2009 & Supp. 2012);
S.C. CODE ANN. § 40-43-30(44) (2012); S.D. CODIFIED LAWS § 36-11-2.2
(2012); TENN. CODE ANN. § 63-10-204(35)(A) (2010 & Supp. 2012); TEX.
Occ. CODE ANN. § 551.003(33) (West 2012); UTAH CODE ANN. § 58-17b102(54) (LexisNexis 2012 & Supp. 2013); VT. STAT. ANN. tit. 26, § 2022(14)
(2012); VA. CODE ANN.§ 54.1-3300 (West 2012); WASH. REV. CODE ANN.§
18.64.011(23) (2012); W. VA. CODE ANN.§ 30-5-3 (2012) (amended 2013);
Wrs. STAT. ANN.§ 450.01(16) (2012); WYO. STAT. ANN.§ 33-24-124 (2012).
76.

1. The Duty to W am Patients about Risks Generally Associated with
Prescription Drugs Would Remain with Prescribers, Not Pharmacists
State courts have traditionally, and quite consistently, held that a
pharmacist has no general duty to warn a customer of the risk of harm
that might be encountered from drugs which are accurately dispensed
upon a valid and legal prescription, 81 unless (1) the prescription itself
Administration's Mandate to Ensure Postmarketing Drug Safety, 306
JAMA 1595, 1595 (2011).
79.

As part of the Controlled Substances Act, "a pharmacist may not fill a
written order from a practitioner, appearing on its face to be a prescription
[for a controlled substance], if he knows the practitioner issued it in other
than the usual course of medical treatment." United States v. Hayes, 595
F.2d 258, 260 (5th Cir. 1979) (construing 21C.F.R§1306.04(a)). See also
21 U.S.C. § 829(e)(2) (2012) (noting a "valid prescription" is "a
prescription that is issued for a legitimate medical purpose in the usual
course of professional practice ... ").

80.

For example, it was a piece of federal legislation ( 0 BRA-90) 's articulating
conditions for state receipt of Medicaid funds that prompted widespread
adoption of prospective drug utilization review software by pharmaci~ts
nationwide. See Thomas R. Fulda et al., Current Status of Prospective
Drug Utilization Review, 10 J. OF MANAGED CARE PHARMACY 433 (2004);
see also United States v. Jae Gab Kim, 449 F.3d 933, 937 (9th Cir. 2006)
(sentencing a pharmacist to five months inc~rceration, three . yea:s
supervised release, and a $15,000 fine for sellmg pseudoephedrme m
violation of federal Controlled Substances Act and state law); United
States v. Munoz, 430 F.3d 1357, 1364 (11th Cir. 2005) (sentencing
defendant to ten months' imprisonment and a $10,000 fine for dispensing
drugs without a valid prescription in violation of FDCA).

81.

See Downing v. Hyland Pharmacy, 194 P.3d 944, 946 (Utah 2008) (quoting
Schaerrer v. Stewart's Plaza Pharmacy, 79 P .3d 922, 929 (Utah 2003))
("So long as a pharmacist's ability to distribute prescription drugs is
limited by the highly restricted, FDA-regulated drug distribution system in
this country, and a pharmacist cannot supply a patient with prescription

See,. e.g., 42 U.~·~· § 1396r-8(g)(2)(A)(ii) (2012) (conditioning federal
fund~n~ for Med~ca~d on states' establishing standards for counseling of

Medicaid beneficianes by pharmacists).
77.

78.

See, e.g., 42_ U.S.C. § 1395w-104(c)(2)(C)(i) (2012) (requiring "an annual
~omp:ehensive medication review" for each Medicare Part D beneficiary
.furmshed perso~- to-person or using telehealth technologies . . . by a
licensed pharmacist or other qualified provider").
The entire prescription drug regulatory system dating back to the Food
D:ug and Co~metic Act of 1938 depends squarely on pharmacists t~
withhold certam products until receipt of a valid prescription. 21 U.S.C. §
353 (2012). See also PETER BARTON HUTT ET AL., FOOD & DRUG LAW 490
(3d ed: 2007) ("[This section of the FDCA] relies upon state law to
determme what professional training is required for licensure to administer
prescription drugs."). More recently, however, the Food and Drug
Amend~ents Act of 2007 (FDAAA) also contemplates pharmacists'
~derl?omg product-specific certification and further limiting dispensing of
high-nsk products only in response to a valid prescription plus "evidence or
other documentation of safe-use conditions, such as laboratory test
results," or checking a product-specific registry as part of the Risk
Evaluation and Mitigation Strategies (REMS) system created by FDAAA.
Food&: Drug Amendments Act of 2007, 21U.S.C.§355-l(f)(3) (2012). See
also Dima M. Qato & G. Caleb Alexander, Improving the Food and Drug
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ing reliance on prescription drugs, and increasing number of prescription
drugs available for use has led many pharmacists to play a greater role
in coordinating drug therapy for patients than ever before.
In addition to the state laws regulating the practice of pharmacy,
federal law has relied heavily on pharmacists' professional standards in
structuring the federal health care delivery system (specifically in the
l~ws governing both Medicaid 76 and Medicare77) and regulation of drugs
(m the context of the federal Food, Drug and Cosmetic Act (FDCA)?s

and Controlled Substances Act). 79 To the extent that state laws governing the practice of pharmacy are not as rigorous as the federal
expectations, the federal statutes have created both regulatory and
statutory consequences for pharmacists who fall short of the federal
standards. 80
Despite the myriad state and federal laws governing the pharmacistpatient relationship, pharmacists have never had a general duty to warn
patients about the risks associated with prescription drugs; this duty to
warn has traditionally fallen instead into the realm of medicine (and
more recently nursing) than pharmacy. Like all professionals, though,
pharmacists are responsible for exercising due care in the course of their
practice. As explained below, adding diagnosis codes to prescriptions
would not affect the existing boundaries between the practices of
medicine, nursing, and pharmacy, but would likely increase the level of
care expected of pharmacists.

STAT. ANN. § 37:1164(41) (2007); ME. REV. STAT. tit. 32, § 13702-A (28)
(2012); MD. CODE ANN., HEALTH Occ. § 12-lOl(t)(l) (Supp. 2012); MICH.
COMP. LAWS ANN. § 333.17707(5) (West 2008); MINN. STAT. ANN. §
151.01(27) (West 2011 & Supp. 2013); MISS. CODE ANN. § 73-21-73(bb)
(2012); Mo. ANN. STAT. § 338.010(1) (2012); 2013 Montana Laws 220
(codified with some differences in language at MONT. CODE ANN. § 37-7101(34) (2012)); NEB. REV. STAT. § 38-2837(1) (2012); NEV. REV. STAT.
ANN. § 639.0124 (West 2012); N.H. REV. STAT. ANN.§ 318:l(XIV) (2013);
N.J. REV. STAT.§ 45:14-41 (2013); N.M. STAT. ANN.§ 61-11-2(BB) (2012);
N.Y. EDUC. LAW § 6801(1) (2012); N.C. GEN. STAT. ANN. § 90-85.3(r)
(2012); N.D. CENT. CODE ANN. § 43-15-01(24) (2012); Omo REv. CODE
ANN.§ 4729.0l(B) (LexisNexis 2012); OKLA. STAT. ANN. tit. 59, § 353.1(28)
(West 2012); OR. REV. STAT. § 689.005(28) (2012); 63 PA. STAT. ANN. §
390-2(11) (West 2012); R.I. GEN. LAWS § 5-19.1-2 (2009 & Supp. 2012);
S.C. CODE ANN. § 40-43-30(44) (2012); S.D. CODIFIED LAWS § 36-11-2.2
(2012); TENN. CODE ANN. § 63-10-204(35)(A) (2010 & Supp. 2012); TEX.
Occ. CODE ANN. § 551.003(33) (West 2012); UTAH CODE ANN. § 58-17b102(54) (LexisNexis 2012 & Supp. 2013); VT. STAT. ANN. tit. 26, § 2022(14)
(2012); VA. CODE ANN.§ 54.1-3300 (West 2012); WASH. REV. CODE ANN.§
18.64.011(23) (2012); W. VA. CODE ANN.§ 30-5-3 (2012) (amended 2013);
WIS. STAT. ANN.§ 450.01(16) (2012); WYO. STAT. ANN.§ 33-24-124 (2012).
76.

I. The Duty to Warn Patients about Risks Generally Associated with

Prescription Drugs Would Remain with Prescribers, Not Pharmacists
State courts have traditionally, and quite consistently, held that a
pharmacist has no general duty to warn a customer of the risk of harm
that might be encountered from drugs which are accurately dispensed
upon a valid and legal prescription, 81 unless (1) the prescription itself
Administration 1s Mandate to Ensure Postmarketing Drug Safety, 306
JAMA 1595, 1595 (2011).
79.

As part of the Controlled Substances Act, "a pharmacist may not fill a
written order from a practitioner, appearing on its face to be a prescription
[for a controlled substance], if he knows the practitioner issued it in other
than the usual course of medical treatment." United States v. Hayes, 595
F.2d 258, 260 (5th Cir. 1979) (construing 21C.F.R§1306.04(a)). See also
21 U.S.C. § 829(e)(2) (2012) (noting a "valid prescription" is "a
prescription that is issued for a legitimate medical purpose in the usual
course of professional practice . . . ").

80.

For example, it was a piece of federal legislation (OBRA-90)'s articulating
conditions for state receipt of Medicaid funds that prompted widespread
adoption of prospective drug utilization review software by pharmaci~ts
nationwide. See Thomas R. Fulda et al., Current Status of Prospective
Drug Utilization Review, 10 J. OF MANAGED CARE PHARMACY 433 (2004);
see also United States v. Jae Gab Kim, 449 F.3d 933, 937 (9th Cir. 2006)
(sentencing a pharmacist to five months inc~rceration, three. yea:s
supervised release, and a $15,000 fine for sellmg pseudoephedrme m
violation of federal Controlled Substances Act and state law); United
States v. Mufi.oz, 430 F.3d 1357, 1364 (11th Cir. 2005) (sentencing
defendant to ten months' imprisonment and a $10,000 fine for dispensing
drugs without a valid prescription in violation of FDCA).

81.

See Downing v. Hyland Pharmacy, 194 P.3d 944, 946 (Utah 2008) (quoting
Schaerrer v. Stewart's Plaza Pharmacy, 79 P .3d 922, 929 (Utah 2003))
("So long as a pharmacist's ability to distribute prescription drugs is
limited by the highly restricted, FDA-regulated drug distribution system in
this country, and a pharmacist cannot supply a patient with prescription

See!. e.g., 42 U.~·~· § 1396r-8(g)(2)(A)(ii) (2012) (conditioning federal
fund~n~ for Me.d~ca~d on states' establishing standards for counseling of

Med1ca1d beneficiaries by pharmacists).
77.

78.

See, e.g., 42 U.S.C. § 1395w-104(c)(2)(C)(i) (2012) (requiring "an annual
~omp~ehensive medication review" for each Medicare Part D beneficiary
_furmshed perso~- to-person or using telehealth technologies . . . by a
licensed pharmacist or other qualified provider").
The entire prescription drug regulatory system dating back to the Food

D~ug and Co~metic Act of 1938 depends squarely on pharmacists t~
withhold certam products until receipt of a valid prescription. 21 U.S.C. §
353 (2012). See also PETER BARTON HUTT ET AL., FOOD & DRUG LAW 490
(3d ed: 2007) ("[This section of the FDCA] relies upon state law to
determme what professional training is required for licensure to administer
prescription drugs."). More recently, however, the Food and Drug
Amend~ents Act of 2007 (FDAAA) also contemplates pharmacists'
u~der~orng product-specific certification and further limiting dispensing of
h1gh-nsk products only in response to a valid prescription plus "evidence or
other documentation of safe-use conditions, such as laboratory test
results," or checking a product-specific registry as part of the Risk
Evaluation and Mitigation Strategies (REMS) system created by FDAAA.
Food~ Drug Amendments Act of 2007, 21U.S.C.§355-l(f)(3) (2012). See
also D1ma M. Qato & G. Caleb Alexander, Improving the Food and Drug
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contains "patent, clear, or obvious errors" or (2) the pharmacist has
knowledge of patient-specific information that would indicate that a
particular patient has a higher risk profile for a particular drug. 82
Pharmacies and pharmacists have been exempted from a duty to warn
due to the learned intermediary doctrine. 83 As articulated by courts, the

learned intermediary doctrine prevents pharmacists from interfering with
the doctor-patient relationship because it "prevents pharmacists from
constantly second-guessing a prescribing doctor's judgment simply in
order to avoid his or her own liability to the customer. "84
Even where courts have decided that the learned intermediary doctrine protects pharmacists from a duty to warn, the decisions have been
qualified because the foreseeability of injury to an individual consumer
"varies greatly depending on the medical history and condition of the
individual - facts which we cannot reasonably expect the pharmacist to
know." 85 But when in fact a pharmacist is aware of a patient's individual
allergies or diagnoses, the learned intermediary doctrine does not
foreclose a pharmacist's potential for liability because the pharmacist has
knowledge of a customer-specific risk. 86 At a minimum, pharmacists have
a duty to warn physicians and patients when a prescription drug is
contraindicated for a specific patient or when a patient is concurrently
taking two drugs which are known to cause serious adverse effects in
some patients when taken together, 87 but there remains a disagreement

drugs without an intervening physician's prescription, we will not impose a
duty upon the pharmacist to warn of the risks associated with the use of
prescription drugs."); Pysz v. Henry's Drug Store, 457 So. 2d 561, 562 (Fla.
Dist. Ct. App. 4th 1984) (holding that it is the physician, not the
pharmacist, who has the duty to know the drug that he is prescribing and
to warn and monitor the patient properly); Adkins v. Mong, 425 N.W.2d
151, 154 (Mich. Ct. App. 1988) (dismissing negligence claim against
pharmacy because "there exists no legal duty on the part of a pharmacist
to monitor and intervene with a customer's reliance on drugs prescribed by
a licensed treating physician"); Morgan v. Wal-Mart Stores, Inc., 30
S.W.3d 455, 467 (Tex. Ct. App. 2000) (cautioning that imposing a
generalized duty to warn would unnecessarily interfere in the physician and
patient relationship); Allberry v. Parkmor Drug, Inc., 834 N.E.2d 199, 203
(Ind. Ct. App. 2005) (holding that a pharmacist had no duty to give
patient the manufacturer's product information, which contained certain
warnings about the use of the drug, as such information was not included
in the prescription itself); Cottam v. CVS Pharmacy, Inc., 764 N.E.2d 814,
821 (Mass. 2002) (holding that in the absence of a voluntarily assumed
duty "where the pharmacist has no specific knowledge of an increased
danger to a particular customer, the pharmacist has no duty to warn that
customer of potential side effects").
82.

Morgan, 30 S.W.3d at 467 (noting that the action does not claim either
that the pharmacy had any knowledge of the patient's medical history or
should have known of contraindications that would impose upon the
pharmacy an additional duty to warn the patient); Deed v. Walgreen Co.,
927 A.2d 1001, 1002-03 (Conn. Super. Ct. 2007) (holding that pharmacists
did not have "specific knowledge of potential harm" sufficient to trigger
duty to warn where patient's primary care physician had written majority
of 149 prescriptions filled by pharmacy). But see McKee v. Am. Home
Prods., Corp., 782 P.2d 1045, 1050 (Wash. 1989) ("[T]he patient must look
to the physician [for information on the potential adverse effects of a
prescription drug], for it is only the physician who can relate the
propensities of the drug to the physical idiosyncrasies of the patient."). See
generally David J. Marchitelli, Liability of Pharmacist Who Accurately
Fills Prescription for Harm Resulting to User, 44 A.L.R.5th 393, at § 2[a]
(2011).

83.

Morgan, 30 S.W.3d at 469 (holding that the learned intermediary doctrine
does not impose on pharmacists a generalized duty to warn patients of
potential adverse reactions absent special circumstances); Moore v. Mem'l
Hosp., 825 So.2d 658, 664 (Miss. 2002) (extending the "learned
intermediary" doctrine to pharmacists in Mississippi). See, e.g., Cottam,
764 N.E.2d at 821 ("This court has already recognized the learned
intermediary doctrine in the context of prescription drug manufacturers.
Because the physician is the appropriate person to perform the duty of
warning a patient of the possible side effects of prescription drugs, we now
extend this doctrine to pharmacies." (citations omitted)). See also
Fakhouri v. Taylor, 618 N.E.2d 518, 519 (Ill. App. Ct. 1993); Leesley v.
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West, 518 N.E.2d 758, 760 (Ill. App. Ct. 1988); Eldridge v. Eli Lilly & Co.,
485 N.E.2d 551, 551 (Ill. App. Ct. 1985).
84.

Klasch v. Walgreen Co., 264 P.3d 1155, 1159 (Nev. 2011).

85.

Leesley, 518 N.E.2d at 762 (citing Eldridge, 485 N.E.2d 551).

86.

Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1129 (Ill. 2002) ("For
the reasons set forth above, we hold that a narrow duty to warn exists
where, as in the instant case, a pharmacy has patient-specific information
about drug allergies, and knows that the drug being prescribed is
contraindicated for the individual patient. In such instances, a pharmacy
has a duty to warn either the prescribing physician or the patient of the
potential danger."); Lasley v. Shrake's Country Club Pharmacy, Inc., 880
P.2d 1129, 1132-34 (Ariz. Ct. App. 1994) (imposing a duty for failing to
warn the customer when filling two prescriptions that adversely interacted
with one another); Klasch, 264 P.3d at 1156 ("We conclude that when a
pharmacist has knowledge of a customer-specific risk with respect to a
prescribed medication, the pharmacist has a duty to exercise reasonable
care in warning the. customer or notifying the prescribing doctor of this
risk."); Walton v. Bayer Corp., 643 F.3d 994, 1000 (7th Cir. 2011) ("What
a pharmacy sometimes knows, however, without investigation, and the
manufacturer will not know and even a treating physician may not know,
is susceptibilities of particular customers of the pharmacy to the side
effects of a drug that it sells them - susceptibilities because of other drugs
that the pharmacy knows the customer is taking, or a pre-existing physical
or mental condition (again known to it) that makes the drug
contraindicated for the customer - and then it must warn either the
customer or his physician. But not otherwise." (citations omitted)).

87.

Keffer v. Lorzenz, 2012 WL 3235398, at ~ 17 (D.C. Super. Ct. 2012)
(noting pharmacists likely had a duty to warn because patient was "at risk
of a specific, defined, and foreseeable harm of which the pharmacists knew
or should have known," specifically the concurrent use of two drugs known
to cause serious adverse events when taken together).
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contains "patent, clear, or obvious errors" or (2) the pharmacist has
knowledge of patient-specific information that would indicate that a
particular patient has a higher risk profile for a particular drug. 82
Pharmacies and pharmacists have been exempted from a duty to warn
due to the learned intermediary doctrine. 83 As articulated by courts, the

learned intermediary doctrine prevents pharmacists from interfering with
the doctor-patient relationship because it "prevents pharmacists from
constantly second-guessing a prescribing doctor's judgment simply in
order to avoid his or her own liability to the customer. "84
Even where courts have decided that the learned intermediary doctrine protects pharmacists from a duty to warn, the decisions have been
qualified because the foreseeability of injury to an individual consumer
"varies greatly depending on the medical history and condition of the
individual - facts which we cannot reasonably expect the pharmacist to
know." 85 But when in fact a pharmacist is aware of a patient's individual
allergies or diagnoses, the learned intermediary doctrine does not
foreclose a pharmacist's potential for liability because the pharmacist has
knowledge of a customer-specific risk. 86 At a minimum, pharmacists have
a duty to warn physicians and patients when a prescription drug is
contraindicated for a specific patient or when a patient is concurrently
taking two drugs which are known to cause serious adverse effects in
some patients when taken together ,87 but there remains a disagreement

drugs without an intervening physician's prescription, we will not impose a
duty upon the pharmacist to warn of the risks associated with the use of
prescription drugs."); Pysz v. Henry's Drug Store, 457 So. 2d 561, 562 (Fla.
Dist. Ct. App. 4th 1984) (holding that it is the physician, not the
pharmacist, who has the duty to know the drug that he is prescribing and
to warn and monitor the patient properly); Adkins v. Mong, 425 N.W.2d
151, 154 (Mich. Ct. App. 1988) (dismissing negligence claim against
pharmacy because "there exists no legal duty on the part of a pharmacist
to monitor and intervene with a customer's reliance on drugs prescribed by
a licensed treating physician"); Morgan v. Wal-Mart Stores, Inc., 30
S.W.3d 455, 467 (Tex. Ct. App. 2000) (cautioning that imposing a
generalized duty to warn would unnecessarily interfere in the physician and
patient relationship); Allberry v. Parkmor Drug, Inc., 834 N.E.2d 199, 203
(Ind. Ct. App. 2005) (holding that a pharmacist had no duty to give
patient the manufacturer's product information, which contained certain
warnings about the use of the drug, as such information was not included
in the prescription itself); Cottam v. CVS Pharmacy, Inc., 764 N.E.2d 814,
821 (Mass. 2002) (holding that in the absence of a voluntarily assumed
duty "where the pharmacist has no specific knowledge of an increased
danger to a particular customer, the pharmacist has no duty to warn that
customer of potential side effects").
82.

Morgan, 30 S.W.3d at 467 (noting that the action does not claim either
that the pharmacy had any knowledge of the patient's medical history or
should have known of contraindications that would impose upon the
pharmacy an additional duty to warn the patient); Deed v. Walgreen Co.,
927 A.2d 1001, 1002-03 (Conn. Super. Ct. 2007) (holding that pharmacists
did not have "specific knowledge of potential harm" sufficient to trigger
duty to warn where patient's primary care physician had written majority
of 149 prescriptions filled by pharmacy). But see McKee v. Am. Home
Prods., Corp., 782P.2d1045, 1050 (Wash. 1989) ("[T]he patient must look
to the physician [for information on the potential adverse effects of a
prescription drug], for it is only the physician who can relate the
propensities of the drug to the physical idiosyncrasies of the patient."). See
generally David J. Marchitelli, Liability of Pharmacist VVho Accurately
Fills Prescription for Harm Resulting to User, 44 A.L.R.5th 393, at § 2[a]
(2011).

83.

Morgan, 30 S.W.3d at 469 (holding that the learned intermediary doctrine
does not impose on pharmacists a generalized duty to warn patients of
potential adverse reactions absent special circumstances); Moore v. Mem'l
Hosp., 825 So.2d 658, 664 (Miss. 2002) (extending the "learned
intermediary" doctrine to pharmacists in Mississippi). See 1 e.g., Cottam,
764 N.E.2d at 821 ("This court has already recognized the learned
intermediary doctrine in the context of prescription drug manufacturers.
Because the physician is the appropriate person to perform the duty of
warning a patient of the possible side effects of prescription drugs, we now
extend this doctrine to pharmacies." (citations omitted)). See also
Fakhouri v. Taylor, 618 N.E.2d 518, 519 (Ill. App. Ct. 1993); Leesley v.
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West, 518 N.E.2d 758, 760 (Ill. App. Ct. 1988); Eldridge v. Eli Lilly & Co.,
485 N.E.2d 551, 551 (Ill. App. Ct. 1985).
84.

Klasch v. Walgreen Co., 264 P.3d 1155, 1159 (Nev. 2011).

85.

Leesley, 518 N.E.2d at 762 (citing Eldridge, 485 N.E.2d 551).

86.

Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1129 (Ill. 2002) ("For
the reasons set forth above, we hold that a narrow duty to warn exists
where, as in the instant case, a pharmacy has patient-specific information
about drug allergies, and knows that the drug being prescribed is
contraindicated for the individual patient. In such instances, a pharmacy
has a duty to warn either the prescribing physician or the patient of the
potential danger."); Lasley v. Shrake's Country Club Pharmacy, Inc., 880
P.2d 1129, 1132-34 (Ariz. Ct. App. 1994) (imposing a duty for failing to
warn the customer when filling two prescriptions that adversely interacted
with one another); Klasch, 264 P.3d at 1156 ("We conclude that when a
pharmacist has knowledge of a customer-specific risk with respect to a
prescribed medication, the pharmacist has a duty to exercise reasonab~e
care in warning the. customer or notifying the prescribing doctor of this
risk."); Walton v. Bayer Corp., 643 F.3d 994, 1000 (7th Cir. 2011) ("What
a pharmacy sometimes knows, however, without investigation, and the
manufacturer will not know and even a treating physician may not know,
is susceptibilities of particular customers of the pharmacy to the side
effects of a drug that it sells them - susceptibilities because of other drugs
that the pharmacy knows the customer is taking, or a pre-existing physical
or mental condition (again known to it) that makes the drug
contraindicated for the customer - and then it must warn either the
customer or his physician. But not otherwise." (citations omitted)).

87.

Keffer v. Lorzenz, 2012 WL 3235398, at ~ 17 (D.C. Super. Ct. 2012)
(noting pharmacists likely had a duty to wa.rn because patient was "at risk
of a specific, defined, and foreseeable harm of which the pharmacists knew
or should have known," specifically the concurrent use of two drugs known
to cause serious adverse events when taken together).
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between jurisdictions whether pharmacists have a duty to warn physicians or patients when a dose in excess of the manufacturer's recommenrecommendation (and FDA approval) has been prescribed. 88 While
contraindications are seen as straightforward warnings that do not
require a pharmacist to make an independent medical judgment, 89 dosage
decisions appear to cross the line from the practice of pharmacy into the
practice of medicine. 90

The addition of diagnostic information to outpatient prescriptions
would do nothing to shift the burden of the general duty to warn from
prescribers to pharmacists; it would, however, ~ik~ly increase the nur~ber
of situations where pharmacists detect prescription errors and patientspecific risks, situations which would trigger pharmacists' professional
duty of due care.
2. Pharmacists' Duty of Due Care Would Be Heightened with Addition of
Diagnosis Codes for Medicare and Medicaid Reimbursement

88.

89.

90.

See Horner v. Spalitto, 1 S.W.3d 519, 523 (Mo. Ct. App. 1999) (finding
that the pharmacist is "in the best position" to contact the patient's
physician to discuss any potential problems with the patient's
prescription); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1250 (Pa. Super.
Ct. 1986) ("Pharmacists and a pharmacologist testified that a pharmacist
who receives a prescription which has inadequate instructions as to
maximum dosage has a duty to either ascertain if the patient is aware of
the limitation concerning the use of the medication or to contact the
prescribing physician to call the inadequacy of the prescription to the
doctor's attention. Experts testified further that under the facts of this case
a reasonably prudent pharmacist would have taken steps to correct the
error of the prescribing physician."). See also McKee v. Am. Home Prods.,
Corp., 782 P.2d 1045, 1053 (Wash. 1989) ("We agree pharmacists should
have a duty to be alert for patent errors in a prescription, for example:
obvious lethal dosages, inadequacies in the instructions, known
contraindications, or incompatible prescriptions, and to take corrective
measures."). But see Fakhouri, 618 N.E.2d at 519 (denying request to
impose upon pharmacists a duty to warn their customers of prescribed
dosages of medication in excess of the manufacturer's recommended limits).
'.'A c~ntraindication is a serious limitation on a drug's use, necessarily
rmplymg grave consequences if it is ignored. As one court has noted a
contraindication refers to 'a circumstance under which the drug must ne~er
be given."' Happel, 766 N.E.2d at 1128 (quoting Hand v. Krakowski, 453
N.Y.S.2d 121, 123 (N.Y. App. Div. 1982)). "It requires no medical
judgment simply to notify a physician or a patient of such a
contraindication." Happel, 766 N.E.2d at 1128.

See Eldridge v. Eli Lilly & Co., 485 N.E.2d 551, 553 (Ill. App. Ct. 1985)
("A prescription which is excessive for one patient may be entirely
reasonable for the treatment of another. To fulfill the duty which the
plaintiff urges us to impose would require the pharmacist to learn the
customer's condition and monitor his drug usage. To accomplish this, the
pharmacist would have to interject himself into the doctor-patient
relationship and practice medicine without a license."). See also
~,rumag~im v. Eckel, 94 A.D.3~ 1391, 1393 (N.Y. Sup. Ct. 2012)
( Imposmg a duty upon a pharmacist to contact the prescribing physician
whenever there has been a change in dosage - within medically acceptable
ranges - of a particular patient's medication would, in essence, require the
pharma~ist to question the physician's judgment regarding the
appropriateness of each customer's prescription. Sound policy reasons exist
for not imposing such a duty."); McKee, 782 P.2d at 1051 ("Neither
manufacturer nor pharmacist has the medical education or knowledge of
the medical history of the patient which would justify a judicial imposition
of a duty to intrude into the physician-patient relationship."). But see Riff,
508 A.2d at 1253 ("Expert testimony established that the 'reasonable
pharmacist' has an affirmative duty to read the prescription and to be
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Given the "poisonous character" of prescription medications, pharmacists are generally required to exercise a "duty of care and caution"
when dispensing drugs. 91 As part of this duty, pharmacists are expected
to review a prescription before it is dispensed to identify: (1) apparent
errors with the prescription and clarify any questions with the prescriber, 92 and (2) potential drug-drug interactions, drug-disease contraindications, therapeutic duplication, or other potential patient-specific
adverse drug events. 93 Pharmacists often rely upon computer systems to
aware of patent inadequacies in the instructions as to maximum safe
dosage of known toxic drugs and medicines.").
91.

Eldridge, 485 N.E.2d at 552 ("A pharmacist owes a duty of ordinary care
in practicing his profession, but such care requires the highest degree of
prudence, thoughtfulness and diligence, and it is prop.orti.oned to the
danger involved." (emphasis added)). See generally March1telh, supra note
82, at § 2[a].

92.

Despite the increased adoption of electronic prescribing as part of their role
in "interpret [ing]" and "evaluat[ing]" prescriptions pharmacists still
encounter sloppy writing and inappropriate directions, which can lead to
adverse drug events. Randall Stross, Chicken Scratches v. Electronic
N.Y.
TIMES
(Apr.
28,
2012),
Prescriptions,
http://www.nytimes.com/2012/04/29/business/e-~r~scriptions-red~ce~

errors-but-their-adoption-is-slow.html? _r=O. Add1t10nally, prescnpt10n
errors are a known reality in our health care system. See Riff, 508 A.2d at
1253 ("Fallibility is a condition of the human existence. Doctors, like other
mortals, will from time to time err through ignorance or inadvertence. An
error in the practice of medicine can be fatal; and so it is reasonable that
the
medical
community
including
physicians,
pharmacists,
anesthesiologists, nurses and support staff have established profes~ional
standards which require vigilance not only with respect to primary
functions, but also regarding the acts and omissions of the other
professionals and support personnel in the health care team. Each has an
affirmative duty to be, to a limited extent, his brother's keeper.").
93.

42 U.S.C. § 1396r-8(g)(2)(A)(i) (2012). Physicians may not be aware of all
contraindications associated with the drugs they prescribe. See, e.g.,
Happel, 766 N.E.2d at 1121 (Ill. 2002) (noting the physicia1: did not ~ow
that Toradol was contraindicated for patients with allergies to aspmn).
But, at present, pharmacists may similarly be unaware of all of a patient's
conditions. See Fulda et al., supra note 80 (recognizing that drug-disease
contraindications may only be identified "when disease information is
available or using surrogate indicators").
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between jurisdictions whether pharmacists have a duty to warn physicians or patients when a dose in excess of the manufacturer's recommenrecommendation (and FDA approval) has been prescribed. 88 While
contraindications are seen as straightforward warnings that do not
require a pharmacist to make an independent medical judgment, 89 dosage
decisions appear to cross the line from the practice of pharmacy into the
practice of medicine. 90

The addition of diagnostic information to outpatient prescriptions
would do nothing to shift the burden of the general duty to warn from
prescribers to pharmacists; it would, however, likely increase the nur~ber
of situations where pharmacists detect prescription errors and pat1entspecific risks, situations which would trigger pharmacists' professional
duty of due care.
2. Pharmacists' Duty of Due Care Would Be Heightened with Addition of
Diagnosis Codes for Medicare and Medicaid Reimbursement

88.

89.

90.

See Homer v. Spalitto, 1 S.W.3d 519, 523 (Mo. Ct. App. 1999) (finding
that the pharmacist is "in the best position" to contact the patient's
physician to discuss any potential problems with the patient's
prescription); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1250 (Pa. Super.
Ct. 1986) ("Pharmacists and a pharmacologist testified that a pharmacist
who receives a prescription which has inadequate instructions as to
maximum dosage has a duty to either ascertain if the patient is aware of
the limitation concerning the use of the medication or to contact the
prescribing physician to call the inadequacy of the prescription to the
doctor's attention. Experts testified further that under the facts of this case
a reasonably prudent pharmacist would have taken steps to correct the
error of the prescribing physician."). See also McKee v. Am. Home Prods.,
Corp., 782 P.2d 1045, 1053 (Wash. 1989) ("We agree pharmacists should
have a duty to be alert for patent errors in a prescription, for example:
obvious lethal dosages, inadequacies in the instructions, known
contraindications, or incompatible prescriptions, and to take corrective
measures."). But see Fakhouri, 618 N.E.2d at 519 (denying request to
impose upon pharmacists a duty to warn their customers of prescribed
dosages of medication in excess of the manufacturer's recommended limits).
'.'A c~ntraindication is a serious limitation on a drug's use, necessarily
implymg grave consequences if it is ignored. As one court has noted a
contraindication refers to 'a circumstance under which the drug must ne~er
be given."' Happel, 766 N.E.2d at 1128 (quoting Hand v. Krakowski, 453
N.Y.S.2d 121, 123 (N.Y. App. Div. 1982)). "It requires no medical
judgment simply to notify a physician or a patient of such a
contraindication." Happel, 766 N.E.2d at 1128.

Given the "poisonous character" of prescription medications, pharmacists are generally required to exercise a "duty of care and caution"
when dispensing drugs. 91 As part of this duty, pharmacists are expected
to review a prescription before it is dispensed to identify: (1) apparent
errors with the prescription and clarify any questions with the prescriber, 92 and (2) potential drug-drug interactions, drug-disease contraindications, therapeutic duplication, or other potential patient-specific
adverse drug events. 93 Pharmacists often rely upon computer systems to
aware of patent inadequacies in the instructions as to maximum safe
dosage of known toxic drugs and medicines.").
91.

Eldridge, 485 N.E.2d at 552 ("A pharmacist owes a duty of ordinary care
in practicing his profession, but such care requires the highest degree of
prudence, thoughtfulness and diligence, and it is prop.orti?ned to the
danger involved." (emphasis added)). See generally March1telh, supra note
82, at § 2[a].

92.

Despite the increased adoption of electronic prescribing as part of their role
in "interpret [ing]" and "evaluat[ing]" prescriptions pharmacists still
encounter sloppy writing and inappropriate directions, which can lead to
adverse drug events. Randall Stross, Chicken Scratches v. Electronic
N.Y.
TIMES
(Apr.
28,
2012),
Prescriptions,
http://www.nytimes.com/2012/04/29/business/e-~r~scriptions-red~ce~

errors-but-their-adoption-is-slow .html?_r=O. Add1t10nally, prescnption
errors are a known reality in our health care system. See Riff, 508 A.2d at
1253 ("Fallibility is a condition of the human existence. Doctors, like other
mortals, will from time to time err through ignorance or inadvertence. An
error in the practice of medicine can be fatal; and so it is reasonable that
the
medical
community
including
physicians,
pharmacists,
anesthesiologists, nurses and support staff have established profes~ional
standards which require vigilance not only with respect to pnmary
functions, but also regarding the acts and omissions of the other
professionals and support personnel in the health care team. Each has an
affirmative duty to be, to a limited extent, his brother's keeper.").

8:

~:e Eldrid~e :· Eli L~lly
Co., 48.5 N.E.2d 551, 553 (Ill. App. Ct. 1985)
( A prescription which is excessive for one patient may be entirely
reasonable for the treatment of another. To fulfill the duty which the
plaintiff urges us to impose would require the pharmacist to learn the
customer's condition and monitor his drug usage. To accomplish this, the
pharmacist would have to interject himself into the doctor-patient
relationship and practice medicine without a license."). See also
~,rumag~im v. Eckel, 94 A.D.3~ 1391, 1393 (N.Y. Sup. Ct. 2012)
( Imposmg a duty upon a pharmacist to contact the prescribing physician
whenever there has been a change in dosage - within medically acceptable
ranges - of a particular patient's medication would, in essence, require the
pharma~ist to question the physician's judgment regarding the
appropriateness of each customer's prescription. Sound policy reasons exist
for not imposing such a duty."); McKee, 782 P.2d at 1051 ("Neither
manufacturer nor pharmacist has the medical education or knowledge of
the medical history of the patient which would justify a judicial imposition
of a duty to intrude into the physician-patient relationship."). But see Riff,
508 A.2d at 1253 ("Expert testimony established that the 'reasonable
pharmacist' has an affirmative duty to read the prescription and to be
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93.

42 U.S.C. § 1396r-8(g)(2)(A)(i) (2012). Physicians may not be aware of all
contraindications associated with the drugs they prescribe. See, e.g.,
Happel, 766 N.E.2d at 1121 (Ill. 2002) (noting the physicia1: did not ~ow
that Toradol was contraindicated for patients with allergies to aspmn).
But, at present, pharmacists may similarly be unaware of all of a patient's
conditions. See Fulda et al., supra note 80 (recognizing that drug-disease
contraindications may only be identified "when disease information is
available or using surrogate indicators").
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use diagnostic infor~ation (at this point provided entirely by patients,
unle~s they are takmg one of the few outpatient drugs reimbursed by
Medicare Part B) to warn them about contraindications for specific
.
94 E
pat rents.
ven so, at least one long-term (twenty-month) study has
f~und that nearly 50 percent of drug problem interventions by pharmaCISts ~ere _problems that required the pharmacist's independent
profess10nal Judgment as opposed to problems flagged by drug utilization
r~view softwar~. 95 Once the validity and appropriateness of the prescription are established, the pharmacist is then expected to (3) dispense the
cor~ect medic~tion in the dosage and quantity prescribed, (4) offer each
patient or designated caregiver counseling on safe and appropriate use of
the_ medication_ as prescribed (an offer which may be refused by the
patient or caregiver), 96 and (5) maintain records with patient information
to facilitate future counseling. 97 While these standards are technically a
~atter of state law, the state laws governing them have been heavily
mfluenced by the federal Medicaid funds conditioned on states' adoption
of the standards pursuant to the Omnibus Budget Reconciliation Act of

94.

See, e.g., Keffer v. Lorzenz, 2012 WL 3235398, at , 2 (D.C. Super. Ct.
2012) ("CVS's pharmacy personnel used a computerized prescription
s~stem (the 'CVS system') that informed them of Mr. Keffer's prescription
history, t~~t he had been prescribed both Cymbalta and Vyvanse, and that
he was fillrng both medications simultaneously. In addition the CVS
system notified CVS 's personnel that they should not fill the two
prescriptions without first contacting Mr. Keffer's physicians to confirm
that they wanted him to take both medications at the same time.");
Happel, 766 N.E.2d at 1121 (noting a "'drug interaction' warning would
have flashed across the [pharmacist's] screen, halting the prescription
process for customers" for whom the drug was contraindicated until the
pharmacist had consulted with the patient's physician); Morgan, 30
S.W.3d at 469 (encouraging the use of computer systems to assist
pharmacists in "p~~venting the s~le o_f potenti~lly fatal drugs"); Klasch,
264 P.3d at 1157 ( Walgreens mamtarns a 'patient profile' for each of its
custo_mers, which i~s phar~acists_ use to identify any potential allergic
react10ns, harmful rnteract10ns with other medications, or adverse side
effects that a customer may have to a particular medication.").

95.

Fulda et al., supra note 80, at 437 ("Approximately one half of the
documented medication problems would not have been detected by
compute~-generated alerts available at that time. This suggests that
[prospective Drug Utilization Review] systems can assist pharmacists but
cannot identify all of the problems that must be addressed to assure
appropriate drug use.").

96.

See Jesse C. Vivian & Joseph L. Fink, OBRA '90 at Sweet Sixteen: A
Retrospective Review, . 33 U.S. PHARMACIST 59 (?.008), available at
http://www.uspharmacist.com/content/d/feature/c/10126.

97.

~~-U.S.C. § 1396r-8(g)(2)(A)(ii)(II)(bb) (2012); Vivian & Fink, supra note
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1990 (OBRA-90). 98 Inclusion of diagnosis information as part of the
Medicare and Medicaid programs would better inform four of these five
practices (i.e., all but the correct dispensation of the product) and, as a
result, likely heighten the standard of care pursuant to each of these
practices.
As observed by one court, the burden of warning a single physician
or patient may be small, 99 but in the aggregate (especially with the
increasing number of insured patients due to the Supreme Court's
decision upholding the Affordable Care Act) 100 the increased resources
necessary to satisfy the augmented duty to warn created by the addition
of diagnostic information to all outpatient prescriptions may be significant. io1 The burden on pharmacists may be heightened, too, where
patient care for comorbid conditions remains fragmented among specialists and no one prescriber is aware of all of a patient's diagnoses or
medications. 102 To the extent, though, that the practice of pharmacy
"should increase the overall quality of health care, " 103 inclusion of
98.

Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104
Stat. 1388 (1990) (codified as amended at 42 U.S.C. § 1396r-8g (1994)).
See also Vivian & Fink, supra note 96.

99.

Happel, 766 N.E.2d at 1124 ("The burden on defendant of imposing this
duty [to warn] is minimal. All that is required is that the pharmacist
telephone the physician and inform him or her of the contraindication.
Alternatively, the pharmacist could provide the same information to the
patient. Since this burden of warning about a contraindication is extremely
small, this factor also favors the imposition of a duty here.").

100. The Robert Wood Johnson Foundation estimates that the health care
system will have thirty million newly insured patients once the Patient
Protection and Affordable Care Act is fully implemented. See CATHERINE
DOWER & EDWARD O'NEIL, ROBERT WOOD JOHNSON FOUND., PRIMARY
CARE HEALTH WORKFORCE IN THE UNITED STATES REPORT 2 (2011),
available
at
http://www.rwjf.org/content/dam/farm/reports/issue_briefs/2011/rwjf706
13.
101. See Leesley v. West, 518 N.E.2d 758, 763 (Ill. App. Ct. 1988) (explaining
that the burden of conveying the warnings pharmacies receive from drug
manufacturers to its customers would be very burdensome because it may
well mean that pharmacists must bear the additional costs of reproducing
the material they receive); McKee v. Am. Home Prods., Corp., 782 P.2d
1045, 1053 (Wash. 1989) (noting that requiring pharmacists to warn
patients of risks of off-label use "would result in the pharmacist second
guessing numerous prescriptions to avoid liability. This would not only
place an undue burden on pharmacists, but would likely create antagonistic
relations between pharmacists and physicians.").
102. Mary E. Tinetti et al., Designing Health Care for the Most Common
Chronic Condition-Multimorbidity, 307 JAMA 2493, 2493 (2012).
103. Horner v. Spalitto, 1 S.W.3d 519, 523-24 (Mo. Ct. App. 1999) (relying on
Kenneth R. Baker, The OBRA 90 Mandate and Its Developing Impact on
the Pharmacist7s Standard of Care, 44 DRAKE L. REV. 503, 517 (1996)).
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use diagnostic information (at this point provided entirely by patients
unle~s they are taking one of the few outpatient drugs reimbursed b;
Medicare Part B) to warn them about contraindications for specific
94
patients. Even so, at least one long-term (twenty-month) study has
f~und that nearly 50 percent of drug problem interventions by pharmacists were problems that required the pharmacist's independent
professional judgment as opposed to problems flagged by drug utilization
r~view softwar~. 95 Once the validity and appropriateness of the prescript10n are est~bhs~ed; the pharmacist is then expected to (3) dispense the
cor~ect med1cat10n m the dosage and quantity prescribed, (4) offer each
patient or designated caregiver counseling on safe and appropriate use of
the. medication. as prescribed (an offer which may be refused by the
patient or caregiver), 96 and (5) maintain records with patient information
to facilitate future counseling. 97 While these standards are technically a
-:natter of state law, the state laws governing them have been heavily
mfluenced by the federal Medicaid funds conditioned on states' adoption
of the standards pursuant to the Omnibus Budget Reconciliation Act of

94.

See, e.g., Keffer v. Lorzenz, 2012 WL 3235398, at , 2 (D.C. Super. Ct.
2012) ("CVS's pharmacy personnel used a computerized prescription
s~stem (the 'CVS system') that informed them of Mr. Keffer's prescription
history, t?~t he had been prescribed both Cyrnbalta and Vyvanse, and that
he was fillmg both medications simultaneously. In addition the CVS
system notified CVS's personnel that they should not
the two
prescriptions without first contacting Mr. Keffer's physicians to confirm
that they wanted him to take both medications at the same time.");
Happel, 766 N.E.2d at 1121 (noting a "'drug interaction' warning would
have flashed across the [pharmacist's] screen, halting the prescription
process for customers" for whom the drug was contraindicated until the
pharmacist had consulted with the patient's physician); Morgan, 30
S.W.3d at 469 (encouraging the use of computer systems to assist
pharmacists in "p~~venting the s~le o.f potenti~lly fatal drugs"); Klasch,
264 P.3d at 1157 ( Walgreens mamtarns a 'patient profile' for each of its
custo_mers, which i~s phar~acists_ use to identify any potential allergic
react10ns, harmful rnteract1ons with other medications, or adverse side
effects that a customer may have to a particular medication.").

fil1

95.

Fulda et al., supra note 80, at 437 ("Approximately one half of the
documented medication problems would not have been detected by
compute~-generated alerts available at that time. This suggests that
[prospective Drug Utilization Review] systems can assist pharmacists but
cannot identify all of the problems that must be addressed to assure
appropriate drug use.").

96.

See Jesse C. Vivian & Joseph L. Fink, OBRA '90 at Sweet Sixteen: A
Retrospective Review, . 33 U.S. PHARMACIST 59 (?.008), available at
http://www.uspharmac1st.com/content/d/feature/c/10126.

97.

~~.U.S.C. § 1396r-8(g)(2)(A)(ii)(II)(bb) (2012); Vivian & Fink, supra note
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1990 (OBRA-90). 98 Inclusion of diagnosis information as part of the
Medicare and Medicaid programs would better inform four of these five
practices (i.e., all but the correct dispensation of the product) and, as a
result, likely heighten the standard of care pursuant to each of these
practices.
As observed by one court, the burden of warning a single physician
or patient may be small, 00 but in the aggregate (especially with the
increasing number of insured patients due to the Supreme Court's
decision upholding the Affordable Care Act) 100 the increased resources
necessary to satisfy the augmented duty to warn created by the addition
of diagnostic information to all outpatient prescriptions may be significant. 101 The burden on pharmacists may be heightened, too, where
patient care for comorbid conditions remains fragmented among specialists and no one prescriber is aware of all of a patient's diagnoses or
medications. 102 To the extent, though, that the practice of pharmacy
"should increase the overall quality of health care, "103 inclusion of
98.

Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104
Stat. 1388 (1990) (codified as amended at 42 U.S.C. § 1396r-8g (1994)).
See also Vivian & Fink, supra note 96.

99.

Happel, 766 N.E.2d at 1124 ("The burden on defendant of imposing this
duty [to warn] is minimal. All that is required is that the ~ha~ma~ist
telephone the physician and inform him or her of the contrarnd1cat10n.
Alternatively, the pharmacist could provide the same information to the
patient. Since this burden of warning about a contraindication is extremely
small, this factor also favors the imposition of a duty here.").

100. The Robert Wood Johnson Foundation estimates that the health care
system will have thirty million newly insured patients once the Patient
Protection and Affordable Care Act is fully implemented. See CATHERlNE
DOWER & EDWARD O'NEIL, ROBERT WOOD JOHNSON FOUND., PRIMARY
CARE HEALTH WORKFORCE IN THE UNITED STATES REPORT 2 (2011),
available
at
http://www.rwjf.org/content/dam/farm/reports/issue_briefs/2011/rwjf706
13.
101. See Leesley v. West, 518 N.E.2d 758, 763 (Ill. App. Ct. 1988) (explaining

that the burden of conveying the warnings pharmacies receive from drug
manufacturers to its customers would be very burdensome because it may
well mean that pharmacists must bear the additional costs of reproducing
the material they receive); McKee v. Am. Home Prods., Corp., 782 P.2d
1045, 1053 (Wash. 1989) (noting that requiring pharmacists to warn
patients of risks of off-label use "would result in the pharmacist second
guessing numerous prescriptions to avoid liability. This would not only
place an undue burden on pharmacists, but would likely create antagonistic
relations between pharmacists and physicians.").
102. Mary E. Tinetti et al., Designing Health Care for the Most Common
Chronic Condition-Multimorbidity, 307 JAMA 2493, 2493 (2012).
103. Horner v. Spalitto, 1 S.W.3d 519, 523-24 (Mo. Ct. App. 1999) (relying on
Kenneth R. Baker, The OBRA 90 Mandate and Its Developing Impact on
the Pharmacist's Standard of Care, 44 DRAKE L. REV. 503, 517 (1996)).
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diagn.ostic i1:1formation on prescriptions seems a logical next step, 104
especially with the added potential that the claims database would
provide for even greater drug safety surveillance and comparative
effectiveness research.
B. Potential Role of Outpatient Prescription Drug Database in Informing
FDA Drug Safety Surveillance

Use of patient-specific information gathered in the context of health
care treatment relationships for purposes other than patient treatment is
always accompanied by privacy concerns - prescription drug information
105
is no exception. To the extent that individual patient privacy concerns
have been weighed against the informational needs of a functional
federal healt~ care sy~tem (including a drug safety surveillance system),
the balance IS found m the HIP AA Privacy Rule 106 and the Food and
Drug. A~~nistratio~ Amendments Act of 2007 (FDAAA). 107 Reflecting
the s1gmficant public health interest in drug safety surveillance, 10s the
HIP ~A an~ FDAAA standards expressly allow pharmacists and pharmacies to disclose otherwise-protected health information to the FDA to
report adverse events or engage in post-marketing surveillance without
patient consent.109
104. Marc A. Rodwin, Rooting Out Institutional Corruption to Manage
~~appropriate Off-Label Drug Use, 4_1 J_. L. MED. & ETHICS 654, 659 (2013)
( Data from tracked off-label prescnpt10ns would help to set priorities for
the evaluation of the risks and benefits of off-label use, target education
about drug therapy to physicians, and - where appropriate - warn the
public. Physicians should be required to indicate on each prescription the
purpose for which the drug is prescribed.").
105. For an excellent summary of these concerns, as well as the state and
~ederal :privacy law that governs protection of prescription health
mforma~10n, see generally Christopher R. Smith, Somebody's Watching Me:
Protecting Patient Privacy in Prescription Health Information, 36 VT. L.
REv. 931 (2012). In addition to the privacy concerns there are also cost
and quality of care concerns that may accompany 'data breaches that
co~promise Medicare and Medicaid beneficiary numbers. Julie K.
Taitsman et al., Protecting Patient Privacy and Data Security, 368 NEW
ENG. J. MED. 977, 977 (2013).
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Pursuant to the authority granted in FDAAA (and in compliance
with HIP AA), 110 the FDA is building an active post-market risk iden~ifi
cation and analysis system. 111 This system, known as the Sentmel
system, relies heavily on claims data 112 from both government and
private health insurance programs to actively track adverse events,
identify treatment trends and patterns, and export data in a form
appropriate for further aggregation, statistical analysis, and rep?rting. 113
While the FDA may have the authority to access the Medicare databases access alone does nothing to facilitate the cross-linking of the
existin~ Part D pharmacy-generated outpatient pre~crip~i?n dr:1g claim
databases with the Part B physician-generated office vIS1t claim databases necessary to link outpatient prescriptions to patient diagnoses, a
significant weakness of the current Medicare ?ataba~e sy~tem. 114 Furt~er,
patient information that does not have an immediate impact on reimbursement is often omitted from these systems. 115 Inclusion of ICD-10CM codes on Medicare Part D claims for outpatient prescription drugs
as a condition of reimbursement would take care of both of these
weaknesses in the current Sentinel system and significantly strengthen
FDA's ability to track adverse events and the trends _and patt.erns of
prescription drug use in patient populations di~propor~10nately msured
through Medicare (i.e., the elderly and chromcally disabled) and underrepresented in the FDA pre-market approval process and most postmarket clinical research.
HEALTH CARE PRIVACY AND SECURITY LAW 3:26-3:27 (2003) (citing 45
C.F.R. § 164.512(b)(l)(iii) (2012)); HIPAA Compliance for Reporters to
FDA
.
Med Watch,
FDA.Gov,
http://www.fda.gov/Safety /MedWatch/HowToReport/uc.:0:085589.htn:i
(last updated Jun. 25, 2009) (" [T]he Privacy Rule spec~fically permits
covered entities (such as pharmacists, physicians or hospitals) to. report
adverse events and other information related to the quality, effectiveness
and safety of FDA-regulated products both to the manufacturers and
directly to FDA.").
110. 21 U.S.C. § 355(k)(3)(C)(i)(I) (2012) (referencing the HIPAA Privacy
Rule).

106. See generally 45 C.F.R. §§ 160, 164 (2012).

111. § 355(k)(3)(C) (2012).

107. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 11085, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.).

112. § 355(k)(3)(A) (2012) (providing a definition of "data" for purposes of
active post-market risk identification).

108. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The
Food, Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME
L. REV. 419, 482 (2010) ("In effect, Congress determined that the public
he~lth benefits of having [an active drug safety surveillance] system are
weighty enough to override individuals' interest in keeping their data out
of it.").

113. § 355(k)(3)(C)(i). For an example of how d~t~bases are used to identify
off-label prescribing habits in children, see Mmam C. J.M. Sturkenbo?m
et al., Drug Use in Children: Cohort Study in Three European Countr~es,
337 BRIT. MED. J. 1338, 1339 (2008) (recognizing that this study, which
relied upon physician-generated data from electronic medical r~c~rd
databases from three different European countries, reflects prescnbmg
habits and not patient adherence).

109. Kristen
~~sati, Using Electronic Health Information for
Pharmacovzgzlance: The Promise and the Pitfalls, 2 J. HEALTH & LIFE Ser.
L. 171 (2009); LISA M. BOYLE & DAVID M. MACK, HIP AA: A GUIDE TO
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114. See OIG PART D REIMBURSEMENT REPORT, supra note 2.
115. Roos et al., supra note 45, at 48.
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diagn.ostic ir:formation on prescriptions seems a logical next step, 104
especially with the added potential that the claims database would
provide for even greater drug safety surveillance and comparative
effectiveness research.
B. Potential Role of Outpatient Prescription Drug Database in Informing
FDA Drug Safety Surveillance

Use of patient-specific information gathered in the context of health
care treatment relationships for purposes other than patient treatment is
always accompanied by privacy concerns - prescription drug information
105
is no exception. To the extent that individual patient privacy concerns
have been weighed against the informational needs of a functional
federal healt~ care sy~tem (including a drug safety surveillance system),
the balance IS found m the HIP AA Privacy Rule 106 and the Food and
Drug. A~~nistratio~ Amendments Act of 2007 (FDAAA). 107 Reflecting
the s1gmficant public health interest in drug safety surveillance, 10s the
HIP AA and FDAAA standards expressly allow pharmacists and pharmacies to disclose otherwise-protected health information to the FDA to
report adverse events or engage in post-marketing surveillance without
patient consent.109
104. Marc A. Rodwin, Rooting Out Institutional Corruption to Manage
~~appropriate Off-Label Drug Use, 4.1 J: L. MED. & ETHICS 654, 659 (2013)
( Data from tracked off-label prescnpt10ns would help to set priorities for
the evaluation of the risks and benefits of off-label use, target education
about drug therapy to physicians, and - where appropriate - warn the
public. Physicians should be required to indicate on each prescription the
purpose for which the drug is prescribed.").
105. For an excellent summary of these concerns, as well as the state and
~ederal :privacy law that governs protection of prescription health
mforma~1on, se~ generally Christopher R. Smith, Somebody's Watching Me:
Protecting Patient Privacy in Prescription Health Information, 36 VT. L.
REV. 931 (2012). In addition to the privacy concerns there are also cost
and quality of care concerns that may accompany 'data breaches that
co~promise Medicare and Medicaid beneficiary numbers. Julie K.
Ta1tsman et al., Protecting Patient Privacy and Data Security, 368 NEW
ENG. J. MED. 977, 977 (2013).
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Pursuant to the authority granted in FDAAA (and in compliance
'th HIP AA) 110 the FDA is building an active post-market risk identifiw1
'
S . 1
cation and analysis system. 111 This system, known as the entme
112
system, relies heavily on claims data from both government and
private health insurance programs to actively track adverse events,
identify treatment trends and patterns, and export data in a form
appropriate for further aggregation, statistical analysis, and rep?rting. 113
While the FDA may have the authority to access the Medicare databases access alone does nothing to facilitate the cross-linking of the
existin~ Part D pharmacy-generated outpatient pre~crip~i?n dr~g claim
databases with the Part B physician-generated office v1s1t claim databases necessary to link outpatient prescriptions to patient diagnoses, a
significant weakness of the current Medicare ~ataba~e sy~tem. 114 Furt~er,
patient information that does not have an immediate impact on reimbursement is often omitted from these systems. 115 Inclusion of ICD-10CM codes on Medicare Part D claims for outpatient prescription drugs
as a condition of reimbursement would take care of both of these
weaknesses in the current Sentinel system and significantly strengthen
FDA's ability to track adverse events and the trends .and patt.erns of
prescription drug use in patient populations di~propor~10nately msured
through Medicare (i.e., the elderly and chromcally drnabled) and underrepresented in the FDA pre-market approval process and most postmarket clinical research.
HEALTH CARE PRIVACY AND SECURITY LAW 3:26-3:27 (2003) (citing 45
C.F.R. § 164.512(b)(l)(iii) (2012)); HIPAA Compliance .for Reporters to
FDA
Med Watch,
FDA.Gov,
http://www.fda.gov/Safety /MedWatch/HowToReport/uc.:0:085589.ht:O:
(last updated Jun. 25, 2009) (" [T]he Privacy Rule spec~fically permits
covered entities (such as pharmacists, physicians or hos:p1tals) to. report
adverse events and other information related to the quality, effectiveness
and safety of FDA-regulated products both to the manufacturers and
directly to FDA.").
110. 21 U.S.C. § 355(k)(3)(C)(i)(I) (2012) (referencing the HIPAA Privacy
Rule).

106. See generally 45 C.F.R. §§ 160, 164 (2012).

111. § 355(k)(3)(C) (2012).

107. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 11085, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.).

112. § 355(k)(3)(A) (2012) (providing a definition of "data" for purposes of
active post-market risk identification).

108. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The
Food, Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME
L. REV. 419, 482 (2010) ("In effect, Congress determined that the public
he~lth benefits of having [an active drug safety surveillance] system are
weighty enough to override individuals' interest in keeping their data out
of it.").

113. § 355(k)(3)(C)(i). For an exam~le of how d~t~bases are used to identify
off-label prescribing habits in children, see Mmam C. J.M. Sturkenbo?m
et al., Drug Use in Children: Cohort Study in Three European Countr~es,
337 BRIT. MED. J. 1338, 1339 (2008) (recognizing that this study, which
relied upon physician-generated data from ele~tronic medical r~c?rd
databases from three different European countries, reflects prescnbmg
habits and not patient adherence).

109. Kristen
1'.l~sati, Using Electronic Health Information for
Pharmacovzgzlance: The Promise and the Pitfalls, 2 J. HEALTH & LIFE Ser.
L. 171 (2009); LISA M. BOYLE & DAVID M. MACK, HIP AA: A GUIDE TO
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C. Potential Role of Outpatient Prescription Drug Database for Comparative Effectiveness Research and Coverage Decisions

evidence for new technologies subject to the FDA pre-m~rket ~pproval
ocess (all new prescription drugs) may be limited to a smgle mtended
pr and clinical evidence may not provide
·
· £ormat·10n on a
much m
,,123 Add"
use,
. .
.
.
.
product's "real world benefit m typical pa~ient c~re s~ttmgs.
.
itionally, recent studies on the informational bias. m peer-reviev:ed
literature call into question the current body of evidence supportmg
many, if not most, of the products on the market. 124
Within the Department of Health and Human Services, the Agency
for Healthcare Research and Quality (AHRQ) is charged with "conduct[ing] and support[ing] research with respect. to the outcomes,
effectiveness, and appropriateness of health care servi_ces and procedures
in order to identify the manner in which diseases, disorders, and other
health conditions can most effectively and appropriately be prevented,
diagnosed, treated, and managed clinically" con~!stent with ~he needs
and priorities of the Medicare program. 125 Indeed, [~HRQ] believes th~t
the principal function of CED is to generate i:ew eviden~e. on the ben~fit
or harm of an item or service among the Medicare beneficiary popula~wn
based on rigorous scientific inquiry. "126 The Medicare pati~nt pop':lat10n,
which includes the elderly, chronically disabled, and patients with end
stage renal disease who are treated with dialysis, is often excluded from
clinical trials conducted to evaluate products for FDA pre-market
.
.
approval. 127
Similarly, many of the patients historically covered by Medicaid children, pregnant women, people with disabilities, an~ the elderly - _are
also often excluded from clinical trials for both ethical and pra~tic~l
reasons. Inclusion of diagnosis codes in the Medicare and Me~ic~1d
claims databases would significantly increase the amount of prescnpti?n
drug use data available for drug safety surveillance in these other~nse
underrepresented patient populations, many of whom are 1?-or~ phy_si?ally, socially, and economically vulnerable than those studied m chmcal
trials.
· t
In an attempt to address the underrepresentation of these patien
populations in clinical trials, Medicare Parts A and B claims databases

Prescribers are able to recommend any FDA-approved drug for any
use they deem in their patients' best interests. 116 Often these recommendations differ from the intended use(s) studied in the clinical trials and,
in many specialties and diseases, become the standard of care. 117 Likewise, previously accepted treatments are occasionally called into question
by new research or evolving scientific thought, and CMS has tried to
respond effectively to emerging evidence. 118 Instead of denying coverage
outright for these newer or newly questioned technologies, CMS has
occasionally used a "Coverage with Evidence Development" (CED)
program to "provide Medicare coverage while further evidence is developed. "119
CMS generally relies on clinical evidence to determine whether particular items or services should be considered "reasonable and necessary"
for purposes of Medicare Part B coverage. 12° For prescription drugs
covered under Part B, CMS looks to evidence beyond that considered for
"medically accepted indications," including medical literature and other
indicia of accepted standards of care. 121 Even with the expanded universe
of evidence available for Part B coverage, information may still be
significantly limited for both very new and older products, making wellinformed coverage determinations impossible. 122 In particular, clinical
116. These uses likely fall into the category of items and services where CMS
"believed that the enthusiasm of interested parties was disproportionate to
the persuasiveness of the then-current evidence base." Draft Guidance for
the Public, Industry & CMS Staff Coverage with Evidence Development in
the Context of Coverage Decisions, CTRS FOR MEDICARE & MEDICAID
SERVS.
(Nov.
29,
2012)
[hereinafter
Draft
Guidance],
http://www.cms.gov/medicare-coverage-database/details/medicarecoverage-document-details.aspx?MCDid=23.
117. See Kesselheim, supra note 3, at 238 ("[Scientifically unsupported] off-label
use may also be reasonable and appropriate in circumstances where
collection of rigorous evidence is impossible.").
118. See Draft Guidance, supra note 116.
119. CMS originally grounded its authority for this policy in Sections
1862(a)(l)(A) and 1862(a)(l)(E) of the Social Security Act (42 U.S.C. §
1395y(a)(l)), but more recently decided that the policy was not consistent
with Section 1862(a)(l)(A). Id.
120. 42 U.S.C. § 1395y(a)(l)(A) (2006); Draft Guidance, supra note 116.
121. MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.4.2 ("FDA
approved drugs used for indications other than what is indicated on the
official label may be covered under Medicare [Part B] if the carrier
determines the use to be medically accepted, taking into consideration the
major drug compendia, authoritative medical literature and/ or accepted
standards of medical practice." (emphasis added)).
122. Draft Guidance, supra note 116.
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123. Id.
124. See, e.g., Andrew P. Prayle et al., Compliance with Mand~tory Reporting
of Clinical Trial Results on Clinical Trials.gov: Cross-Sectional Stu_dy, 344
BRIT. MED. J. 7373 (2012); Sylvain Mathieu et al., <?omparison of
Registered 8 Published Primary Outcomes in Randomized Controlled
Trials, 302 JAMA 977 (2009).
125. 42 U.S.C. § 1320b-12 (2012). Medicare coverage determinations may then
be made pursuanj; to the research conducted by the Agency. See §
1395y(a)(l)(E) (cross-referencing the research conducted pursuant to 42
u.s.c. § 1320b-12).
126. Draft Guidance, supra note 116.
127. Id.
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C. Potential Role of Outpatient Prescription Drug Database for Comparative Effectiveness Research and Coverage Decisions

evidence for new technologies subject to the FDA pre-m~rket ~pproval
process (all new prescription drugs) may b~ limited to_ a smgle__mtended
and clinical evidence may not provide much mformat10n on a
~:~duct's "real world benefit in t~pical pa~ient c~re s~ttings." 123 ~ddi
tionally, recent studies on the mformational bias. m peer-reviev:ed
literature call into question the current body of evidence supportmg
many, if not most, of the products on the market. 124
Within the Department of Health and Human Services, the Agency
for Healthcare Research and Quality (AHRQ) is charged with "conduct[ing] and support[ing] research with respect. to the outcomes,
effectiveness, and appropriateness of health care servi_ces and procedures
in order to identify the manner in which diseases, disorders, and other
health conditions can most effectively and appropriately be prevented,
diagnosed, treated, and managed clinically" con~~stent with ~he needs
and priorities of the Medicare program. 125 Indeed, [~HRQ] believes th~t
the principal function of CED is to generate 1:-ew eviden~e- on the ben~fit
or harm of an item or service among the Medicare benefi~iary popula~ion
based on rigorous scientific inquiry." 126 The Medicare pati~nt pop1:lat10n,
which includes the elderly, chronically disabled, and patients with end
stage renal disease who are treated with dialysis, is often excluded from
clinical trials conducted to evaluate products for FDA pre-market
.
.
approval. 127
Similarly, many of the patients historically covered by Medicaid children, pregnant women, people with disabilities, an~ the elderly- _are
also often excluded from clinical trials for both ethical and pra~tic~l
reasons. Inclusion of diagnosis codes in the Medicare and Me~ic~id
claims databases would significantly increase the amount of prescnpti?n
drug use data available for drug safety surveillance in these other~"'nse
underrepresented patient populations, many of whom are ~or~ phy_si?ally, socially, and economically vulnerable than those studied m chrncal
trials.
· t
In an attempt to address the underrepresentation of these patien
populations in clinical trials, Medicare Parts A and B claims databases

Prescribers are able to recommend any FDA-approved drug for any
use they deem in their patients' best interests. 116 Often these recommendations differ from the intended use(s) studied in the clinical trials and,
in many specialties and diseases, become the standard of care. 117 Likewise, previously accepted treatments are occasionally called into question
by new research or evolving scientific thought, and CMS has tried to
respond effectively to emerging evidence. 118 Instead of denying coverage
outright for these newer or newly questioned technologies, CMS has
occasionally used a "Coverage with Evidence Development" (CED)
program to "provide Medicare coverage while further evidence is developed. "119
CMS generally relies on clinical evidence to determine whether particular items or services should be considered "reasonable and necessary"
for purposes of Medicare Part B coverage. 12° For prescription drugs
covered under Part B, CMS looks to evidence beyond that considered for
"medically accepted indications," including medical literature and other
indicia of accepted standards of care. 121 Even with the expanded universe
of evidence available for Part B coverage, information may still be
significantly limited for both very new and older products, making wellinformed coverage determinations impossible. 122 In particular, clinical
116. These uses likely fall into the category of items and services where CMS
"believed that the enthusiasm of interested parties was disproportionate to
the persuasiveness of the then-current evidence base." Draft Guidance for
the Public, Industry &J CMS Staff Coverage with Evidence Development in
the Context of Coverage Decisions, CTRS FOR MEDICARE & MEDICAID
SERVS.
(Nov.
29,
2012)
[hereinafter
Draft
Guidance],
http://www.cms.gov/medicare-coverage-database/details/medicarecoverage-document-details.aspx?MCDid=23.
117. See Kesselheim, supra note 3, at 238 ("[Scientifically unsupported] off-label
use may also be reasonable and appropriate in circumstances where
collection of rigorous evidence is impossible.").
118. See Draft Guidance, supra note 116.
119. CMS originally grounded its authority for this policy in Sections
1862(a)(l)(A) and 1862(a)(l)(E) of the Social Security Act (42 U.S.C. §
1395y(a)(l)), but more recently decided that the policy was not consistent
with Section 1862(a)(l)(A). Id.
120. 42 U.S.C. § 1395y(a)(l)(A) (2006); Draft Guidance, supra note 116.
121. MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.4.2 ("FDA
approved drugs used for indications other than what is indicated on the
official label may be covered under Medicare [Part BJ if the carrier
determines the use to be medically accepted, taking into consideration the
major drug compendia, authoritative medical literature and/ or accepted
standards of medical practice." (emphasis added)).
122. Draft Guidance, supra note 116.
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123. Id.
124. See, e.g., Andrew P. Prayle et al., Compliance with Mand~tory Reporting
of Clinical Trial Results on Clinical Trials.gov: Cross-Sectional Stu_dy, 344
BRIT. MED. J. 7373 (2012); Sylvain Mathieu et al., ?omparison of
Registered &J Published Primary Outcomes in Randomized Controlled
Trials, 302 JAMA 977 (2009).
125. 42 U.S.C. § 1320b-12 (2012). Medicare coverage determinations may then
be made pursuan! to the research conducted by the Agency. See §
1395y(a)(l)(E) (cross-referencing the research conducted pursuant to 42
u.s.c. § 1320b-12).
126. Draft Guidance, supra note 116.
127. Id.
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ar~ alre~dy available and have been used for research purposes, 128 and
private msurers a:e working to create a claims database covering a
broader cross-sect10n of the population. 129 Increased use of electronic
~edical records, especially those that meet the meaningful use standards
issued under HITECH, 130 may provide robust databases for some
131
research, but they are inherently provider-based datasets that may not
128. The Dartm?ut~ Atlas ~roject has used Medicare claims data to provide
comprehensive mformation and analysis about the national, regional and
local markets, as well as individual hospitals and their affiliated physi~ians.
FAQ,
DARTMOUTH
ATLAS
OF
HEALTH
CARE
~~tp://www.dartmouth~tlas.org/tools/faq/ (last visited Apr. 19, 2014)
( The Centers for Medicare and Medicaid Services (CMS), the federal
agency. that collects data for every person and provider using Medicare
health msurance, makes available a uniform national claims database for
rese3:rch purposes."). See also John Carreyou, Access to Widen on
Medicare Data, WALL ST. J., Dec. 8, 2011, at A6 ("In an abrupt policy
chan_ge, the J:?epartment of Health and Human Services will make its huge
Medicare claims database more broadly available to the public, to help
consumers and employers make better-informed decisions about medical
care. In particular, the federal agency will relax its restrictions on the
rele3:se of information about individual doctors who participate in
Medicare, the $524 billion federal program for the elderly and disabled
reversing a three-decade position that doing so would violate physicians;
privacy rights.").
129. See Anna Wilde Mathews, Health Insurers Will Give Claims Data to
Institute,. WA~L ST. J. (Sept. 19, 2011), available at http://
www.onlme.WSJ.com/ article /SB100014240S311190337 4004576581131849595
492.html ("Researchers have sometimes struggled to perform such studies
on ~he commercially insured population. They often turn to Medicare data,
which reflect a mostly elderly patient base as well as the federal
government's unique payment model. The Health Care Cost Institute will
start with claims from UnitedHealth Group Inc., Aetna Inc., Humana Inc.
~~d. the nor_iprofit Kaiser Permanente, and the carriers are also providing
m1tial fundmg to set it up.").
130. David C. Classen & David W. Bates, Finding the Meaning in Meaningful
Use, _365 NEW ENG. J. MED. 855, 856 (2011) ("The meaningful-use criteria
~equi:e the collection of specific quality measures: in particular, 15
mpat1ent and 6 outpatient quality measures that will have to be collected
and reported to meet these criteria. The stage 2 criteria for quality
measures will raise t~e bar further, although they are still in a draft stage.
~roadl~, the hope 1s that stage 2 will encourage providers to begin
1mprovmg process, whereas stage 3 will result in improved outcomes.").
131. See, e.g., Kenne~h Jung et al., .Automated Detection of Systematic OffLabel Drug Use in Free Text of Electronic Medical Records, 2013 AMIA
SU_M~TS TRANSL_ATIONAL SCI. PROCEEDINGS 94 (2013). See also Peter Jaret,
Mining Electronic Recor~s for Revealing Health Data, N.Y. TIMES, Jan. 14,
2013,
http://www.nyt1mes.com/2013/0l/15/health/mining-electronicrecords-~or-rev:aling-health-data.html ("The monitoring and analysis of
electromc .medical records, some scientists say, have the potential to make
every patient a i:articipant in a vast, ongoing clinical trial, pinpointing
treatments and side effects that would be hard to discern from anecdotal
case reports or expensive clinical trials.").
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reflect patient adherence. 132 Medicare Part D and Medicaid outpatient
prescription drug claims databases, if populated with d~a~nosis c?de~,
have the unique value of both capturing off-label prescnbmg habits m
typical community based treatment settings (as opposed to the specialized research settings of clinical trials) 133 and patient adherence data. 134
Further, unlike the shorter-term clinical trials (which at their longest
may extend to a year's use of a product), outpatient prescription drug
claims databases populated with diagnosis information would allow
researchers to follow patient adherence in the context of long-term
management of chronic conditions over the course of years, including the
combination therapies that often go untested in conventional clinical
trials. 135 At a minimum, researchers could use the outpatient prescription
drug claims data to identify and provide information on which treatr:ient
regimens are better tolerated, or more consistently observed by patients
over time, than others - a measurement which has previously been used

132. STEVEN R. FELDMAN, COMPARTMENTS: How THE BRIGHTEST, BEST
TRAINED AND MOST CARING PEOPLE CAN MAKE JUDGMENTS THAT ARE
COMPLE;ELY AND UTTERLY WRONG 18 (2009) ("Dermatologists prescribe
patients medications but don't get to see what p~tients do .with ~he
medicines . . . . It turns out many patients don t use their topical
medications as directed, and over the long run, their use of medication
steadily drops. But dermatologists didn't know this.").
133. The potential disconnect between clinical trial research centers and typical
treatment settings is one factor that CMS will consider in its decision _to
apply CED to items or services. In addition, CMS looks at. the potential
disconnect between clinical trial endpoints and relevant patient outcomes
in the Medicare population, the enrollment criteria of the clinical tri~ls
(which often excludes elderly patients wi~h sign~fican.t: rel~va~~ comorb1d
conditions), and whether later clinical evidence 1dent1f1es s1gmficant harm
or lack of meaningful benefit of a previously-accepted treatment. Draft
Guidance, supra note 116.
134. See David Brandes et al., Implications of Real-World Adherence on CostEffectiveness Analysis in Multiple Sclerosis, 16 J. MED. ECON. 547, 547
(2013) (" [E]conomic analyses of [multiple scl:rosis] therapies sho~ld
incorporate real-world adherence rates where ava1labl~, ra~her than relyn1:g
exclusively on trial-based efficacy estimates .when co.nsi~ermg the e~ono1?1c
value of treatment alternatives, and that highly eff1cac1ous therapies with
low adherence may yield real-world efficacy that is substantially lower than
that observed in closely monitored clinical trials."); Ruby Grymonpre et
al., Validity of a Prescription Claims Database to Estimat~ fv!edication
Adherence in Older Persons, 44 MED. CARE471, 476 (2006) (fmdmg strong
correlation between prescription drug claim database information and
actual patient adherence for discrete prescriptions to be taken regularly).
135. See, e.g., Theodore Pincus, Limitations of Randomized ?Zin.ical Trials t.o
Recognize Possible Advantages of Combination Therapies in Rheumatic
Diseases, 23 SEMINARS IN ARTHRITIS & RHEUMATOLOGY 2, 3 (1993).
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ar~ alre~dy available and have been used for research purposes, 12s and
private msurers a:e working to create a claims database covering a
broader cross-section of the population. 129 Increased use of electronic
~edical records, especially those that meet the meaningful use standards
ISsued under HITECH, 130 may provide robust databases for some
131
research, but they are inherently provider-based datasets that may not
128. The Dartm?ut~ Atlas ~roject has used Medicare claims data to provide
comprehensive mformation and analysis about the national, regional and
local markets, as well as individual hospitals and their affiliated physi~ians.
FAQ,
DARTMOUTH
ATLAS
OF
HEALTH
CARE
~~tp://www.dartmouth~tlas.org/tools/faq/ (last visited Apr. 19, 2014)
( The Centers for Medicare and Medicaid Services (CMS), the federal
agency. that collects data for every person and provider using Medicare
health msurance, makes available a uniform national claims database for
rese8:rch purposes."). See also John Carreyou, Access to Widen on
Medicare Data, WALL ST. J., Dec. 8, 2011, at A6 ("In an abrupt policy
chan_ge, the J:?epartment of Health and Human Services will make its huge
Medicare claims database more broadly available to the public, to help
consumers and employers make better-informed decisions about medical
care. In particular, the federal agency will relax its restrictions on the
rele8:se of information about individual doctors who participate in
Medicare, the $524 billion federal program for the elderly and disabled
reversing a three-decade position that doing so would violate physicians;
privacy rights.").
129. See Anna Wilde Mathews, Health Insurers Will Give Claims Data to
Institute,_ W~L ST. J. (Sept. 19, 2011), available at http://
www.onlme.WSJ.com/ article /SB1000142408311190337 40045 76581131849595
492.html ("Researchers have sometimes struggled to perform such studies
on ~he commercially insured population. They often turn to Medicare data,
which reflect a mostly elderly patient base as well as the federal
government's unique payment model. The Health Care Cost Institute will
start with claims from UnitedHealth Group Inc., Aetna Inc., Humana Inc.
~~d. the no1:1-profit Kaiser Permanente, and the carriers are also providing
mitial fundmg to set it up.").
130. David C. Classen & David W. Bates, Finding the Meaning in Meaningful
Use, _365 NEW ENG. J. MED. 855, 856 (2011) ("The meaningful-use criteria
:equr:e the collection of specific quality measures: in particular, 15
mpatient and 6 outpatient quality measures that will have to be collected
and report~d t? meet these criteria. The stage 2 criteria for quality
measures will raise t~e bar further, although they are still in a draft stage.
"!3roadl~, the hope is that stage 2 will encourage providers to begin
1mprovmg process, whereas stage 3 will result in improved outcomes.").
131. See, e.g., Kenne~h Jung et al., Automated Detection of Systematic OffLabel Drug Use in Free Text of Electronic Medical Records, 2013 AMIA
S~~TS TRANSL_ATIONAL Ser. PROCEEDINGS 94 (2013). See also Peter Jaret,
Mining Electronic Recor~s for Revealing Health Data, N.Y. TIMES, Jan. 14,
2013,
http://www.nytimes.com/2013/0l/15/health/mining-electronicrecords-~or-rev~aling-health-data.html ("The monitoring and analysis of
electromc_med1cal re~o_rds, so_me scientists say, have the potential to make
every patient a ~artic1pant rn a vast, ongoing clinical trial, pinpointing
treatments and side effects that would be hard to discern from anecdotal
case reports or expensive clinical trials.").
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reflect patient adherence. 132 Medicare Part D and Medicaid outpatient
prescription drug claims databases, if populated with d~a~nosis c?de_s,
have the unique value of both capturing off-label prescnbmg habits m
typical community based treatment settings (as opposed to the specialized research settings of clinical trials) 133 and patient adherence data. 134
Further, unlike the shorter-term clinical trials (which at their longest
may extend to a year's use of a product), outpatient prescription drug
claims databases populated with diagnosis information would allow
researchers to follow patient adherence in the context of long-term
management of chronic conditions over the course of years, including the
combination therapies that often go untested in conventional clinical
trials. 135 At a minimum, researchers could use the outpatient prescription
drug claims data to identify and provide information on which treatr_nent
regimens are better tolerated, or more consistently observed by patients
over time, than others - a measurement which has previously been used

132. STEVEN R. FELDMAN, COMPARTMENTS: How THE BRIGHTEST, BEST
TRAINED AND MOST CARING PEOPLE CAN MAKE JUDGMENTS THAT ARE
COMPLE;ELY AND UTTERLY WRONG 18 (2009) ("Dermatologists prescribe
patients medications but don't get to see what p~tients do .with _the
medicines . . . . It turns out many patients don t use their topical
medications as directed, and over the long run, their use of medication
steadily drops. But dermatologists didn't know this.").
133. The potential disconnect between clinical trial research centers and typical
treatment settings is one factor that CMS will consider in its decision _to
apply CED to items or services. In addition, CMS looks at. the potential
disconnect between clinical trial endpoints and relevant patient outcomes
in the Medicare population, the enrollment criteria of the clinical tri~ls
(which often excludes elderly patients wi~h sign~fican_t~ rel~va~~ comorb1d
conditions), and whether later clinical evidence 1dent1fies s1grnficant harm
or lack of meaningful benefit of a previously-accepted treatment. Draft
Guidance, supra note 116.
134. See David Brandes et al., Implications of Real- World Adherence on CostEffectiveness Analysis in Multiple Sclerosis, 16 J. MED. ECON. 547, 547
(2013) ("[E]conomic analyses of [multiple sclerosis] therapies sho~ld
incorporate real-world adherence rates where availabl~, ra~her than rely1~g
exclusively on trial-based efficacy estimates.when co_ns1~ermg the e~ono1?1c
value of treatment alternatives, and that highly efficac10us therapies with
low adherence may yield real-world efficacy that is substantially lower than
that observed in closely monitored clinical trials."); Ruby Grymonpre et
al., Validity of a Prescription Claims Database to Estimat~ fv!edication
Adherence in Older Persons, 44 MED. CARE471, 476 (2006) (fmdmg strong
correlation between prescription drug claim database information and
actual patient adherence for discrete prescriptions to be taken regularly).
135. See, e.g., Theodore Pincus, Limitations of Randomized Clin_ical Trials ~o
Recognize Possible Advantages of Combination Therapies in Rheumatic
Diseases, 23 SEMINARS IN ARTHRITIS & RHEUMATOLOGY 2, 3 (1993).
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to evaluate the comparative effectiveness of drugs within a treatment
class. 136
Comparative effectiveness research (CER) is "research that compares
the clinical outcomes, effectiveness and appropriateness of items serv~ces, and_ procedures that are used to prevent, diagnose, or treat
diseases, disorders, and other health conditions. "137 Unlike most clinical
t~ials, which are conducted to determine the safety and efficacy of a
smgle drug, CER can provide information on the relative risks and
benefits of multiple treatment options. There remains much debate on
whether CER should be considering the costs of treatment options or
used for drug coverage determinations in the United States 138 but there
is wi~espread acceptance that the U.S. health care syst~m can only
benefit from a better understanding of which treatment options work
best for which patients. 139 While the current Medicare and Medicaid
out~atie~t prescription drug claims databases may be able to provide
longitudmal data on drug use generally, the inclusion of ICD-10-CM
codes would imbue the claims databases with the potential for deeper
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refinement in defining and understanding diseases and conditions,
eventually leading to more customized medical management programs. 140
Given the underrepresentation of much of the Medicare and Medicaid patient population and informational bias in the existing universe of
clinical evidence and the potential of a robust, accurately coded claims
database to capture real-world prescription drug use information, which
can in turn provide evidence of long-term efficacy and safety of drugs (or
lack thereof), CMS should continue to provide Medicare and Medicaid
prescription drug coverage while further evidence is developed consist~nt
with the agency's existing CED program for Part B coverage. In domg
so a revised Medicare Part D and Medicaid billing policy (as made
p;ssible through electronic prescribing and ICD-10-CM coding) could
play a critical role in better informing and reforming health care of those
who have been traditionally underrepresented in the clinical evidence.
CONCLUSION

138. Many other countries have already decided to include costs in their
comparative effectiveness programs. Keckley & Frink supra note 137 at
56 ("~t least sixteen developed systems in the world fe~ture a comparative
effectiveness program to define effective care. Comparative effectiveness
prog:ams in Britain, Australia, Canada, Germany, and others align
provi~er payments with adherence to recommendations of comparative
effectiveness programs, but each program is unique in design and
application.").

On first glance, adding ICD-10-CM diagnosis codes to outpatient
prescriptions appears to be an obvious "win-win" situation for fiscal
stability and public health - real-time coverage determinations for
purposes of controlling federal health care costs and meaningful data
collection to improve public health. CMS would be able to better police
its Medicare Part D and Medicaid spending, and pharmacists, FDA, and
researchers would have meaningful information for prescription review,
drug safety surveillance, and comparative effectiveness research. B1:1t
strict enforcement of Medicare Part D and Medicaid coverage laws m
the short-term could undermine all of these policy goals.
While most health care providers desperately try to comply with all
relevant laws and regulations, they are also driven by their vocation to
treat their patients effectively. Given the immediate nature of health and
illness and the often abstract and distant nature of laws and regulations,
combined with the sheer fact that at some point we will all be patients,
it would be unwise to underestimate the likelihood (and fervent wish of
many) that health care providers may take steps to effectively treat a
patient despite the laws and regulations that stand in the way. One such
step may be miscoding a diagnosis to get a needed prescription paid.
Where coverage denials are perceived as arbitrary and out-of-pocket
payment for prescription drugs is not a viable option, the "right" choice
between accurately reporting diagnoses or effectively treating a patient
can get blurred. When national health care policies are implicated, I

139. CER has received Congressional support as part of the Medicare
Modernization Act of 2003 and the American Recovery and Reinvestment
Act ~f 2009. Keckl~y & Frink, supra note 137, at 59 (providing an
overview of the ongomg debate about including treatment costs in CER)·
INST. OF MED., KNOWING WHAT WORKS IN HEALTH CARE: A ROADMAP FO~
THE NATION 205 (Jill Eden et al. eds., 2008), available at
http://www.nap.edu/openbook.php?record_id=l2038&page=205.

140. Keckley & Frink, supra note 137, at 77. See also Travis B. Murdoch &
Allan S. Detsky, The Inevitable Application of Big Data to Health Ca~e,
309 JAMA 1351, 1351 (2013) ("Big data [such as that collected m
insurance claims databases] offers the potential to create an observational
evidence base for clinical questions that would otherwise not be possible
and may be especially helpful with issues of generalizability.").

136. See. generally Lon S. Schneider et al., Effectiveness of Atypical
Antipsychotic Drugs in Patients with Alzheimer's Disease, 355 NEW ENG.
J. MED. 1525, 1525 (2006) (studying the number of patients with at least a
~inimal impr_o"."e_ment on a standardized symptom rating scale during a
timeframe of lmtial treatment to the discontinuation of treatment).
137. Paul H. Keckley & Barbara B. Frink, Comparative Effectiveness: A
Strategic Perspective on What It Is and What It May Mean for the United
States, 3 J. HEALTH & LIFE. Ser. L. 53, 58 (2009) (citing DOUGLAS
PEDDICORD, AM. MED. INFORMATICS Ass'N, THE AMERICAN RECOVERY AND
REINVESTMENT ACT OF 2009 1 (2009)). See also INST. OF MED., INITIAL
NATIONAL PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH 1
(2009),
available
at
http://www.iom.edu/-/media/Files/Report%20Files/2009/ComparativeEff
ect1venessResearchPriorities / CER%20report 320brief%2008-l 3-09. pdf.
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to evaluate the comparative effectiveness of drugs within a treatment
class. 136
Comparative effectiveness research (CER) is "research that compares
t~e clinical outcomes, effectiveness and appropriateness of items, serv~ces, and procedures that are used to prevent, diagnose, or treat
diseases, disorders, and other health conditions. "137 Unlike most clinical
t~ials, which are conducted to determine the safety and efficacy of a
smgle drug, CER can provide information on the relative risks and
benefits of multiple treatment options. There remains much debate on
whether CER should be considering the costs of treatment options or
used for drug coverage determinations in the United States 138 but there
is wi~espread acceptance that the U.S. health care syst~m can only
benefit from a better understanding of which treatment options work
best for which patients. 139 While the current Medicare and Medicaid
out~atie~t prescription drug claims databases may be able to provide
long1tudmal data on drug use generally, the inclusion of ICD-10-CM
codes would imbue the claims databases with the potential for deeper
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refinement in defining and understanding diseases and conditions,
eventually leading to more customized medical management programs. 140
Given the underrepresentation of much of the Medicare and Medicaid patient population and informational bias in the existing universe of
clinical evidence and the potential of a robust, accurately coded claims
database to capture real-world prescription drug use information, which
can in turn provide evidence of long-term efficacy and safety of drugs (or
lack thereof), CMS should continue to provide Medicare and Medicaid
prescription drug coverage while further evidence is developed consist~nt
with the agency's existing CED program for Part B coverage. In domg
so a revised Medicare Part D and Medicaid billing policy (as made
p~ssible through electronic prescribing and ICD-10-CM coding) could
play a critical role in better informing and reforming health care of those
who have been traditionally underrepresented in the clinical evidence.
CONCLUSION

138. Many other countries have already decided to include costs in their
comparative effectiveness programs. Keckley & Frink supra note 137 at
56 ("~t least sixteen developed systems in the world fe~ture a comparative
effectiveness program to define effective care. Comparative effectiveness
pro~ams in Britain, Australia, Canada, Germany, and others align
provi~er payments with adherence to recommendations of comparative
effectiveness programs, but each program is unique in design and
application.").

On first glance, adding ICD-10-CM diagnosis codes to outpatient
prescriptions appears to be an obvious "win-win" situation for fiscal
stability and public health - real-time coverage determinations for
purposes of controlling federal health care costs and meaningful data
collection to improve public health. CMS would be able to better police
its Medicare Part D and Medicaid spending, and pharmacists, FDA, and
researchers would have meaningful information for prescription review,
drug safety surveillance, and comparative effectiveness research. B1:1t
strict enforcement of Medicare Part D and Medicaid coverage laws m
the short-term could undermine all of these policy goals.
While most health care providers desperately try to comply with all
relevant laws and regulations, they are also driven by their vocation to
treat their patients effectively. Given the immediate nature of health and
illness and the often abstract and distant nature of laws and regulations,
combined with the sheer fact that at some point we will all be patients,
it would be unwise to underestimate the likelihood (and fervent wish of
many) that health care providers may take steps to effectively treat a
patient despite the laws and regulations that stand in the way. One such
step may be miscoding a diagnosis to get a needed prescription paid.
Where coverage denials are perceived as arbitrary and out-of-pocket
payment for prescription drugs is not a viable option, the "right" choice
between accurately reporting diagnoses or effectively treating a patient
can get blurred. When national health care policies are implicated, I

139. CER has received Congressional support as part of the Medicare
Modernization Act of 2003 and the American Recovery and Reinvestment
Act ~f 2009. Keckl~y & Frink, supra note 137, at 59 (providing an
overview of the ongorng debate about including treatment costs in CER)·
INST. OF MED., KNOWING WHAT WORKS IN HEALTH CARE: A ROADMAP FO~
THE NATION 205 (Jill Eden et al. eds., 2008), available at
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Allan S. Detsky, The Inevitable Application of Big Data to Health Ca~e,
309 JAMA 1351, 1351 (2013) ("Big data [such as that collected m
insurance claims databases] offers the potential to create an observational
evidence base for clinical questions that would otherwise not be possible
and may be especially helpful with issues of generalizability.").

136. See. generally Lon S. Schneider et al., Effectiveness of Atypical
Antipsychotic Drugs in Patients with Alzheimer's Disease, 355 NEW ENG.
J. MED. 1525, 1525 (2006) (studying the number of patients with at least a
~inimal impr.o"."e_ment on a standardized symptom rating scale during a
timeframe of rnitial treatment to the discontinuation of treatment).
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States, 3 J. HEALTH & LIFE. SCI. L. 53, 58 (2009) (citing DOUGLAS
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(2009),
available
at
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suggest erring on the side of accurate information at the cost of immediate, strict enforcement of the letter of the law to bolster better evidencebased decisions in the future. Fortunately (at least in this context),
administrative agencies are afforded tremendous discretion in their
enforcement policies, especially when enforcement involves a complicated
balancing of a number of factors that are peculiarly within the agency's
. 141 c·iven t he comp1e:xity of the legal framework here the
expert ISe.
informational limits of scientific evidence and diagnostic coding: the
vulnerability of the patient populations insured under Medicare and
Medicaid, and the opportunities to improve both individual patient
safety and public health tied up in this enforcement policy it seems
unlikely that any federal court would compel CMS to apply' the strict
letter of the coverage laws.
Accordingly, in order to better control federal health care costs and
improve public health in the long-term (possible only through collection
and use of accurate information), CMS should make inclusion of an ICD10-CM diagnosis code a condition of payment for all Medicare Part D
and Medicaid claims for outpatient prescription drugs but suspend strict
enforcement of the coverage laws unless there is widespread consensus in
the medical community that a particular treatment is always ineffective
or harmful. The alternatives are unsatisfying: either a continuation of
the status quo - essentially unchecked federal spending on prescription
drugs that further threatens the fiscal stability of the Medicare and
Me~icaid programs, exacerbated by poorly understood prescription drug
use m vulnerable populations - or worse.
While the inclusion of ICD-10-CM codes on outpatient prescriptions
may be a simple proposal with significant potential for improving public
health and patient safety, it is neither an easy nor inexpensive one. It
would be a tremendous disservice to patients, taxpayers, health care
providers, researchers, and policymakers alike to implement the proposal
solely as a means of reducing federal health care spending on off-label
prescriptions. With strict enforcement of the coverage laws and the
accompanying systemic incentives to miscode created by widespread
coverage denials, we could easily end up with the worst of all options - a
significant investment of time and money in a claims database corrupted
by inaccurate information that neither meaningfully polices federal
health care spending nor provides sufficiently robust data for improved
practice of pharmacy, drug safety surveillance, or comparative effectiveness research. Let us hope it does not come to that.
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